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Abstract
Polypharmacology is considered as the future of drug discovery and emerges as
the next paradigm of drug discovery. The traditional drug design is primarily
based on a ”one target-one drug” paradigm. In polypharmacology, drug molecules
always interact with multiple targets, and therefore it imposes new challenges in
developing and designing new and effective drugs that are less toxic by eliminating
the unexpected drug-target interactions. Although still in its infancy, the use of
polypharmacology ideas appears to already have a remarkable impact on modern
drug development.
The current thesis is a detailed study on various pharmacology approaches at
systems level to understand polypharmacology in complex brain and neurodegn-
erative disorders. The research work in this thesis focuses on the design and con-
struction of a dedicated knowledge base for human brain pharmacology. This phar-
macology knowledge base, referred to as the Human Brain Pharmacome (HBP) is
a unique and comprehensive resource that aggregates data and knowledge around
current drug treatments that are available for major brain and neurodegenerative
disorders. The HBP knowledge base provides data at a single place for building
models and supporting hypotheses. The HBP also incorporates new data obtained
from similarity computations over drugs and proteins structures, which was an-
alyzed from various aspects including network pharmacology and application of
in-silico computational methods for the discovery of novel multi-target drug can-
didates.
Computational tools and machine learning models were developed to characterize
protein targets for their polypharmacological profiles and to distinguish indica-
tions specific or target specific drugs from other drugs. Systems pharmacology ap-
proaches towards drug property predictions provided a highly enriched compound
library that was virtually screened against an array of network pharmacology based
derived protein targets by combined docking and molecular dynamics simulation
workflows. The developed approaches in this work resulted in the identification
of novel multi-target drug candidates that are backed up by existing experimen-
tal knowledge, and propose repositioning of existing drugs, that are undergoing
further experimental validations.
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Chapter 1
Introduction and Motivation
1.1 Human Brain Disorders
Brain disorders cause up to 25% of global death and disability [1] and account for
more than 34% of the global burden of diseases [2]. Therefore, there is a need for
increasing awareness among the community for developing preventive strategies
and remedies for these disorders [3]. The social and economic burden arising from
brain diseases is even larger than reported because many brain disorders are not
accounted for since they arise from factors outside of the nervous system [4], such
as those diseases arising from HIV infections [5]. Brain disorders impose high
economic burden on society with larger annual costs than the cost of all other
disease areas [6]. The significant economic burden on the healthcare system [7]
directly and indirectly [8] imposes additional severe impacts on social behavior or
leading to suicides [9],[10].
1.2 Neurodegenerative Disorders
With approximately 100 billion neurons and approximately 100 trillion synapses,
the complexity of the human brain and its continuous operation renders it vul-
nerable to abnormal functions and injuries [11]. Abnormalities in specific brain
functions, such as memory, movement and cognition, result in neurodegenerative
disorders that are characterized by a slow progressive loss of neurons [12]. The loss
of neurons in normal physiological aging is not as significant as compared to the
loss from neuronal atrophy in selected areas of the brain due to neurodegenerative
diseases [13]. There are many known and unknown factors causing the nervous
system degeneration that results in the primary connectivity failure in the neu-
ronal circuitry [14], which consequently affects the normal information processing
1
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by the brain and hence, lead to neurodegenerative disorders.
Alzheimer’s disease, the most common type of dementia that affects millions of
people, has no treatment available today that can reverse or stop its progression
[15]. It is clear that Alzheimer’s disease and dementia are associated with signifi-
cant mortality [16]. Parkinson’s disease is another age-related common neurologi-
cal disorder with significant morbidity and disability [17], whose current treatment
strategies involve symptomatic management only [18], [19]. The increasing number
of available treatment options further complicates the management of the disease
[20]. Multiple sclerosis and amyotrophic lateral sclerosis cause neurological dis-
ability and shortened life spans in young adults [21]. The limited and partially
effective treatment options puts pressure for the development of new and more
effective treatments [22] that have reduced side effects[23]. Current treatments for
the vast majority of neurodegenerative disorders are only symptomatic, tempo-
rary and do not alter disease progression and pursuit of new therapeutic strategies
collectively by pharmaceutical industries, academic researchers and disease foun-
dations is the only means to make progress against the challenges presented by
these diseases [24].
1.3 Complexities in Disease Mechanims
Neurodegeneration is the principal pathology associated with most neurodegener-
ative disorders, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lat-
eral sclerosis and Huntington’s disease [25]. However, controversies in classifying
different forms of neurodegenerative disorders often result in unclear demarkation
between them [26]. Some disorders (e.g. multiple sclerosis, epilepsy, schizophrenia
and tumors) are not usually classified as degenerative while for other disorders
there are problems in diagnostically labeling them with correct terminology (e.g.
differentiating between Parkinson’s and Lewy body dementia, between Alzheimer’s
and fronto-temporal, and between the dysphasic versions of dementia) [27]. Cur-
rent classification problems result from multiple pathophysiological processes that
are common to different diseases [28]. Even though research on neurodegenerative
diseases has progressed in the last four decades and there are journals entirely
devoted to the topic [29], the challenges for developing treatments continue to
grow [30]. It remains unclear if a single molecular target or a single pathways is
involved in the disease progression, and if targeting it would be sufficient to reverse
the disease’s progress [24].
To understand the multifactorial and complex cellular mechanisms behind neu-
rodegenerative diseases, system biology approaches that include mathematical
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models followed by experimental validations are being used by researchers [31].
For example, to predict the conformational state of the mutant protein huntingtin
(Htt) that interacts with high number of glutamine amino acids and forming aggre-
gates that are associated with Huntington’s disease. In-silico systems approaches
and modeling will improve our understanding of the complex nature of these ”sys-
tem biology diseases” or ”complex diseases” [32]. These complex diseases have
multifactorial etiologies and the associated dysfunctions resulting from a large
number of interacting biomolecules can be differentiated between a normal and
a diseased state when studied at the network level [33]. New therapeutic strate-
gies with multi-functional drugs for various central nervous system targets may
enhance the treatment of neurodegenerative disorders [34],[35]. Recent advances
in omics technologies and the availability of the resulting data in public databases
opens up new areas of research such as systems biology and network pharmacol-
ogy approaches. Such integrative network approaches will allow us to develop an
understanding of the biological context within which molecular level interactions
result in adverse phenotypes at the organ and organism level [36].
1.4 The Human Brain Pharmacome
The Human Brain Pharmacome (HBP) is a knowledge base that represents our
knowledge on the human brain pharmacology. The HBP pharmacome has been
designed and generated as a knowledge resource over the course of this research
project. The HBP pharmacome is a first of its kind geared towards gathering
and integrating biochemical knowledge about all known drugs and developmen-
tal/experimental compounds that are relevant to the human brain disorders. It
integrates all the interacting targets of these drugs, pathways involving these tar-
gets and phenotypic data associated to these targets. The HBP also includes
chemical properties and similarities information calculated for the drugs and pro-
teins structures. To the best of our knowledge, the HBP pharmacome is a unique
attempt to retrieve and collect therapeutic data around various human brain dis-
eases and extend it by knowledge concerning pocket geometries, pathways and
structural similarities between therapeutic compounds . The HBP will serves its
purpose in building a knowledge base that would facilitate biomedical research in
the area of complex brain and major neurodegenerative disorders (NDD).
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1.5 The Grand Vision of the Human Brain Phar-
macome - a Knowledge Base representing
Human Brain Pharmacology
The grand vision of the HBP is to build a knowledge base to facilitate the study of
integrative systems pharmacology approaches towards understanding brain phar-
macology and design new therapeutic strategies. The HBP pharmacome continues
to develop as a knowledge resource integrating all relevant and multi-scale biolog-
ical and chemical knowledge from open source databases, biomedical literature,
patent documents, electronic health records, clinical trials outcomes and genome
wide association studies. The HBP pharmacome will serve a useful purpose in al-
lowing the study of integrative approaches over the collected data and knowledge
represented by the pharmacome.
The complete vision of the HBP is outlined in Figure 1.1, which will be followed by
the current state of the HBP to describe how far the vision has been accomplished.
The foundation layer of the HBP starts with the integration of relevant data from
various public databases which will be extended with the information retrieved
from biomedical literature, patent documents and electronic health records. This
will allow to exploit mining strategies, on top of the data driven approaches, to
retrieve further relevant information for integrating with the existing knowledge.
There is a large amount of hidden knowledge available as free-text in biomedical
literature and valuable information about intellectual property and scientific in-
ventions in patent documents. Information retrieval and mining strategies will be
used to retrieve and gather the valuable information from the millions of these doc-
uments. The data collection and retrieval will be followed by a curation pipeline.
As the curation effort for such a knowledge resource is substantial, an automated
curation pipeline needs to be designed. All the relevant information in the HBP
pharmacome will not only be collected, but will be properly organized and in-
terlinked. The pharmacome will be modeled in such a way that would utilize
mining. This properly organized knowledge model will facilitate an automated
update mechanism that is crucial for the incorporation of new and up-to-date
knowledge as it becomes available. The entire information gathering strategies
should be designed in such a way that periodic updates can be easily applied.
The automated update system will also allow for customized alerts and query sys-
tem for informing researchers of the appearance of new knowledge in patents and
biomedical literature. For this purpose, the HBP data layer will be stored in a
structured format such as Resource Description Framework (RDF) format.
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Figure 1.1: The outline envisioning the Human Brain Pharmacome knowl-
edge base design. The HBP knowledge base will allow easy integration of new
knowledge to the existing data, make predictions on top of it, run simulations
and validate the new findings.
The disease focus of the HBP is on human brain diseases and major neurodegen-
erative disorders. Pathways dictionaries and disease specific pathways ontology
will be used to retrieve pathways mentions from biomedical literature and the re-
trieved pathways information will highlight the important pathways modulation
by drugs treatments. This will enable understanding true mode of action of the
drugs at pathway level. Mapping SNP and phenotypic data within the pharma-
come will help to identify common genetic factors that influence a disease state
[37]. Similarly, new knowledge will be derived from a series of computations to
extend further the pharmacome knowledge base.
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The HBP knowledgebase spans over a multi-scale of heterogenous data that al-
lows for building models, proposing hypotheses and making new predictions. The
prediction layer includes a variety of modeling approaches and tools that can be
applied on the pharmacome data. Such modeling approaches include network
models and machine learning-based classifier models. The network models can be
applied over the networks of drugs and their associated targets. Network-based
predictions could be very useful to identify new and interesting associations be-
tween drugs and their targets. Drugs and protein targets can be predicted for
their polypharmacological profiles for the design of new and effective multi-target
drugs. Machine learning-based classifier models can predict the affect profile of
new compounds for a disease area or a specific class of drug targets. The clas-
sifier models can also have potential applications in drug re-purposing and the
prediction of adverse side effects.
The HBP data at a high resolution, ranging from molecular to atomic level, makes
it as another useful resource for the development of virtual screening strategies and
molecular simulations. The simulation layer will allow the rapid in-silico testing
of new compound structures that interact with an array of multiple protein tar-
gets. The simulation studies include protein-ligand docking calculations, binding
pose evaluation and ranking, and molecular dynamics (MD) simulations. The
MD simulations are followed by molecular mechanics-based optimizations around
the interaction of chemical compounds with their targets. These simulations will
help to identify molecular mechanisms linked to desired or adverse drug actions.
The HBP will be able to provide the opportunity of deploying brute-force virtual
screening workflows built on docking-MD simulation workflows that can be used
for the identification of potential novel chemical scaffolds, multi-target drugs and
the prediction of secondary targets.
Finally, the predictions made that are based on the application of modeling and
simulation methods on the HBP data would need validations. The validations
can be quickly performed by in-silico methods and later on by in-vitro methods.
Realizing this vision will require several years to achieve, the following section
provides a firm foundation for the HBP continued growth.
1.6 Current State of the Human Brain Pharma-
come
The HBP pharmacome, at its current state, is represented as a relational data
model. At present, the HBP pharmacome captures information about all available
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drugs that are approved, that are in development and experimental compounds
that are therapeutically relevant for human brain disorders. For all of the drugs
and experimental compounds, their associated targets and the involved pathways
are collected. Side effects data for all approved drugs is also retrieved and saved
in the pharmacome. For all of the protein targets, human and mouse phenotypic
associations are linked when available. New chemical data is externally generated
for existing drugs and therapeutic compounds, along with their protein targets.
This data is added to the HBP, enlarging its database and possible usage. Struc-
tural data for drug molecules are cleaned, energy minimized and stored in the
pharmacome. Structural similarities between the drug compounds are computed
by external tools and the results are incorporated in the pharmacome. 3D struc-
tures for the interacting protein targets for major neurodegenerative disorders are
manually selected, their possible pockets are detected, similarities between their
pocket geometries are calculated and the results are incorporated in the HBP. Re-
sults of classifier models built for discriminating neurodegenerative disease drugs
and GPCRs antagonists are also saved in the form of probabilities that indicate the
likelihood of compounds being similar to NDD drugs or being similar to antagonist
ligands for a specific class of targets. Currently, the ”Pharmacome Tools” [38],
an analysis tool developed as a Cytoscape plugin specifically for the drug-target
networks obtained from the HBP, allows us to filter large networks for highly spe-
cific sub-networks and make predictions of new associations between a set of drugs
and protein targets. This tool can also filter the network for polypharmacological
protein targets, or select a set of highly specific protein targets in the network
context for virtual screening.
Keeping the grand vision of the HBP pharmacome in mind, the following list
presents the work done within the current HBP pharmacome. Some of the work
has been published and some of the results are ready to be published.
• In the predictions layer of the HBP, machine learning-based classifier models
were built on the available drug data for NDD disorders and GPCR antag-
onists. The methodology and initial results have been published in [39] for
classifying NDD drugs and interesting findings for GPCR antagonists clas-
sifier are ready to publish.
• An application note about ”Pharmacome Tools” to filter large drug-protein
network and predict new drug-protein associations has been submitted re-
cently [38].
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• In the simulation layer, a framework for the deployment of docking-MD work-
flows has been successfully established [40] which has been used to execute
virtual screening experiments.
• A methodology to increase positive hits selection from virtual screening by
molecular docking is published in [41].
• New multi-target drugs are identified by executing MD simulations on a set
of multiple targets and the results are ready to publish.
1.7 Unique Features of The Human Brain Phar-
macome
The HBP pharmacome is a comprehensive knowledge base resource that brings
together existing data from a wide variety of public resources and incorporates new
data computed from the data after curation. It is unique in that the drug-target
data is manually curated for major NDD disorders. Furthermore, an automated
curation pipeline and an automated update mechanism will be integrated in the
future that will allow efficiently extending the pharmacome by applying mining
strategies. Currently, it includes drug target networks that are analyzed with
analysis, and subsequent predictions can be made using tools specifically devel-
oped for the HBP pharmacome. The HPB pharmacome allows rapid selection,
prioritization and analysis of drug-target combinations, providing highly focused
data for further in-silico pharmacology studies that includes virtual screening by
docking, binding pose selection, high-throughput molecular dynamics simulations
and molecular mechanics-based free energy calculations. For supporting integra-
tive systems approaches, phenotypic data from phenomic database and pathways
from pathways databases are linked to the drug targets in the pharmacome. Data
obtained from the brain interactome, an ongoing PhD project, will also be inte-
grated in the future.
1.8 Related Work and Limitations of Current
Information Sources
There exist several knowledge base resources that integrate data about human
diseases in general or that specialize in a few individual disorders. Moreover, the
integrated data in specialized resources is very limited in dimensionality. The
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following is a list of some specialized resources with a brief summary about each
resource.
• SMIRDB. The Stanley Medical Research Institute online database [42] is
a genomic based database that contains fully annotated clinical metadata
and gene expression patterns. This database allows for developing an under-
standing of the genetic effects of human brain disease particularly bipolar,
schizophrenia, and depression but not all NDDs. Therefore, the main fo-
cus of SMIRDB lies mainly on gene expression data for selected biopolar
disorders.
• INDD. The Integrative Neurodegenerative Disease Database [43] is devel-
oped at the University of Pennsylvania (Penn) by converting single disease
focused databases comprised from individual clinical research groups at Penn
to a new integrated database. The database is intended to be used for com-
parative studies on major NDD disorders. The INDD has been designed to
integrate clinical data about Alzheimer’s disease, Parkinson’s diseases, Fron-
totemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis from the
respective clinical databases that exist in different research groups.
• DND. A Database of Neurodegenerative Diseases [44] includes very limited
data sets and exemplifies other specialized resources that collect very specific
datasets. The current version of the database provides links to 728 abstracts,
203 genes/proteins and 137 drugs.
• NeuoDNet. NeuroDNet [45] is a platform for constructing and analyzing
disease specific genetic networks and boolean networks for 12 NDD disorders,
generated from signaling molecules and protein-protein interactions. This
database is used for understanding the disease mechanism at network level.
The disease networks are based on the human genome data with protein
coding genes linked to more than 300 genes reported in clinical studies of
neurodegenerative diseases.
• Neurocarta. It is a recently developed database resource [46] that consoli-
dates information about genotype to phenotype associations across multiple
resources to explore gene-disease associations. Neurocarta focuses mainly
on the genetic basis of neurodevelopmental disorders that contain manu-
ally curated information on neurodevelopmental disorders. To understand
the genetic functions in the context of diseases, Neurocarta aggregates data
from multiple disease gene resources.
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• Other specialized resources. Some specialized databases, such as AlzGene or
PDGene, focus on data subsets that contain highly specific knowledge about
certain diseases. These databases are inherently incomplete with regards
to representing knowledge about other neurodegenerative diseases. Generic
databases such PharmGKB [47], Therapeutic Target Database (TTD) [48]
or Comparative Toxicogenomic Database (CTD) [49] that contain general
data have the advantage of retrieving data about any particular disease, but
there is a need of substantial amount of efforts for curation. A list of some
specialized database resources is compiled in Table 1.1.
Table 1.1: List of databases that collect very specific datasets, and their
indication areas.
Database Indication
AlzGene [50] Alzeheimer’s disease
AlzPathway [51] Alzheimer’s disease
PDGene [52] Parkinson’s disease
MSGene [53] Multiple Sclerosis
HD Research Crossroads DB [54] Huntington’s disease
ALSoD [55] Amytrophic Lateral Sclerosis
As seen above, there exist several resources that make the required data available
but are disintegrated and not completely overlapping. To address this, the HBP
focuses on aggregating and curating the knowledge around all disorders concerning
the brain with a sub speciality for major neurodegenerative disorders. The HBP
provides the opportunities at a single place to allow for a) efficient retrieval of the
focused data, b) construction of computable models and speculation of hypotheses
on top of it, and c) the efficient analysis of the underlying data for specific research
questions.
1.9 Utilities of the Human Brain Pharmacome
The HBP captures diverse knowledge about human brain pharmacology for the
purpose of allowing in-silico systems pharmacology approaches towards under-
standing of the biochemical interactions within the context of brain disorders.
It provides multi-scale computable biological and network models comprised of
biomolecular interactions in the disease conditions. The data in the HBP is tightly
integrated that represents the relevant knowledge for efficient retrieval. The in-
tegrated data and information is used to derive knowledge from computations
that enables molecular simulations on top of the HBP knowledge base. From our
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perspective, we envision a variety of possible integrative systems pharmacology
approaches that could be adapted using the HBP pharmacome. From the relevant
biological and chemical knowledge it offers a framework to support competitive
intelligence and decision making.
Figure 1.2 outlines the different usage scenarios that come from using the HBP in
different perspectives. This outline represents some of the major usage areas of
the HBP that include, for example, pharmaceutical industries by integrating the
HBP pharmacome in an existing semantic framework based on RDF/triple store,
chemoinformaticians that can take the advantage of simulations for activity/AD-
METOX predictions, and marketing for the integration of patent information in
the context of network pharmacology. Studying integrative systems approaches
that combines various tools and technologies in the area of systems pharmacol-
ogy is one of the main objectives presented in this research work. The systems
pharmacology approach is built up on the underlying network models presented
in the HBP that consists of biomolecular interaction networks. The network and
classifier models are used to identify multi-target drugs and design target class
specific or disease area specific focused libraries of compounds from large chemical
databases. The drug-target networks in the HBP are analyzed with the help of
tools develop specifically for the HBP to guide structure-based and ligand-based
design that facilitates running compute extensive simulations. The HBP can be
efficiently utilized to elucidate the drugs mechanism of actions at molecular and
pathway level to facilitate the design of new drug candidates and repositioning of
existing drugs.
1.10 Contribution of the Thesis Work
The research contained in this thesis contributes the following major aspects to
the HBP:
• Human Brain Pharmacome design and foundation development
– Database schema design for structured storage of the HBP data
– Data collection, integration and curation
• Usage of the HBP pharmacome for drug-target networks analyses
• Systems pharmacology approaches towards drugs properties prediction
– Prediction of NDD from non-NDD drugs
Chapter 1. Introduction and Motivation 12
Figure 1.2: Integrative systems approaches towards brain pharmacology by
utilizing the HBP as a central knowlege base.
– Prediction of GPCR antagonists from non-GPCR anotagonists
• Approaches towards toxicological targets prediction
• In-silico pharmacology approaches towards targeted polypharmacology
– Exploring polypharmacology by binding site similarity
– Exploring polypharmacology by chemical similarity
• Running compute intensive simulations to identify novel and re-purposing
drug candidates
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1.11 Outline of the Thesis
Going along the complete vision of the HBP that is depicted in this chapter, an
outline of the integrative systems approaches towards brain pharmacology and
polypharmacology as described in various chapters of this thesis, is given below.
Chapter 2 focuses on the HBP data layer and provides an overview of the data
sources, the data collection and retrieval process as well as curation and the design
of a relational database schema to efficiently store and manage the HBP pharma-
come.
Chapter 3 provides applications of network pharmacology within the HBP pharma-
come by presenting examples in drug-target networks analyses and network-based
predictions. This chapters also gives an overview of the customized pharmacome
tools develop for the drug-target networks within the HBP pharmacome.
Chapter 4 and 5 deal with the prediction layer of the HBP from another perspec-
tive by providing application scenarios in designing classifier models specific for
indication areas or specific target classes. Examples are also provided that have
the potential applications in the area of drug re-purposing.
Chapter 6 and 7 represent the simulation layer of the HBP pharmacome. In these
chapters, integrative approaches guiding towards both structure-based and ligand-
based design methods are exploited to study targeted polypharmacology. The
input from the prediction layer is taken forward towards the simulation layer by
executing successful deployment of docking-MD workflows to identify multi-target
drugs.
The outcome from the predictions and simulations is verified at each step to obtain
reliable results. The new findings are taken forward for experimental validations.
Finally, Chapter 8 gives an overall conclusions and future perspectives of our
integrative systems approaches towards brain pharmacology.

Chapter 2
Data Collection, Curation and
Pharmacome Design
2.1 Introduction
The HBP is a comprehensive knowledge base that collects and represent the knowl-
edge around the human brain disorders and their treatments. It contains a series
of chemical and biological networks that represent a scientific understanding of
the drugs, their molecular targets, protein-protein relationships, drug-drug rela-
tionships, and drug-protein interactions that occur in the brain. Data for the
HBP pharmacome is collected from various knowledge base resources that are
publicly available. These resources are not focused on specific diseases, instead
they offer a specific type of knowledge for many diseases. Currently, there is no
single, uniform and standardized resource available that can provide complete and
comprehensive knowledge concerning the brain and neurodegenerative disorders
at one place. There exist a few specialized genomic databases such as SMRID [42]
that provides a comprehensive web-based system for understanding the genetic
effects of human brain diseases. Some specialized resources collect genome wide
association studies in a single specific disease such as AlzGene [50] for Alzheimer’s
Disease and PDGene [52] for Parkinson’s Disease. Several other attempts have
been made to develop integrated neurodegenerative disease databases [44], [43]
and several commercial databases that are either focusing on specific topics or are
not freely accessible [56]. Another issue is the dispersed pieces of data present
in heterogenous resources that are publicly available. In a recent study concern-
ing commercial and public bioactivity databases [57] it was found that each data
source contains unique data that is the result of citing different scientific articles.
Integrating data from various data sources is useful because there is no complete
15
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overlap in their underlying data. Furthermore, different databases focus on either
data subsets or collect a large amount of general data.
This chapter focuses mainly on data aggregation from widely used publicly avail-
able database resources. The data is annotated (e.g. addition of structural data)
that can be extended later with addition of new knowledge. Manual data curation
is performed and a database schema is designed for efficient data storage and han-
dling, that will enable easy retrieval of the required data. Descriptions about all
of the individual database resources are provided, that are integrated in the HBP.
The major entities of the HBP pharmacome are described. An illustration of the
HBP schema design is also presented in this chapter. At the end, an overview of a
general workflow is presented that highlights the major components and analysis
modules of the research work that leverage on the HBP.
2.2 Data Collection
The data for the HBP as collected from various knowledge resources are described
in the following sections. There exist many sources of publicly available knowledge
bases that contain information about drug-targets interactions. The knowledge
base resources described below are used to extract information about drugs and
their targets. These resources are selected on the basis of the triple-store informa-
tion integrated in their databases, specifically the connected information about a
drug, its actual or potential use in a specified disease, and its interacting protein
targets. Moreover, various other knowledge base resources are referring to and
integrating the information from these databases. A brief description about each
knowledge base resource is given below.
2.2.1 MeSH Brain Diseases
A list of all brain disorders, diseases and disease subtypes, which have pathological
conditions affecting the brain are present in the MeSH [58] database. These terms
can be used as query words to search other publicly available knowledge base
resources. The disease list is comprised of more than 270 brain disorders, disease
stages and/or subtypes as shown in Table 3.1.
2.2.2 DrugBank
DrugBank [59] is a database of drugs annotated richly with the relevant informa-
tion concerning the compounds and their targets. Its first version was released in
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Table 2.1: List of some MeSH disease terms and disease subtypes collected
for all disorders in the human brain.
MeSH Disease Term MeSH Disease Term
Epilepsia Partialis Continua Alzheimer Disease, Peripheral
sensory- neuropathies
Epilepsies, Myoclonic Alzheimer’s Disease
Epilepsies, Partial Alzheimer’s Disease, Dementia
Epilepsy Amyotrophic Lateral Sclerosis
Epilepsy, Absence Anxiety
Epilepsy, Benign Neonatal Anxiety disorder, Chemotherapy-
Induced Emesis, Dyspepsia
Epilepsy, Complex Partial Major- Depressive Disorder
Epilepsy, Generalized Anxiety Disorders, Depression
Epilepsy, Post-Traumatic Anxiety or Panic Attacks
Epilepsy, Reflex Attention-Deficit/Hyperactivity
Disorder
Epilepsy, Rolandic Attention-Deficit/Hyperactivity
Disorder, Sleep Disorders
Epilepsy, Temporal Lobe Multiple Sclerosis
Epilepsy, Tonic-Clonic Multiple Sclerosis, Chronic Progres-
sive
Epileptic encephalopathy Multiple Sclerosis, Relapsing-
Remitting
Parkinsons Disease Multiple System Atrophy
Parkinsons Disease 6, Autosomal
Recessive Early-Onset
Irritable Bowel Syndrome (IBS)
Parkinson disease, juvenile, autoso-
mal recessive
Schizophrenia, Anxiety and Demen-
tia
Parkinson Disease, Secondary ....
Parkinsonian Disorders ....
Parkinson’s Disease Psychosis ....
Restless legs syndrome, Parkinson’s
disease
....
2006 and has gradually improved with subsequent addition of information. The
current version of DrugBank contains approximately 150 data fields for each drug.
It is widely used in the field of pharmaceutical research. There are 1424 FDA
approved small molecule drugs and 5210 experimental drugs that are interacting
with 4326 unique drug targets in version 3.0 of the DrugBank database. This
version (accessed in early 2011) was used to extract data for all brain related dis-
eases. The data include the drug names, their interacting biomolecular targets
(e.g. proteins or enzymes) and their pharmacological mode of action.
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2.2.3 Comparative Toxicogenomic Database
The Comparative Toxicogenomic Database (CTD) [49] is another useful resource
of drugs, therapeutic chemicals and target genes involved in human diseases. Its
contents include manually curated and literature derived drug-target interactions.
Like DrugBank, this database is also cross-referenced by various other knowledge
bases that integrate its curated information into their products. In addition to the
curated drug-target interactions, a significant number of drug-target associations
are derived by inference and provided to the user. Thus, this database also contains
inferred associations between chemicals and genes as well as between chemicals
and diseases. The CTD database (accessed in early 2011) was used to extract
data regarding brain drugs. As of 2011, it contained over 240,300 interactions
between 5,931 chemicals and more than 17,000 target genes accounting for more
than 3,800 diseases. Only the curated data was extracted and the inference based
derived interactions were excluded.
2.2.4 Therapeutic Target Database
As its name suggests, Therapeutic Target Database (TTD) [48] is a useful resource
specializing in therapeutic drug targets. The TTD database provides information
about therapeutic targets that are mainly proteins and enzymes targets involved
in various diseases. It also includes the interacting drugs and their corresponding
indications. Both the targets and their drugs are classified as either approved
by FDA or those studied in the ongoing clinical trails. TTD database includes
348 FDA approved targets, 292 clinical trail targets and more than 1200 research
targets (that are not yet approved therapeutic targets) for all known human dis-
eases. Likewise, there are 1514 FDA approved drugs and 1212 clinical trail drugs
that are investigated at various clinical phases I–IV. There are also more than
10,000 preclinical and experimental drugs present in TTD database. The disease
annotations are provided separately for both drugs and therapeutic targets in this
database. The TTD database (accessed in early 2011) was used to extract data
concerning brain drugs and their targets.
2.2.5 EMBL-STITCH Database
The STITCH database [60] from the European Molecular Biology Laboratory
(EMBL) is another drug-target interaction network database for small molecules
and proteins. The interactions present in the STITCH database are integrated
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from more than 20 databases, including DrugBank and CTD, and from the lit-
erature. The interactions between small molecules and protein targets are scored
based on the experimental evidences, manually annotated data and literature de-
rived information. There are about 500,000 chemicals in total, which are interact-
ing with more than 27,000 human proteins in this database. Interactions present
only in human were considered. The interactions are scored in the range from
1 to 999. The higher the score, the higher is the probability that represents the
strength of the pharmacological interaction of a chemical with a protein. Ver-
sion 3.0 of STITCH database (accessed in early 2012) was used to extract the
drug-target interactions for all brain drugs There are more than 500 brain related
chemicals/drugs in this database that have, on the average, interactions with more
than 2000 human proteins.
2.2.6 Activity, Side Effects and Pathways Databases
Apart from the source databases that contain drug-target interactions, there are
other specialized databases that were used to annotate the drugs data present in
the brain pharmacome. These databases are briefly described in Table 2.2.
2.3 Major Entities and Features Extracted from
Source Databases
There are three major entities which are extracted from the above mentioned
source databases. These entities are primarily drugs, their targets and the diseases.
The drugs and targets are further categorized subsequently into approved, devel-
opmental or experimental classes in the context of one or more brain diseases. For
each individual entity, all relevant features are extracted that are possibly present
in the source databases and additional new features are calculated from external
computations. The features or attributes are associated to individual entities that
have predefined relationships and are backed up by evidences.
2.4 Data Curation
The pharmacome database is manually curated for the drugs involved in major
neurodegenerative disorders (NDD). For each drug, its indication area, its target
proteins, its corresponding references to the primary articles or patent documents
are checked and merged (if the same drug is present in more than one databases,
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Table 2.2: List of databases with brief descriptions that were used to extract
activities, side-effects and pathways data.
Database Name Description
ChEMBL [61] This database contains millions of small drug-like
molecules, their 2D structures, calculated properties and
bioactivity values. It is maintained by European Bioin-
formatics Institute (EBI).
BindingDB [62] This database contains binding affinity data for drug-
like molecules against proteins that are considered to be
drug targets. BindingDB is an academic project sup-
ported by the NIH.
PDSP KiDB [63] This database contains Ki or affinity values for a large
number of drugs and drug candidates for a wide range of
targets, including receptors, enzymes, ion channels and
transporters.
KEGG [64] This database resource contains pathways that integrate
genomic, chemical and systematic functional informa-
tion. KEGG pathways are graphical representations of
cellular process for the higher order functions of genes.
SIDER [65] This database is a resource for side effects information
of approved drugs. The information about side effects
is extracted from public documents and drug labels.
but has additional data or references in the respective database). Similarly, ref-
erences to the source databases and referenced documents are also checked for
correctness concerning individual drugs, targets and drug-target associations. If
the indication area is not related to any NDD disorder, it is excluded from the
NDD database. When the data is collected from various source databases by
using scripts or Java based XML parsers, the results are carefully evaluated for
correctness and completeness. It is made sure that data for all FDA approved
drugs related to NDD disorders are collected. The redundant data resulting from
overlapping entries present in more than one data sources are unified and their cor-
responding identifiers and references are stored. Similarly, general chemical terms
or terms referring to therapeutic classes such as ”plan extracts”, ”xanthine deriva-
tives”, ”choline-esterase inhibitors” are excluded during the curation, because such
terms refer to more than one chemical entities that could not be uniquely identified
in the database.
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2.5 Pharmacome Schema Design
Two separate schemas are designed for the brain pharmacome to store the data
relating to all general brain disorders and NDD disorders (i.e. Alzheimer’s disease,
Parkinson’s disease, Epilepsy and Multiple Sclerosis) in particular. Data concern-
ing all brain disorders are stored in the Human Brain Pharmacome, while the data
concerning major NDD disorders are stored in the Neurodegenerative Disorders
Pharmacome (NDP).
2.5.1 Human Brain Pharmacome Schema
The HBP pharmacome is stored in a relational database management system run-
ning MySQL. The schema for the HBP database (Figure 2.1 is designed for efficient
storage and retrieval of the drug-targets interactions and their corresponding at-
tributes or features.
Figure 2.1: The HBP pharmacome schema representing relationships between
major entities (i.e drugs and their protein-targets that are extracted from various
knowledge bases relevant for brain diseases).
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2.5.1.1 Major Entity Classes
There are three major entity classes in the HBP, which are briefly described as
the following:
1. A MeSH disease term indicating a brain disorder or disease sub-type as
shown in Table 3.1 in non-normalized form.
2. A drug or therapeutic compound interacting with a human gene/protein
target in a brain disorder indication area. The drugs are referred to by
their generic names as the brand/trade names or CAS numbers are not
always present for each drug in all of the source databases. Therefore, a
drug is uniquely identified by its generic name or the active pharmaceutical
ingredient.
3. A gene or its protein product that interacts with a brain drug or compound.
An official gene symbol adapted from HUGO [66] gene nomenclature is used
to refer to a target gene or their protein products. The unique HGNC gene
symbols for the target genes are also mapped to their corresponding UniProt
[67] accession number, Entrez gene-id or ENSEMBL protein-id.
For each active compound and target record, the local identifiers are also stored
in their respective database tables. Each drug or compounds are distinguished
by their drug groups that indicates their current status as an approved or a de-
velopmental drug that is in clinical trails. Drugs that are withdrawn from the
market or discontinued are separated from the approved and experimental drugs.
Similarly, protein targets are also distinguished according to their status as a suc-
cessful therapeutic targets or as a clinical trail targets. Chemical structures for
drugs and compounds, as well as protein crystal structures for target proteins, are
also retrieved from the Protein Data Bank (PDB) [68] when they are available.
Drugs are annotated with their pharmacological mechanism of action (MOA) or
direct interaction type (e.g. increase or decrease of activity) with a protein target.
References are also recorded for drugs, target proteins or drug-target interactions
when available in the form of Pubmed IDs or patent document IDs.
2.5.2 NDP Pharmacome Schema
A separate database schema is used for storing all drug related data that are in-
volved in four neurodenerative diseases. This schema is similar to the schema of
HBP but is manually curated for Alzheimers Disease (AD), Parkinsons Disease
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(PD), Epilepsy/Seizures and Multiple Sclerosis (MS). All FDA approved, devel-
opmental and experimental drugs, plus therapeutic chemicals, that are used in
NDD indication areas are stored in NDP pharmacome, the schema is shown in
Figure 2.2. The major entity classes in the NDP pharmacome are the same as
described for the HBP pharmacome.
Figure 2.2: NDP pharmacome schema that shows the relationships between
the drugs and their targets involved in major neurodegenerative disorders.
2.5.2.1 Collection of Compound Structures
Molecular structures of compounds are obtained from DrugBank and TTD databases.
If a structure for a compound is not available in these databases, it is searched
and obtained from STITCH database. The structures are saved in the form of
SMILES strings in the pharmacome.
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2.5.2.2 Annotation with Acitivity and Computed Features
The data within the NDP pharmacome is further annotated with activity data,
side-effect data and pathway data from specialized databases. Activity data is
extracted for all NDD drugs from ChEMBL, KIDB and BindingDB databases.
Side effects are retrieved from the SIDER database, and pathways are retrieved
from the KEGG database, by focusing on pathways involving drugs and diseases
in human (Figure 2.3).
Drug-drug chemical structures similarities and protein-protein binding site sim-
ilarities are also computed by using external software tools and the results are
imported into the NDP pharmacome as drug and target features. Details of drug-
drug and protein-protein binding site similarities are presented in the chapter
”Drug Target Networks Analysis”.
Figure 2.3: NDP pharmacome where activity data for drug-target inter-
actions, pathways, side effects and calculated structural similarity values are
stored.
Chapter 2. Data Collection, Curation and Pharmacome Design 25
2.6 HBP Representation as RDF
Information in the HBP pharmacome is structured in the form of an RDBMS
storage and is being converted to RDF format (a common representation format
for knowledge that supports its modeling using graphs). RDF format will represent
the HBP data in triples, whose components can be traced back to their original
sources and will make the addition and updating of new knowledge very easy. The
RDF models will allow the easy integration of heterogeneous data present in the
HBP pharmacome and provide a framework for future extension and to allow the
pharmacome’s integration into other existing semantic frameworks.
2.7 Statistics for the Complete HBP
1. >3,500 Drugs and active compounds.
2. >500 Brain disorders and/or disease subtypes.
3. 14,000 Interacting protein targets.
2.8 Statistics for the Complete NDD-focused HBP
1. 700 Drugs (approved drugs, in clinical trials, and discontinued drugs)
648 Compounds with chemical structures.
2. 5,600 Protein targets for 4 major NDD disorders.
∼2,000 Protein targets with 3D structures.
7,255 Unique genes involved in protein-protein interactions.
482 Identified successful/therapeutic drug targets.
196 Identified clinical trial targets.
487 Identified research targets.
1,956 Targets with marker and mechanisms in NDDs.
3. ∼23,000 Target pair-wise binding site similarities extracted from ∼2 million
pairs of similarity calculations.
4. 3,046 Drug pair-wise chemical similarities.
Chapter 2. Data Collection, Curation and Pharmacome Design 26
2.9 Conclusions
Often there is no stand alone database publicly available that contains all the re-
quired resources regarding a specific area of interest at a single place. It is there-
fore, necessary to combine multiple resources to achieve the required data that is
as complete and as comprehensive as possible. The extent of data completeness
can be obtained by bringing together dispersed pieces of relevant data scattered
in multiple heterogenous resources. An obvious advantage of collecting data from
heterogenous resources about a common topic of interest is the availability of the
data to a possible extent in a predefined and well formed structure enabling effi-
cient reuse of the data later on. A framework for integration of data from multiple
data sources is thus very necessary. Therefore, designing an efficient schema for
the database plays a vital role, because new and additionally computed data such
as chemical similarity and binding site similarity data can be easily integrated.
The knowledge represented in the HBP knowledge base spans a multiscale range
of resolutions - from systems biology to atomistic information. This multiscale
resolution of data will allow us to use the data in several ways that include the
guidance of both ligand-based and structure-based design for the rapid qualifica-
tion of novel chemical entities and reuse of existing drugs in other indications. One
of the main goals of developing the HBP knowledge base in this research work, is
to have a pharmacology knowledge base that enables the exploration of integra-
tive systems approaches towards brain pharmacology and polypharmacology. An
automated update mechanism is very important to frequently update the HBP
with new knowledge that arrives in the subject domain.
Chapter 3
Drug Target Networks Analysis
3.1 Introduction
There has been tremendous success in drug discovery and the use of new thera-
peutic agents during the past few decades [69]. However, in the recent years, the
number of new drug approvals has decreased [70]. This lack of success and the
decline in new drugs suggests limitations in our understanding of human phar-
macology [71]. Moreover, its not always clear why some drugs work successfully
while other drugs produce adverse side effects after their extensive use [72]. It is
unclear because both the successful ones and those leading to adverse effects have
apparently similar properties. To understand the beneficial and adverse effects of
drugs, analytical methods such as integrative systems biology and network-based
approaches are useful. Using network pharmacology approaches can not only help
understanding existing drug-target relationships, but also find new applications
for existing drugs [73]. Understanding drug-target networks can also help pre-
dict polypharmacological profiles of drugs and predict side effects by discovering
off-targets for existing drugs [74], [75].
Network pharmacology is being considered as an important new paradigm in drug
discovery [76]. Understanding polypharmacology in the light of integrated network
biology enables the expansion of available space of druggable targets [77]. How-
ever, there are considerable challenges coming in the rational design of drugs with
polypharmacology. For example, how to avoid unwanted polypharmacology [78].
While current methods of uncovering the complex relationships between the drugs
and their targets have failed, there is a need for the development of new meth-
ods to validate the polypharmacological properties of drugs and their effects [79].
Network pharmacology is one of the new tools that could help develop new chem-
ical entities and treatments by relating the drug-target interactions with patients
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phenotypic data drug treatments [80].
Graphs and networks concepts that play important roles in a wide variety of disci-
plines, are also widely used in the field of chemical and biological informatics [81].
With the availability of high-throughput assays, computational tools, and network
analysis through graph theory, its currently possible to analyze large-scale biologi-
cal networks (e.g. protein-protein interaction networks [82]). The large amount of
data that is coming out of genome-wide gene expression profiles, protein-protein
and protein-drug interactions generate enormous complexity if their interrelation-
ships are studied [83]. Network-based approaches are used in many steps of the
drug-discovery pipeline that help to facilitate visualization, interpretation and
analysis of the available heterogeneous data for understanding the molecular basis
of diseases [84], [85], [86].
Even with increasing popularity of the network-based approaches in the drug dis-
covery pipeline, there is, however, a limitation on the availability and completeness
of the drug-protein and protein-protein interaction data. The interaction data that
is available is far from complete and a portion of the available data is biased to-
ward a certain area of interest [87]. In the context of networks, a complete data set
would include all experimental data for all biological interactions between protein-
protein and protein-drugs when they are physically possible. Inconsistency may
arise in networks with incomplete data that would effect the underlying network
models. Therefore, care should be taken when deriving conclusions from analyzing
such data. In spite of the complex and integrated heterogeneous data collected
from various sources, the topology of drug-target interaction networks implicitly
depends on data completeness of the drug properties and target families [88].
3.1.1 Targeted Networks Analysis
Adapting systems pharmacology approaches to study the complex associations
between the drugs and targets at a network level will not only help understand
the underlying complexities, but will also facilitate the discovery of new and inter-
esting relationships. These new insights should help reveal a drug’s mechanisms
of action and off-target effects, and thus improve drug discovery for complex dis-
eases [89]. To maximize the potential advantages of network-based approaches,
it is essential to have a systems-level perspective of a disease. The systems-level
perspective that includes interactions and their effects at the molecular-level will
help understand the physiological function of the system [90]. Once the network
level view representing a complete system is generated by the accumulation of
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all experimentally available interaction data for drugs and their targets, the com-
plexity of the network will also increase. Therefore, dealing with large amount
of interaction data to identify patterns, the requirements for new analytical and
visualization tools become higher [91].
This chapter focuses mainly on the creation, visualization and analysis of a large
network describing drug-targets associations involved in neurodegenerative dis-
eases. This network is a part of a larger network entitled as the Human Brain
Pharmacome (HBP). By focusing on major NDD disorders, the HBP is filtered to
create the specialized NDD pharmacome (NDP). Different sub-networks (e.g drug-
drug similarity network, protein-protein pocket similarity network) are generated
from the complex NDD network and analyzed for the perspective of polypharma-
cology. Description about input data preparation, networks creation and analyses
are reported. Network-based predictions of secondary targets for existing drugs
are made. Network-based clustering of drugs are evaluated for the identification
of polypharmacological scaffolds. Functionalities of the Pharmacome tools are
described, which is a Cytoscape plugin developed specifically for the analysis of
HBP drug-target networks. With the help of Pharmacome tools, targets with
polypharmacological profiles are identified and selected for virtual screening.
3.2 Methods and Material
In order to create and analyze drug-target networks, a series of input data prepa-
ration steps are performed. The input data is prepared using various tools and
methodologies. The following is a list of software tools that are used in the creation
and analysis of drug-target networks:
a Molecular Operating Environment (MOE [92]): For molecule 3D structure
generation and similarity calculation.
b SMAP software package [93], [94]: For pocket similarity calculation.
c Cytoscape version 2.8.2 [95]: For network visualization.
[i] ClusterMaker plugin for Cytoscape [96], [97]: For clustering drug-
target network.
[ii] Pharmacome Tools plugin for Cytoscape: For new interactions pre-
diction, polypharmacological filtering of drugs, protein targets and molecular
scaffolds.
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3.2.1 Input Data Preparation
Data for drugs and their targets involved in neurodegenerative disorders are re-
trieved from the HBP database by querying the database for specified attributes
(e.g. disease and status attributes for all NDD drugs). The HBP database is de-
scribed in detail in the chapter Data collection, Curation and Pharmacome Schema
Design. The output of the queries is exported to comma or tab-separated format-
ted files that contain the generic drug names, their associated NDD indications,
their current status and all of their interacting protein targets.
For four major NDD disorders, there are approximately 700 compounds that in-
cludes approved, clinical trial and discontinued drugs, and more than 5600 protein
targets. The network underlying the NDD pharmacome has the following three
different classifications for entities:
1. Approved, developmental and discontinued drugs with therapeutic roles in
NDDs
2. Disease indication area
3. Disease associated human protein targets encoded by gene symbols
The interactions between drugs and their targets involved in NDD indications
lead to a total of 30,211 associations, resulting in an average of ∼40 targets that
interact with a single drug. In fact, about half of the NDD drugs interact with 40
to 60 protein targets as shown in Figure 3.1.
Figure 3.1: NDD drug-target interaction statistics for the drugs present in
NDD pharmacome.
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Drug-target interaction data is prepared initially as a simple interaction format
(SIF), which is one of the standard formats required as an input for networks
generation. In addition to the drug-target interactions present in the network, the
network is extended and populated with externally calculated data. This external
data is the result of similarity calculations between drugs chemical structures and
similarities of the binding sites (i.e. pockets) of the proteins. The drug-drug
similarity and protein-protein binding pocket similarity calculations are described
below.
3.2.2 Drug-Drug Similarity
For all NDD drugs, their structural data is also retrieved from the HBP pharma-
come database. There are approximately 650 drugs with structural data is avail-
able from various databases that include Drugbank [? ], TTD [48] and STITCH
DB [60]. Using the MOE [92] software, the drug structures are prepared by re-
moving salts/counter ions, their 3D coordinates are generated from their 2D SDF
files. Neutral protonation species of molecules are generated and finally molecu-
lar mechanics based energy minimization with MMFF94x (built-in in MOE) force
field is performed. Once the drug structures are prepared, then MACCS struc-
tural keys [98] fingerprints are generated and using SVL [92] scripts, pair-wise
similarities are computed between all drugs. The resulting similarity matrix is
then filtered using a threshold to identify the comounds with highest similarities.
Tanimoto-Coeffiecint (TC), a widely used similarity metric [99] is used for setting
the similarity cut-off value. Similarities between drugs with TC ≥ 0.6 are saved
resulting in a total of 3,046 pair-wise similarities between all NDD drugs within the
HBP. A higher threshold value is selected in order to reduce the number resulting
edges in the similarity network. We did not consider all possible similarity com-
binations (which are more than 200,000) between the drugs to keep the resulting
similarity network smaller and reduce its complexity.
3.2.3 Protein-Protein Binding Pocket Similarity
For all the targets present in the NDD network, that have experimental or the-
oretical structures available, pair-wise binding site similarities are computed. To
compute binding site similarities, structures require some preparation. First, for
all protein targets, their unique identifiers in the form of official gene symbols [66]
are retrieved from the HBP pharmacome database. The corresponding PDB (Pro-
tein Data Bank) [68] identifiers are used to download the 3D structures from the
PDB database as mentioned in Chapter 2. There are approximately 2,000 protein
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targets in the NDD network with available 3D structures: for these targets, in
total, there are more than 9,000 available coordinate files. These structures are
filtered in the following semi-automated manner. For a protein with multiple PDB
structures (e.g from X-ray, NMR, theoretical methods), the one produced using X-
ray crystallography is preferentially picked. If there are multiple X-ray structures,
then the structure with best resolution is selected. If there are no X-ray coordi-
nates available, then the first model in NMR structure bundle is selected. Protein
structures with multiple chains of the individual structures are manually analyzed
with molecular visualization tool Chimera [100]. If the multiple chains are homol-
ogous and the ligand-binding site is not located between multiple chains, then only
a single chain is retained. Once, the structures are selected, all the co-crystalized
bound ligands, cofactors, salts and solvents are removed. The SMAP software
[94] package is used to compute binding site similarities between proteins that is
based on the sequence order-independent profile–profile alignment (SOIPPA) [93]
algorithm. SMAP detects the local binding sites in protein structures and per-
forms similarity comparisons of the protein 3D structural motifs independently of
their sequence order. Binding site similarities are computed for more than ∼2000
proteins, leading to more than two million pair-wise similarity calculations. Once,
the similarity comparisons are completed, the results are filtered for significant
similarities. Significant similarity, as defined in the SMAP algorithm, to exist be-
tween a pair of proteins when the SMAP score is statistically significant at a given
p-value (1.0 x 10−4) threshold and Tanimoto-Coefficient overlap of the two bind-
ing pockets is above a certain threshold (≥ 0.5). From two million comparisons,
approximately 23,000 pairs are filtered that have significant similarities.
A defined pocket (e.g. the one occupied by a co–crystallized ligand) of a protein
was not used for the similarity calculation. Instead, the SMAP was allowed to
compare all possible pockets in a pair of proteins that resulted in a global similarity
score between the proteins. Higher similarities between members of a same target
family (e.g. kinases, carbonic anhydrases etc.) show that the method can detect
similarity in the protein binding pockets and provides a way of validation of the
used method.
3.2.4 Networks Creation
In the drug-target network, the drugs and proteins are the nodes, which are con-
nected by edges. The drugs and proteins nodes within the network are differen-
tiated by their attributes or features associated with them. Similarly, the edges
Chapter 3. Drug Target Networks Analysis 33
connected between the nodes are also distinguished. The edges connecting nodes
are distinguished into three types:
1. an edge between two drugs indicate that their fingerprints are similar.
2. an edge between two protein targets indicate that their 3D binding pockets
are similar, and
3. an edge between a drug and a protein target indicates an experimentally
known interaction that exists between a drug and a protein.
The Cytoscape [101] software environment (version 2.8.2) is used for the creation,
visualization and analyses of drug-target networks. The drug-target interaction
data is comma or tab-separated formatted for importing into Cytoscape. Cy-
toscape assigns unique identifiers to the interacting nodes and connects the nodes
by edges that have interactions specified within the input file. Likewise, edges are
also assigned unique identifiers. When the data for the network is imported, it
resulted in a large drug-target network that comprises of 6,380 nodes and 57,064
edges. After importing the drug-target network, attributes for nodes and edges
are imported from the tab-separated files exported from the HBP database sub-
sequently. Drug and target nodes are distinguished by their attributes. Similarly,
edge types are also distinguished by their attributes describing the interaction
types (see above). Important attributes for nodes and edges are given in the
following subsections.
3.2.4.1 Node Attributes
1. An attribute that classifies a node as a drug or target node if the attribute
value is a string DRUG or GENE.
2. A disease attribute that classifies a drug for its indication area (e.g. attribute
value is the disease name such as Alzheimer’s disease or Epilepsy).
3. A status attribute that classifies a drug for its drug group, which distin-
guishes an approved drug from developmental or withdrawn drugs. The
attribute value could be ”approved”, ”discontinued”, ”Phase I” or so on.
4. A SMILE string is an important attribute for storing a drugs chemical struc-
tural data. The attribute value is a SMILE string. The SMILE attribute is
used to visualize structures for selected drug nodes using CDK toolkit API.
Chapter 3. Drug Target Networks Analysis 34
5. An attribute classifying a target node in a certain pathway. The attribute
value is the name of the pathway in which the gene is involved (e.g KEGG
entity identifier).
6. A protein structure attribute for a target node is assigned if it has a PDB
structure. The attribute values are the PDB ID(s) of the protein.
7. A mode of action (MOA) attribute is given for drug nodes if known.
3.2.4.2 Edge Attributes
1. An edge attribute that defines the interaction types into drug-target inter-
action, drug-drug similarity or target-target binding sites similarity.
2. An edge-score attribute is assigned as the interaction strength for drug-
target interaction. The values are taken from the confidence score given in
the STITCH database.
3. An edge-score attribute that shows the similarity value (Tanimoto Coeffi-
cient) between two drug structures.
4. An edge-score attribute that shows the SMAP similarity score between two
target structures.
3.2.5 Pharmacome Tools Plugin
Cytoscape allows an easy-to-use API for developing plugins for performing specific
analysis tasks over the networks. The ”Pharmacome Tools” Cytoscape plugin
was developed for the analysis and filtering of the NDD drug-target network.
For our complex drug-target network, no specific plugin existed to perform the
required specific tasks over the drug-target network. Therefore, a plugin was
needed for the analyses of this complex network and the Pharmacome Tools plugin
was created. This was developed in Java and can be used directly within Cytoscape
for analyzing complex drug-target network containing different node and edge
types. The CDK Toolkit [102] and MoSS (Molecular Substructure) Mining [103]
are embedded in the plugin for providing molecular structure visualization and
common substructure extraction. The following is a brief description of the major
functionalities available within the Pharmacome Tools plugin:
1. Filtering polypharmacological drugs. Filtering is performed with the user
specified thresholds values. Threshold values are considered for different
edge types in edge score attribute. Filtering is initialized for drug pairs that
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have similarity and interact with targets which also have similarities in the
binding sites.
2. Filtering targets with polypharmacological profiles at a given target proteins
pocket similarity. Threshold values are considered for different edge types in
edge score attribute. Target filtering is initialized for target pairs that have
binding site similarity along with their interacting drugs.
3. Prediction of new targets for existing drugs based on node neighborhood at
the specified threshold values.
4. Extracting common structural scaffold for a set of selected drug nodes with
the help of the MoSS API.
5. Visualization of chemical structures from the SMILE attributes using CDK
toolkit API.
3.2.6 Toxicological Targets Prediction
To find whether a set of targets interacting with the failed or discontinued drugs
is responsible for the drugs toxicity, a set of all interacting targets are retrieved
for both sets of NDD drugs. A machine learning approach with recursive feature
elimination (SVM-RFE) was applied to discriminate for the targets that interact
with approved or discontinued drugs. An interaction matrix was generated that
has the STITCH interaction scores between a drug and its target protein if there
is an interaction present between the drug and its targets. Drug groups are put
in rows and interacting targets are put in columns of this matrix. SVM-RFE will
rank order those targets whose interaction is more common to one of the two drug
groups.
3.3 Results and Discussion
The drug-target network visualizations and analyses are performed within the Cy-
toscape software environment. Figure 3.2 shows the complete and complex NDD
drug-target network. Using Pharmacome Tools, the drug-target network is filtered
and various specific views are generated which are analyzed for polypharmacologi-
cal profiles of drugs or targets. Example of such views are clusters of specific drug
groups or drugs targeting a specific disease.
In the following sections, different drug-target network analyses are performed to
facilitate targeted polypharmacology. Through filtering a set of drugs and targets
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Figure 3.2: The drug-target network. Nodes in red color represent drugs and
those in teal color represent nodes for target proteins. Black lines denote the
edges connecting drugs or targets.
are selected for subsequent in-silico validation of polypharmacology by a virtual
screening workflow that includes molecular docking and molecular dynamics sim-
ulations. The selected targets are also used for virtual screening against a focused
compound library that is designed independently for a specific class of targets or
a specific indication area.
3.3.1 Drug-Drug Similarity Network (Filtered By Indica-
tion Use)
The drug-drug similarity network shows that a large number of NDD drugs have
similar chemical structures as they are connected by edges. Similarities also exist
between drugs used for different NDD indications (e.g. drugs used for Alzheimer’s
disease have similarities to drugs used for Parkinson’s disease or epilepsy). It is
also not surprising that drugs used in one NDD indication area are undergoing
clinical trials in another NDD indication area. Figure 3.3 shows that a large
number of drugs that have therapeutic role in Epilepsy and Seizures have structural
similarities with drugs that are used in Alzheimers disease and Parkinsons disease.
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In this figure drugs used for different indication areas are distinguished by different
colors and are connected by edges when they have structural similarities. This
indicates that similar drugs used in different indications possibly interact with a
common set of targets that are involved in multiple pathophysiological processes
common to different NDD disorders.
Figure 3.3: Drug-drug similarity network filtered by indication use. Color-
coding indicates various NDD indications. Node size denotes the degree of the
node. Edge thickness indicates the degree of chemical structural similarity.
3.3.2 Drug-Drug Similarity Network (Filtered By Drug
Groups)
A network representation for drug groups is shown in Figure 3.4. In this figure,
the FDA approved drugs are shown in red color, the developmental drugs in green
color, and the drugs that are withdrawn or discontinued at various clinical phases
are shown in yellow. It is interesting to note that the discontinued drugs have
structural similarities to the approved or prescription drugs. If the discontinued
and approved drugs have interactions with common target proteins, and also show
structural similarities, then it will be more likely to predict side effects on the basis
of structural similarity and interaction with similar targets. However, a limitation
in this scenario is the lack of availability of side effects data for all drugs. Moreover,
the interaction data is also not complete because the known experimental activities
for both groups of drugs are incomplete. This network can be used for the study of
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toxicity prediction or identification of toxic functional group in the developmental
drugs if they have high similarities to the drugs that have adverse side effects.
Figure 3.4: NDD drug-drug similarity network filtered by drug groups. Color-
coding indicates drug groups. Edges indicate structural similarity between drug
structures.
3.3.3 Network Clustering
Network clustering can be used to understand network architecture [104]. There
are a number of algorithms that can perform network clustering on the basis of var-
ious attributes, but not all clustering algorithms can be applied that require edge
weight attributes. Four of the clustering algorithms available in the Cytoscape
plugin, clusterMaker [105] were used to perform clustering on the drug-target net-
work. The complex NDD drug-target network is a bipartite network that contain
different values for the same edge-score attribute. Values for drug-drug similarities
are the Tanimoto Coefficients that are in the range between 0 and 1, while values
for binding site similarities and confidence scores for interactions have variable
ranges. Therefore, it is difficult to choose a cut-off value for the edge weight to
perform clustering. Different results are achieved by applying different clustering
algorithms. Figure 3.5 shows results of applying different clustering algorithms
on the drug-target network. The Connected Components Clustering resulted in
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a drug-target network that is very densely connected, since only one cluster pro-
duced. The ”Community Clustering (GLay)” resulted in a total of 20 clusters,
with three clusters being very large. The Affinity Propagation Clustering resulted
in more than 200 clusters, which facilitate the isolation of drugs that target a single
protein and proteins that are targeted by a single drug. The ”MCODE Clustering”
algorithm that finds highly interconnected regions in a network produced differ-
ent size clusters that are neither very small as in the case of Affinity Propagation
clustering, nor very large, as in the case of Community Clustering. The resulting
clusters produced by MCODE Clustering isolate sub-networks, which may result
in interesting patterns to be analyzed further. Therefore, this clustering algorithm
should be used to isolate sub-networks that would facilitate the detailed study of
small drug-target networks.
3.3.3.1 Drug-Drug Similarity Networks
Clustering was also performed on drug-drug similarity network that includes only
drug nodes and their similarity edges. The network clustering can isolate clusters
in which the drug nodes have high structural similarities as compared to drugs
in other clusters. In order to observe the results of clusterings on this isolated
drug-drug similarity network, the same clustering algorithms were applied as used
in the drug-target network. Figure 3.6 shows the clustering results using the four
clustering algorithms. The resulting sub-networks contain groups of very similar
drugs that are used for different NDD indications. By specifying the chemical
similarity threshold, variable number of clusters can be obtained that have high,
medium or low structural similarities. One of the advantages of having different
clusters of similar drugs is that one can isolate representative drugs from each clus-
ter to have a diverse set of drugs that can be used as queries against a compound
database in a similarity searching.
3.3.3.2 Target-Target Similarity Network
A sub-network of target proteins that have PDB structures available is isolated
from the main drug-target network. The target proteins are connected when they
have binding site similarities. The nodes within this sub-network are also differ-
entiated by target types (i.e. therapeutic/successful targets, research and clinical
trial targets as classified in the TTD [48] database). A large number of target
proteins, which are either primary or secondary targets of NDD drugs, have sim-
ilar binding pocket geometries. As shown in Figure 3.7, the similarity network is
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(A)
(B) (C)
Figure 3.5: Results of three clustering algorithms applied on the drug-target
network. (A) Community Cluster, (B: Affinity Propagation Clustering, (C):
MCODE Clustering. Drugs are shown in red color and target proteins are
shown in teal color.
densely interconnected that highlights some targets with high degree of connectiv-
ity. When the clustering algorithms mentioned above are applied to this network,
they generate a few clusters that contain many targets having similarities. By
varying level of similarity threshold (i.e. significant SMAP score) as encoded in
the edge score attribute, clusters of targets with high or low similarities can be
isolated. This binding site similarity sub network holds valuable information that
can be utilized for designing highly selective or promiscuous drugs. A sub network
may facilitate designing drugs rationally with desired polypharmacological profiles
that target a group of proteins with similar pockets. Protein-protein physical inter-
actions and knowing their function on the basis of similarity at the pathway level
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(c) C (d) D
Figure 3.6: Drug-drug similarity network clustering. Nodes are colored ac-
cording to disease indications. (A): Community clustering, (B): Connected com-
ponents clustering. (C): Affinity propagation clustering, (D): MCODE cluster-
ing.
will help elucidate the activation or de-activation of pathways that are involved
in complex NDD disorders. Illustrating this idea in the subsequent sections, the
protein similarity network is analyzed in combination with drug-drug similarity
and drug-target interaction networks to identify patterns in the networks that can
be used for the study of targeted polypharmacology.
3.3.4 Functionalities of Pharmacome Tools
3.3.4.1 Filtering Drug-Target Network
The drug-target interaction network is analyzed as a network pharmacology ap-
proach to study polypharmacology. The Pharmacome Tools plugin is used to fil-
ter drugs with polypharmacological profiles, filter the target proteins with similar
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Figure 3.7: Protein-protein binding site similarity network. Node colors repre-
sent the target groups (e.g successful or research targets) and node size denotes
the degree.
binding sites that can be targeted by promiscuous drugs, and predict new drug-
target associations based on drug-drug chemical similarities as well as protein-
protein binding site similarities. The algorithm used in the Pharmacome Tools
plugin uses network neighborhoods identifying sets of drugs and targets with struc-
tural similarities in the presence of their respective drug-target interactions. The
underlying idea is to first isolate drugs and targets that have high similarities
that are extended by exploring the neighborhood of interacting drugs and targets.
Likewise, polypharmacological filtering of target proteins is performed to isolate
target nodes connected by similarity edges and their corresponding edge-related
drug nodes. Subsequently, the resulting neighborhood of such sets of similar drugs
or similar targets is explored for associations at the specified level of interaction
strength. The STITCH confidence score for a drug-target association is taken as
interaction strength. Ideally, protein-ligand binding activity data should be used
as the interaction strength, but the lack of experimental data for most of the
drug-target pairs impose this approximation. The following are some illustrative
examples that demonstrate the use of Pharmacome Tools plugin.
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3.3.4.2 Polypharmacological Filtering of Drugs
Studying the relationships between drugs and their targets at network level can
serve as a useful indication on the polypharmacological behavior of the drugs.
Figure 3.8 shows a view of a sub network that was filtered from the drug-target
network with 6,083 nodes and 57,064 edges. The resulting filtered network contains
only few nodes and edges (277 nodes and 925 edges). Three thresholds were
specified that were used as the similarity cut-offs between drugs and proteins and
confidence scores between a drug and a protein. Setting these three thresholds
resulted in the filtered network as shown in Figure 3.8:
1. A similarity cutoff of TC ≥ 0.75 between drugs,
2. A SMAP similarity threshold ≥ 100 between target proteins and
3. An interaction strength cut-off of≥ 0.90 between a drug and a target protein.
Figure 3.8: Polypharmacological filtering of drug-target network. (Left): The
complete large network with 6083 nodes and 57,064 edges. (Right): The filtered
network with 277 nodes and 925 edges. Filtering is done on the basis of three
cut-off values that can be specified in the Pharmacome Tools.
Two approaches are used for combining the two-step filtering process. The first
approach starts from isolating similar drugs and then explore the neighborhood of
interacting target nodes. Those protein targets are isolated which are connected by
similarity edges. The second approach starts from isolating similar protein targets
and then explore the neighborhood of interacting drug nodes. The difference in
the initial filtering for a set of similar drugs is that the drugs around the similar
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target proteins need not be similar. However, a limitation in the second approach
is the lack of structural data for the target proteins. Therefore, filtering is limited
to the targets that have three-dimensional structural data available in the Protein
Data Bank. The advantages in both filtering approaches are a) narrowing down
the complex and large drug-target network to a smaller sub network that can be
visualized and laid out more clearly than the original bigger network, b) allowing
a more detailed study of targeted polypharmacology on a smaller set of highly
similar drugs interacting with highly similar proteins and c) easing up selection of
drugs or targets with the desired similarity values for virtual screening.
3.3.4.3 Drug Target Interaction Predictions
The systematic approach of predicting new drug-target associations based on drugs
structural or proteins pocket similarities may allow to highlight drugs that have
either polypharmacology or may lead to adverse effects. The Pharmacome Tools
plugin can be used to infer new drug-target associations purely based on similarity.
The new targets predicted for existing drugs would of course need experimental
validation. Although, the drugs that bind to off-targets may introduce negative
effects that could lead to toxicity and other undesired adverse effects [74], they
should be studied for the registered side effects. If no adverse effects are reported
for the drugs, it is more likely the drug will exert its effect through the desired
polypharmacology. The newly predicted associations can be used to discover mode
of action of successful drugs and propose new uses for existing drugs.
The new targets predicted by Pharmacome Tools are not based on the underlying
network topology where associations can be predicted for the near neighbors of the
nodes in the network. The plugin considers only the similarity between drugs and
between the binding sites of their targets. The algorithm in the plugin first detects
a set of drug nodes in the network that are connected by similarity edges with a
user defined similarity threshold. For this set of interconnected similar drugs, all of
the interacting target nodes are obtained that are above a given interaction cut-off.
In the next step, pairs of target proteins are identified that are also interconnected
by similarity edges with a given pocket similarity threshold. Based on the idea of
”similar structure, similar property principle” [106], new edges are created between
the pairs of drugs and target proteins if they are not already connected.
An example network is shown in Figure 3.9 (A) where two types of drug-target
interactions are predicted. Similar to the polypharmacological filtering process
described above, the prediction of new drug-target interactions is also based on
two approaches. The first approach is the prediction of drug-target interactions
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Figure 3.9: An example drug target network. Drug nodes are represented as
rectangles in red color while target nodes are shown as green spheres. (A) Orig-
inal network, (B) Predicted interactions for selected similar drugs interacting
with similar target nodes only. The predicted interactions are shown as dot-
ted lines. (C) Selected similar drugs with all interacting targets and predicted
interactions are shown as dotted lines.
when both drug and target pairs are connected by similarities (Figure 3.9 (B)). The
advantage in the first approach is that it isolates a sub network that includes the
biologically meaningful predictions (since the interacting target nodes also have
similar binding pockets). The new drug-target interactions that are predicted here
are supported by evidences of similarities at both sides. However, a limitation here
is the lack of three-dimensional structural data for the interacting proteins in the
network, because not all protein nodes have structural data available and hence
no pocket similarity results are available for them.
In the second approach, the new predictions are made when only the drug nodes
are connected by edges and their interacting targets need not be connected by
edges (Figure 3.9 (C). The advantage in this approach is that new associations
can be predicted also for those proteins who do not have structural data due to
which no similarities exist between those protein targets. However, a drawback in
this approach will be producing large number of new drug-target associations that
might include redundant or meaningless interactions (if we assume there exists
no pocket similarity between the protein nodes) . But advantage over the first
approach is that the target nodes are not limited to only those with available
structures and more new interactions can be predicted. Redundant interactions
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predictions can be avoided by increasing the thresholds for the drug-drug similarity
and confidence score for the drug-target interactions.
3.3.4.4 Interactions Predictions for NDD Drugs
New drug-target interactions are predicted for NDD drugs present in the NDD
drug-target network. There are total 6,083 nodes that include 724 drugs and 5,666
targets, which are connected by 57,064 drug-target interactions. The Tanimoto-
Coefficient value ranges from 0.6 to 0.98 between the drug nodes, the pocket sim-
ilarity scores ranges from 61 to 1050 between the protein nodes and the STITCH
confidence scores ranges from 50 and 999 between drug and target nodes. Ta-
ble 3.1 shows a number of new interactions predicted at different structural simi-
larity thresholds among the drugs and the number of existing interactions already
reported in STITCH database.
Table 3.1: New drug-target interactions predicted by Pharmacome Tools plu-
gin for the NDD drug-target network. The predicted and existing interactions
are given for various structural similarity thresholds.
Confidence = 0.80 No confidence
Int. pre-
dicted
Int. in
STITCH
TC cut-off Int. pre-
dicted
Int. in
STITCH
TC cut-off
4464 333 TC=0.60 17445 789 TC = 0.60
1284 136 TC=0.70 5090 349 TC = 0.70
888 118 TC=0.75 3221 290 TC = 0.75
559 89 TC=0.80 2048 210 TC = 0.80
289 45 TC=0.85 1091 114 TC = 0.85
The number of interactions that are already reported in the STITCH interaction
database are between 10 to 15% when high confidence score for existing interaction
is considered and a higher similarity threshold is specified. The r number of
predictions can increase further if there are more structural data available for
the targets where binding site similarities data can be added. In this approach,
the Pharmacome Tools algorithm takes into consideration only those targets for
which 3D structures are available and also have significant similarities in protein
binding pockets. On the other hand, the number of reported interactions decreases
(4 to 10%) when no confidence score for the existing interactions is considered.
When only network topology is considered without taking protein binding pockets
similarity into account, the number of possibilities to predict new interactions will
increase further, because the target set is not limited to only those with available
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Figure 3.10: Interaction predictions in a sub-network of approved drugs in-
teracting with approved therapeutic targets only. Target nodes are colored in
teal. Drug nodes are colored according to disease indications, Red: Parkinson’s
disease, Blue: Alzheimers disease, Pink: Epilepsy, Green: Multiple Sclerosis.
Predicted interactions are drawn with a dotted line in pink.
structures. Interesting interactions could be predicted by limiting the drug nodes
to approved drugs that are only interacting with established targets of therapeutic
relevance.
Figure 3.10 shows some of the new interactions predicted for approved drugs that
are used in multiple NDD indications. These interactions are predicted on the
basis of similarity between both drugs and targets. The similarity threshold for
drugs was set to TC ≥ 0.7 and for the targets the SMAP score above 100. As a
way to provide improved predictions based on more rigorous in-silico methods such
as cross-docking and molecular dynamics simulations, a few of these interactions
have been studied, which will be described in detail in a separate chapter. Such
predicted new interactions can be tested experimentally for validation.
3.3.4.5 Polypharmacological Scaffold Detection
Molecular Substructure (MoSS) algorithm is integrated in the Pharmacome Tools
plugin that can help extracting a common molecular substructure present in a set
of drugs acting against multiple targets. The common chemical scaffold can be vi-
sualized over the network with the help of CDK Toolkit. The obvious requirement
is that molecular structures for the drugs are provided.
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Figure 3.11: Polypharmacological scaffold extraction. A: Clusters of drug-
target network as visulaized by community clustering algorithm. B: 2D struc-
tural representations of multiple drugs in one cluster. C: 2D structural represen-
tation of multipe drugs in another cluster. D: Common molecular substructures
detected for drugs shown in B. E: Common molecular substructures detected
for drugs shown in C.
The common molecular scaffold present in the drug structures may reveal the
polypharmacological behavior of those drugs. Exploration of such promiscuous
chemotypes could help guide the design and evaluation of multi-target drugs. A
promiscuous substructure present in a single drug that is active against multi-
ple targets that do not have similarities at the binding site could also show its
polypharmacological behavior, although the drug might bind/interact differently
in a different protein binding site by adapting different conformation. To visualize
common skeletal scaffold in a set of drugs interacting with multiple targets, clus-
tering can be applied over the drug-target network to isolate groups of drugs and
multiple targets. Figure 3.11 shows two examples of polypharmacological scaf-
fold extraction for two sets of drugs selected from two clusters. These drugs are
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clustered and grouped together with their multiple interacting targets by the Com-
munity Clustering algorithm. Molecular substructures that are frequently present
in a set of drugs structures are extracted and visualized (Figure 3.11 D and E).
3.3.4.6 Selection of Targets for Polypharmacology Study
With the help of Pharmacome Tools, important protein targets are selected with
a focus on targeted polypharmacology. As the drug-target network is very large,
including thousands of protein targets and hundreds of established therapeutic
targets, it is a key issue to select a few relevant targets for virtual screening.
Appropriate target selection is one of the first steps in virtual screening prior to
molecular docking and molecular dynamics. To facilitate the study of targeted
polypharmacology, a set of targets is selected on the basis of connectivity in the
drug-target network. The connectivity is presented by binding site similarities and
interaction with approved drugs around these targets that are used in various NDD
indications. Target selection is facilitated by the polypharmacological filtering
algorithm which is one of the useful features of Pharmacome Tools as described
in the previous section.
The rational approach towards polypharmacological target selection includes con-
sideration of binding site similarities and interaction with approved drugs used
in multiple NDD indications. Therefore, the drug-target network is pre-filtered
to include only established targets and those targeted by approved drugs. Fig-
ure 3.12 (A) shows some of the candidate targets that are considered useful for
the study of targeted polypharmacology based on their binding sites similarities
with each other as well interaction with drugs that are used for Alzheimers disease,
Parkinsons disease and epilepsy. Furthermore, these targets also make a visible
cluster in the target-target similarity network, which highlights a higher similarity
between them and similarities to many other target proteins (Figure 3.12 (B)).
Those proteins, which have only X-ray structures are considered. Following is a
list of selected targets for virtual screening:
1. beta-2 Adrenergic receptor (ADRB2)
2. Dopamine D3 receptor (DRD3)
3. Adenosine A2A receptor (ADORA2A)
4. Histamine H1 receptor (HRH1)
5. Chemokine C4 receptor (CXCR4)
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6. Mono-amine Oxidase B (MAOB)
7. Phosphodiesterase 4A (PDE4A)
3.3.5 Toxic Targets Prediciton for Discontinued Drugs
The set of discontinued NDD drugs share a set of common targets that are almost
not interacting with the set of approved drugs used for NDDs. These results shown
in Figure 3.13 demonstrate that most of the discontinued drugs share interactions
with a set of targets. While these interactions are not seen with the set of ap-
proved drugs used in NDD, these observations for the discontinued drugs provide
a possible reason for their toxicity that ultimately lead to their discontinuation.
3.4 Conclusions
A demonstration of the use of HBP for visualization and analysis through in-silico
network pharmacology approaches is presented in this chapter. Using network ap-
proaches enable us to generate a system level view of the specific knowledge that
exists in the HBP knowledge base. Extending the knowledge base to incorporate
additional data further increases the complexity of the underlying networks. It
was observed that even an NDD pharmacome focused part of the HBP resulted
in a large, complex network of drug-target interactions. Such a complex NDD
drug-target network is analyzed from various aspects. Using network algorithms
can reduce the network complexity of drug-target networks. The ”Pharmacome
Tools” plugin is developed to reduce the complex NDD drug-target network by
filtering a set of targets and drugs that are potential candidates for the study of
polypharmacology. The plugin is also able to predict new drug-target associations
that could be investigated for the prediction of off-target effects and the repur-
posing of existing drugs. Functionalities of the Pharmacome Tools plugin were
used to filter the large network, obtain a relevant data set for workflow validation
and to select a highly prioritized set of protein targets for the study of targeted
polypharmacology. A weakness of this approach to select protein targets is that
enough structural data for the protein targets should be available. However, using
the available structural data, a strong point of the approach is that one can still
be able to identify and rationally select a set of protein targets that can be used
in the design of multi-target drugs.
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Figure 3.12: Polypharmacology based selection of targets. A: a sub-network of multiple targets with approved drugs for multiple
NDD indications. Drug nodes are colored by disease indications; anti-epileptic drugs are shown in pink, anti-alzheimer drugs in light
blue and anti-parkinson drugs in brown. B: Protein pocket similarity network highlighting the targets with higher similarities at binding
pockets. Edge-thickness denotes higher binding site similarity between the protein nodes.
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Figure 3.13: Heatmap of drug-target interactions prioritized for discontinued drugs. Drugs sets (approved; above, discontinued; below)
are given in rows and their interacting targets are given in columns. Horizontal dashed line divides the drug groups into known FDA
approved known drugs and discontinued drugs, the arbitrary vertical dashed line highlights the interacting targets common to the set
of discontinued drugs.
Chapter 4
SVM based Classification of
Neurodegenerative Disease Drugs
for Pharmacological Modeling
4.1 Introduction
The enormous complexity of the brain and the poor understanding of neurode-
generative disease mechanism challenges the success rate of drug discovery ef-
forts. These challenges include pharmacokinetic hurdles of therapeutics to reach
the brain and their side effects, impacting drugs development for neurodegener-
ative disorders (NDD) [107]. Another potential complication is the involvement
of multiple targets in a single disease related pathway. Several efforts have been
undertaken to develop targeting strategies that take into the account the complex
pharmacology of brain disorders, including dual the targeting of MAOB and A2A
receptors in Parkinsons disease [108], multi-targeting of amyloidogenesis[109] and
dual inhibition of AChE and serotonin transporter in Alzheimers disease [110].
However, the rational design of ligands acting on multiple targets requires that
such ligands bear certain molecular properties that are represented by molecular
descriptors.
As the descriptor (i.e. feature) space representing these drugs is very large, the
calculation and analysis of all possible descriptors for identifying similar drugs is
computationally expensive. Therefore, machine learning based statistical meth-
ods are well suited to reduce the dimensionality and thus limit the search space.
Learning methods have been widely used in computational chemistry to facilitate
predictions of pharmacokinetic and toxicological properties of chemical agents by
53
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employing a variety of molecular descriptors to characterize structural and physio-
chemical properties of drug molecules [111]. Proper selection of relevant molecular
descriptors using machine-learning methods could be useful for predicting drugs
that treat central nervous system (CNS) disorders [112].
However, selecting an optimal feature subset is an NP-hard optimization prob-
lem [113]. Existing feature selection methods can be categorized into two classes:
filter methods and wrapper methods. Filter methods, such as Principal Compo-
nent Analysis (PCA), rank the features in a rather unsupervised way by using
heuristics based on general data characteristics. Wrapper methods, including a
variety of Support Vector Machines (SVMs), use induction algorithms itself and
iteratively select features by evaluating their usefulness for the target predictor.
Both methods have been already applied to identify drug-like molecules from non-
drug molecules using molecular descriptors [114]. In a recent study, Tang et al.
[115] compared four machine-learning methods to discriminate approved drugs
from experimental ones and showed that SVM models performed best in their test
scenarios. Use of Recursive Feature Elimination (RFE) combined with statistical
learning methods to select the proper set of molecular descriptors has shown to
substantially improve the discrimination of brain drugs from non-brain drugs [6].
Similarly, SVM based classification of CNS drugs based on their molecular descrip-
tors has been reported to outperform other statistical learning methods in selected
scenarios [116]. Our study focuses on the application of this well-established ma-
chine learning approach for characterizing approved drugs in the NDD area with
the goal of being able to differentiate NDD-specific drugs from non-NDD ones.
In order to analyse and distinguish molecular properties that discriminate NDD-
specific drugs from non-NDD ones, we inspected a set of approved drugs for NDDs
in search of specific molecular descriptors. These molecular descriptors may con-
tribute to the established safety and efficacy profiles of these drugs as they are
approved for use in CNS. For this purpose, we applied the SVM-RFE method
[117]. SVM-RFE is a widely adopted state-of-the-art supervised feature subset
selection approach. It has been previously applied with great success to gene se-
lection tasks in microarray expression data [118]. Using this method, we ranked
the features according to their contributions to define the maximally separating
hyper plane. Our analyses show high classification accuracy in classifying NDD
drugs from non-NDD drugs. Higher classification accuracy is achieved with SVM-
RFE as compared to conventional similarity measures and a simple supervised
feature selection and classification algorithm. We propose to use the predictions
made by this classifier to design focused libraries for the discovery of novel NDD
drugs.
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4.2 Methods and Material
The drug data set was compiled carefully before calculating molecular descriptors.
The data set comprised of 160 FDA approved drugs used in NDD disorders such
as Parkinsons disease, Alzheimers diseases, epilepsy and multiple sclerosis, were
collected from various knowledge base resources including DrugBank [? ], CTD
[49], TTD [48] and STITCH DB [60]. An additional set of 253 FDA approved non-
NDD drugs were randomly collected from DrugBank and included in the data set.
A set of 314 molecular descriptors was calculated using MOEs QuaSAR-Descriptor
function [92]. The drug molecules were prepared before calculating descriptors.
Preparation of drug structures included the generation of 3D conformations, re-
moving salts and counter-ions and getting optimized 3D geometries via applying
energy minimization with MMFF94x force field [119]. The final descriptor space
included all 2D descriptors that use only atomic and connectivity properties of the
molecules and all i3D descriptors that use internal spatial information about each
molecule (e.g. potential energy, volume and solvent accessible surface area).
A pairwise correlation matrix was generated for the descriptors to identify highly
correlated set of descriptors. The data set was grouped into two classes and
labelled as NDD+ for NDD drugs and NDD- for non-NDD drugs. The data set
was then partitioned by random sampling into a training set (70%) for machine
learning model selection and a test set (30%) for model assessment.
Molecular descriptors are ranked and selected based on the SVM machine learning
method with recursive feature elimination (SVM-RFE), which utilizes the sensitiv-
ity analysis based on the weights of support vectors in each descriptor dimension.
Given a training set {(xi, yi) — xi  Rp, yi  {+1, 1} i = 1, 2, N} of N
instances, an SVM determines an optimal decision function of the form:
f(x) =
∑
ai.yi.K(x, xi) (4.1)
Where ai can be interpreted as a weight of each xi and K is any kernel function.
SVM-RFE iteratively eliminates features by using the equation of maximally sep-
arating hyper-plane:
w =
∑
ai.yi.xi (4.2)
and removing features corresponding to the dimension argmin (w2i ), j=1,2, . . . . p.
Subsequently, based on those selected descriptors, an SVM (R implementation in
the e1071 package) is trained to classify NDD drugs from non-NDD drugs. We
observe optimal classification performance when using the Radial Basis Function
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(RBF) kernel. In order to stabilize and establish the robustness of the resulting
feature rankings, the resampling technique with cross validation, Multiple SVM-
RFE is used [120]. A generalization error (by 10 fold cross validations) is also
estimated for a number of top ranking descriptors, which shows the performance
of classification based on the number of selected ranked features.
As a comparison, three molecular similarity based approaches were evaluated to
compare the performance of the classification based on similarity measures. 1) The
ShaEP algorithm [121], which calculates molecular electrostatic potential based
descriptors. 2) Feature trees (FTrees) algorithm [122], which represent chemical
properties of molecules by a set of features. 3) MOEs similarity search using
MACCS [123] fingerprints. ShaEP performs a rigid-body superimposition of 3D
molecular models that is achieved by finding similarities in the molecular electro-
static potential (MEP) field followed by volume overlap. The drug structures were
energy minimized with MMFF94x force field and their 3D coordinates were saved
as Tripos Mol2 file format. It is necessary to use Mol2 format because it sup-
ports partial atomic charges calculated for all atoms in a molecule that are needed
for computing the molecular electrostatic potential. Data sets composed of drugs
active against specific target families (e.g. beta-2 adrenergic receptor (ADRB2),
estrogen-related receptor alpha (ESRRA) or acetylcholinesterase (AChE) interact-
ing drugs) and combined clusters were used as queries against all approved drugs
to recover the same drugs by using ShaEP similarities comparisons. Similarities
calculations were performed for all individual NDD approved drugs against the
non-NDD drugs. Average similarities across all NDD drugs were considered for
enrichment analysis and calculation of ROC curves.
Additionally, a simple supervised feature selection and classification algorithm
based on linear discriminant analysis (LDA) [124] was also used as a comparison
to SVM-RFE. LDA seeks to reduce dimensionality while preserving class discrim-
inatory information in terms of features. It is known that the t-score is a natural
and optimal feature selection criteria in LDA if no correlation among features
is observed [125]. This special case of LDA is known as Diagonal Discriminant
Analysis (DDA). In the fields of gene selection and ranking, different LDA based
approaches have been successfully used for gene ranking and selection [126], [127].
These approaches usually consider correlation among features. We used state-
of-the-art LDA feature selection approach that is based on correlation adjusted
t-scores (CAT scores) [127]. Given that the training data belonging to two classes
of sizes n1 and n2 and with means µ1 and µ2, feature specific CAT scores vector
τadj is defined as:
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τadj = P
−1
2 {( 1
n1
+
1
n2
)V }−12 (µ1 − µ2) (4.3)
where P = (ρij) is the correlation matrix and V = diag{σ12 , σ22, . . . , σp2}
is a diagonal matrix containing the variances. Both P and V are obtained from
decomposition of the common covariance matrix
∑
such that
∑
= V
1
2 PV
1
2 .
Notice that when there is no correlation among features, that is when P = I, τadj
reduces to a multiple of V
−1
2 (µ1 µ2) which represents two sample t-score. Thus
definition in equation 4.3 allows a mechanism for feature ranking based on DDA
and LDA.
4.3 Results
We considered Pearson correlations as a measure to identify non-correlated set of
descriptors. The pairwise correlation matrix of descriptors (a subset is shown in
Figure 4.1) shows that a large number of descriptors are inter-correlated. There-
fore, only one of the descriptors in the correlated clusters of descriptors was ran-
domly selected and the rest were discarded if highly correlated (i.e. Pearson
correlation coefficient ±0.8). Through this elimination procedure, a set of 107
non-correlated descriptors was identified for subsequent analysis.
4.3.1 SVM based Descriptor Selection and Classification
A large number of molecular descriptors represent the drugs in the multi-dimensional
feature space. Not all of these descriptors are equally discriminative in classifying
NDD and non-NDD drugs. We notice, in an unsupervised fashion, that many of
these descriptors are highly (in case of Pearson correlation) correlated and there-
fore, will not bring additional information if we use them together. Since the
descriptors may bear even complex relationship among each other, we employ a
supervised descriptor selection and classification method to determine relevant de-
scriptors with respect to their importance towards data classification. To this end,
SVM-RFE is one of the state-of-the-art methods that recursively eliminates the
less relevant features and selects the most relevant features best describing the
data. Table 4.2 shows a list of top 10 ranking descriptors for our NDD drug data
set, ranked by SVM-RFE, on the basis of which we are able to discriminate and
classify NDD drugs from non-NDD drugs. The set of 40 top ranking descriptors
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Figure 4.1: A sub-matrix of the correlation coefficients matrix showing highly
positive or highly negative (in dark) correlations among a set of molecular de-
scriptors. Molecular descriptors are given in rows and columns. Absolute values
are taken for the negative correlation values.
(based on lowest generalization error estimate as shown in Figure 4.2) is used to
train an SVM classifier for our data set. The training data set included only NDD
drugs combined with drugs for disorders other than NDD. To see whether a set
of descriptors would be relevant, the classification was performed using three sets
of descriptors: all descriptors (total 314), non-correlated descriptors (total 107)
and top ranked selected descriptors (top 40). The prediction performance was
evaluated with ten fold cross validation of the underlying classification models for
the three sets of descriptors. Classification results have overall accuracy of about
80% for the top ranked selected set of descriptors.
Table 4.1: Classification accuracies (10x CV) of SMV-RFE and LDA based ap-
proaches for NDD data set using: 1.all descriptors (314), 2. NC (non-correlated
107) and 3. TR (Top Ranked 40, by SVM-RFE and LDA.
Descriptors
sets
SVM Accuracy % LDA Accuracy %
Training Test Training Test
All 82.7 83.9 75.6 74.8
NC 83.0 81.5 74.4 71.5
TR 82.4 79.8 70.3 72.4
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Table 4.1 shows the results of classification accuracy using three sets of descriptors
for our data set comprising NDD drugs mixed with other drugs for other disorders.
The results obtained with SVM are better than the LDA based method. The
classification performance obtained with using non-correlated and a few selected
descriptors is nearly the same as that of considering all descriptors. Therefore, if a
limited number of descriptors can produce comparable results, the advantage will
be efficiently computing a small number of relevant descriptors for a large data set
of molecules in a compound library.
Table 4.2: List of top 10 ranking descriptors that contribute to classification
and predictions of NDD drugs
No Descriptor code Description Avg.Rank1
1 E sol Solvation energy 1.36
2 chiral u Unconstrained chiral center 4.18
3 b double No. of double bonds 13.14
4 PEOE VSA-4 Partial charge/VDW Surface
Area (bin-4)
16.54
5 SlogP VSA8 Log of octanol/water partition
coefficient with subdivided sur-
face area, (bin-8)
18.72
6 DCASA Difference between CASA+
(charge weighted +ve surface
area) and CASA-
19.18
7 vsurf IW7 Hydrophilic INTEGY (INTErac-
tion enerGY) moment (bin-7)
21.88
8 SlogP VSA2 Log of octanol/water partition
coefficient with subdivided sur-
face area, (bin-2)
22.76
9 SMR VSA4 Molar refractivity with subdi-
vided surface area (bin-4)
22.78
10 vsurf HL2 Hydrophilic-Lipophilic(bin-2) 23.20
1 Average rank across 50 iterations for descriptors ranking and selection
Table 4.2 enlists the top ranked descriptors, which were used for classification.
These ranked descriptors include the most widely used descriptors in QSAR stud-
ies (e.g. logP and surface area based descriptors) which describes the molecules
lipophilic or hydrophobic properties and are valuable parameters for determining
the ability of drugs that should be absorbed and penetrated into the brain.
These results show that there are sets of molecular descriptors that can be used to
discriminate NDD drugs from non-NDD drugs. The underlying statistical learning
methods also provide a way of limiting the number of ranked features based on
generalization error estimation. This is helpful because calculating these molecular
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descriptors is compute-intensive and would require a substantial amount of com-
putation time to calculate descriptors for a large number of molecule structures
in a compound database. It is, therefore, desirable to select a minimum number
of top ranked descriptors with lowest generalization error. Figure 4.2 illustrates a
generalization error estimate for a number of ranked descriptors. An independent
test data set that was not included in the feature selection was used for calcu-
lating the generalization error. The generalization error estimate was calculated
for top 50 descriptors only because calculating it for all features will increase the
number of underlying RBF kernel SVMs and hence would require a substantial
amount of computational time. The results indicate that, when compared to using
all 314 molecular descriptors, a similar accuracy can be achieved by using only a
few relevant and highly discriminative descriptors selected by SVM-RFE and with
decreased number of support vectors for the SVM model.
Figure 4.2: Plot of generalization error against a number of ranked descriptors
over the independent test set. The 10x cross validation error estimate shows
that the top 40 descriptors result in higher classification performance.
4.3.2 Similarity Searching
The similarity results obtained by three similarity measures are given Figure 4.3.
Mean ROC-AUC (computed with the help of an R package caTools) of 0.60 was ob-
tained for similarity comparison using ShaEP, 0.56 for similarity results of FTrees
and 0.52 for similarity using fingerprints. These small ROC-AUC values are close
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to random suggesting that a classification strategy based on only structural simi-
larities should not be used in classifying a set of NDD drugs from non-NDD drugs.
Running target family specific clusters of drugs as a query against the remaining
NDD drug data set showed that we could not get a reasonable similarity among
the individual clusters of drugs. The reason for this could be that there are drugs
with common structural properties targeting a specific protein family and different
drugs have variable binding affinities towards different protein targets. Therefore,
only similarity measures that take into account a certain group of drugs compared
to another group of drugs might not work in such case. Such similarities are de-
sirable if one intends to model the characteristic drug features for a given target
family. As shown in Figure 4.4, drugs for various protein targets do not show
similarities to drugs for other targets even if they are targeting proteins involved
in NDD disorders. As the similarity measures do not provide a better solution
to discriminate NDD drugs from non-NDD drugs, we investigate the descriptor
space for NDD drugs to evaluate whether there are shared features among them,
to identify them as NDD drugs. Therefore, we studied all the NDD drugs as a sin-
gle data set regardless of their respective target protein families on their available
molecular descriptors side.
Figure 4.3: ROC curves for three different similarity measures.
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Figure 4.4: Mean ROC-AUC values for similarity comparisons of individual
target family specific drugs with the rest of the NDD drugs. The central line
indicates a random performance. Descriptions of target proteins are given in
Table 4.3.
Table 4.3: Full names and gene symbols of the target proteins for which the
similarity comparisons of their interacting drugs are performed using different
similarity measures.
No Gene Symbol Full name
1 ADRB2 beta-2 Adrenergic Receptor
2 ACHE Acetylcholinesterase
3 CHRM1 Muscarinic Acetylcholine Receptor M1
4 ESRRA Estrogen-related Receptor alpha
5 GABRA2 gamma-Aminobutyric Acid (GABA) A Re-
ceptor, alpha 2
6 HRH1 Histamine Receptor H1
7 NARG2 NMDA Receptor-regulated Protein 2
8 SCNN1A Sodium Channel, non-voltage-gated 1 alpha
subunit
4.3.3 Comparison with LDA Classification
The LDA based method was tested as a comparison to SVM-RFE for the binary
classification of NDD drugs from non-NDD drugs. The LDA based feature selec-
tion and classification algorithm generated a set of ranking descriptors that can be
used in the binary classification, in a similar fashion as SMV-RFE. However, the
classification performance obtained with SVM-RFE was better than that obtained
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with LDA for all three sets of molecular descriptors. The comparisons are given in
Table 4.1. An overall accuracy of 0.72 was obtained for the independent test set
using LDA based ranked descriptors while accuracy of 0.80 was achieved by using
SVM-RFE based ranked descriptors. In our experimental evaluation, however,
DDA case of LDA performs poorly for understandable reasons since it does not
assume any correlation among features. LDA with up to 72% accuracy performs
better than DDA (that has accuracy below 60%), which is still outperformed by
SVM-RFE (see Table 4.1). We assume that this is due to the inherent power
of non-linear kernel machines (SVM) that is achieved by projecting data in high
dimensional non-linear space.
4.3.4 Application in NDD Focused Library Design
The predictions made by using the top ranking descriptors can also be ranked
based on the decision values or probabilities calculated by the underlying machine
learning model. This is very useful in predicting drug molecules with ranges of
probability that presents the likelihood that the molecule will belong to a certain
class. We rank the predictions made by the machine-learning model based on
the decision values or probabilities that are assigned for each drug that falls into
a certain class of drugs. Based on the decision values (Eq. 4.1) as shown in
Figure 4.5, ranks for the corresponding predictions can be used to filter a focused
library of drug-like molecules from large chemical libraries. Figure 4.5 shows that
values above the line at 0 are predictions for drugs as NDD+ while values below
0 are predictions for drugs as NDD-. Clusters of data points falling at -1 or 1 (as
seen in Figure 4.5) for most of the drugs represent that these drugs have similar
distances from the support vectors and have been assigned similar decision values
based on the selected descriptor dimension space. Applying the same model to
the data of a large compound library for which only the top ranked descriptors are
calculated would classify them with a range of probabilities. These probabilities
and rankings can be used here to design a focused library by considering the
predictions with higher probabilities of falling in a certain class of interest with
good confidence level. It remains, however, to be shown that this assumption
holds true empirically if the model learned is applied to physical focused library
construction.
4.3.5 Pharmacological Modeling of Approved Drugs
In order to test the applicability of the proposed model for pharmacological mod-
eling of drugs, the SVM model was applied to a set of all approved drugs collected
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from DrugBank. The top ranked 40 descriptors were calculated for these drugs
and the drugs, which were already present in the training set, were excluded in
order to avoid artificial bias. The new predictions were sorted using the ranks
calculated by the SVM model and top 50 predicted drugs (i.e 5% of all approved
drugs) were selected as shown in Figure 4.5. The predicted drugs were further an-
alyzed by calculating their individual structural similarities with NDD drugs and
their interacting targets were collected from DrugBank, STITCH DB and CTD
databases.
Figure 4.5: Plot of decision values assigned to the approved drugs data set by
the SVM model. The points above the horizontal line at 0 indicate the drugs
predicted as NDD drugs. The dotted line indicates a threshold of selecting the
top 5% predicted drugs for analysis.
Based on the similarities to known NDD drugs (Tanimoto coefficient ≥ 0.6) and
having interactions with common drug targets, 35 drugs were identified. 12 out
of these 35 drugs have known anticonvulsant properties. Further more, protein
binding site similarities were retrieved from in-house database of pre-computed
protein pockets similarities. This database contains the 3D structures of all target
proteins interacting with approved NDD drugs and their binding site similarities
values. Pair-wise similarities between binding pockets are calculated using the
SMAP software package[94]. SMAP detects the binding sites in protein structures
and performs similarity comparison of protein 3D structures independently of their
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sequence. Binding site similarities are computed for more than 2000 proteins with
PDB structures and significant similarities are stored in the database.
The binding site similarities are explored in order to observe the pocket geometries
of multiple proteins that are targeted by a group of similar drugs. The selected
drugs were arranged in a network of drugs interacting with target proteins for visu-
alizations as shown in Figure 4.6 and Figure 4.7. The drugs nodes are represented
by rectangles and the protein targets are shown as circles. An undirected edge
between two drugs indicates structural similarity and that between two proteins
indicates binding site similarity. Likewise, an edge between a drug and a protein
indicates the interaction of that drug with its protein target.
Interestingly, the structural similarities of the predicted drugs with NDD drugs
are not so high. However, the predicted drugs either share protein targets directly
or indirectly through interacting with an NDD drug targeted protein that has
a similar binding pocket. This implies that the prediction of new drug-target
associations of the predicted drugs can be used to streamline drug repurposing
[128] and may result in novel insights that can lead to the identification of novel
drug actions in a different indication area.
4.4 Discussion
A better understanding of the mechanisms by which drugs act against complex
diseases such as neurodegenerative disorders can be achieved by integrating all
available drug-target interaction data at systems pharmacology level to derive in-
silico computational models. We have collected data for drugs that act against
neurodegenerative disorders from various databases. The drug data is analyzed
for their specific molecular features that confer them with approved efficacy and
safety profile to such drugs. These drugs are active against a variety of protein
targets belonging to different protein families and different pathways. We have
observed that similarity measures based on a set of target specific drugs, do not
produce good results in terms of similarity predictions when used in queries. On
the other hand, using machine-learning approaches to study the drugs collectively
for their features offer an alternative to conventional similarity-based approaches.
There are hundreds of molecular features that characterize various physiochemi-
cal properties of the molecules. However, a number of molecular descriptors will
measure the molecular properties in a similar way. Therefore, correlations among
these features should be considered. As shown in our results, removing strongly
correlated features reduced the total number of features by one-third in the first
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Table 4.4: List of predicted and known NDD drugs with their indication
areas and structural similarities. Indication areas for similar NDD drugs with
references are given in Table 4.5
Predicted
Drug
Indication Similar NDD
Drug
Indication Similarity
Lamivudine HIV-1; HBV Cladribine Multiple Scle-
rosis
0.67
Pentazocine Pain Apomorphine Parkinsons
Disease
0.63
Propantheline Antispasmodic;
rhinitis
Di-
phenhydramine
Parkinsons
Disease
0.65
Dronabinol Antipsychotic Vitamin E Alzheimers
Disease
0.80
Mestranol Contraception Estriol Multiple Scle-
rosis
0.80
Desogestrel Contraception Prednisone Multiple Scle-
rosis
0.62
Levallorphan Drug over-
dose
Naltrexone Seizures 0.68
Sulfamethizole Antibacterial Acetazolamide Epilepsy 0.88
Sulfanilamide Vulvovaginitis Dapsone Seizures 0.80
Glutethimide Insomnia Ethosuximide Epilepsy 0.71
Meprobamate Anxiety;
muscle relax-
ant
Felbamate Epilepsy 0.67
place. Furthermore, there are relevant molecular descriptors that should be prop-
erly selected for efficiently discriminating the molecular data. Selection of the
most relevant descriptors is achieved by recursively eliminating the less relevant
descriptors.
Using an SVM-based machine learning approach, the most relevant descriptors
can be selected and used to perform predictions on a larger set of molecular data.
The generalization errors obtained by selecting the varying number of top ranking
descriptors inform us about the model’s classification error that can occur when a
given number of top ranking descriptors is used to classify the data. This is very
beneficial for reducing the high dimensionality of the drugs descriptors space and
selecting a minimum number of descriptors that can be calculated efficiently for a
large number of molecules, hence avoiding compute intensive and time consuming
calculations. Therefore, with the help of this algorithm, a limited number of top
ranking descriptors can be calculated to enrich a molecular library or design an
NDD focused library of molecules by considering the probabilities assigned during
classification.
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Figure 4.6: Drug target network of the selected predicted drugs (left) and
their similar NDD drugs (right) with their common interacting protein targets
(center). Thick lines indicate similarities between drugs and binding site simi-
larities between drug-targets. Thin lines indicate interaction of drugs with the
target genes.
The high sensitivity of the presented SVM-based model to classify NDD drugs
from non-NDD drugs and its satisfactory accuracy of discriminating NDD drugs
from non-NDD drugs is in agreement with previous studies that report on the
efficiency of SVM approach to predicting properties of chemical compounds and
classifying drug-like compounds from others [115], [116]. In fact, identification of
the most important structural features and chemical properties of successful drugs
is the first step towards addressing the challenge of design and optimization of
next-generation multi-target drugs.
4.5 Conclusions
Making the systems pharmacology paradigm a reality requires designing multi-
target compounds with optimized structure-activity relationship (SAR) in such a
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Figure 4.7: Drug target network of some predicted drugs (left) and their sim-
ilar anti-epileptic drugs (right) with their common interacting protein targets
(center). Thick lines indicate similarities between drugs and binding site simi-
larities between drug-targets. Thin lines indicate interaction of drugs with the
target genes.
way that their pharmacological profile towards selective multiple targets is main-
tained. Computational approaches, as we have demonstrated here with the use
of machine learning methods, can play a major part in identifying molecular de-
scriptors that confer certain pharmacological properties to candidate compounds.
Statistical and machine learning methods have previously been used to predict
permeability of CNS drugs. Here we used the learning methods to predict com-
pounds that can be used in NDD indications. We also demonstrated the advantage
of such methods over the conventional similarity based methods. A limitation in
the development of such classifier models is the lack of enough data for sampling
and training. Apart from that, the available data in such models is not experimen-
tally verified to be true negative, therefore, the negative data is not often confirmed
negative which can ultimately result in the performance loss of the underlying clas-
sifier models. This method can be effectively applied to design a highly enriched
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focused library of compounds from a large compound database. The proposed
method has applicability in drug repurposing and some drugs that are used in
non-NDD indications are predicted to be potential candidates for their usefulness
in various CNS disorders. Obviously such predictions, to turn out successful, must
be coupled with modeling and experimental validation for target combinations.
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Table 4.5: List of known NDD drugs with their indication areas from Drug-
Bank and CTD/TTD databases.
NDD Drug Indications (DrugBank Database) Indications (CTD/TTD Database)
Cladribine For the treatment of active hairy cell
leukemia (leukemic reticuloendothe-
liosis) as defined by clinically signifi-
cant anemia, neutropenia, thrombo-
cytopenia, or disease-related symp-
toms.
Therapeutic role in Multiple Sclero-
sis (1 reference in CTD database)
Apomorphine For the acute, intermittent treat-
ment of hypomobility, off episodes
(end-of-dose wearing off and unpre-
dictable on/off episodes) associated
with advanced Parkinson’s disease.
Therapeutic role in Seizures, Park-
isons Disease (23,16 references re-
spectively in CTD database)
Di-
phenhydramine
For the treatment of symptoms as-
sociated with Vertigo/Meniere’s dis-
ease, nausea and vomiting, motion
sickness and insect bite
Therapeutic role in Seizures,
Parkinsons Disease (14, 1 references
respectively in CTD database)
Vitamin E Vitamin E, known for its antioxi-
dant activities, is protective against
cardiovascular disease and some
forms of cancer and has also demon-
strated immune-enhancing effects.
It may be helpful in some neurolog-
ical diseases including Alzheimer’s.
Therapeutic role in Neurodegenera-
tive Diseases, Seizure (10,19 refer-
ences respectively in CTD database)
Estriol Used as a test to determine the gen-
eral health of an unborn fetus.
Multiple Sclerosis (1 reference in
TTD database.
Prednisone For the treatment of drug-induced
allergic reactions, multiple sclerosis
and many other disease
Therapeutic role in Multiple Sclero-
sis (3 references in CTD database)
Naltrexone Used as an adjunct to a medi-
cally supervised behavior modifica-
tion program in the maintenance of
opiate cessation in individuals who
were formerly physically dependent
on opiates and who have successfully
undergone detoxification.
Therapeutic role in Seizure (14 ref-
erences in CTD database).
Acetazolamide For adjunctive treatment of: edema
due to congestive heart failure;
drug-induced edema; centren-
cephalic epilepsies; chronic simple
(open-angle) glaucoma.
Therapeutic role in Seizure,
Epilepsy (3 references against
each in CTD database).
Dapsone For the treatment and management
of leprosy and dermatitis herpeti-
formis.
Marker mechanism in Seizure (6 ref-
erences in CTD database).
Ethosuximide For the treatment of petit mal
epilepsy.
Therapeutic role in Epilepsy (11 ref-
erences in CTD database).
Felbamate For use only in those patients who
respond inadequately to alternative
treatments and whose epilepsy is
so severe that a substantial risk of
aplastic anemia and/or liver failure
is deemed acceptable in light of the
benefits conferred by its use.
Therapeutic role in Epilepsy (10 ref-
erences in CTD database).
Chapter 5
SVM based Classification of
GPCR Antagonists and its
Application in Drug Repurposing
5.1 Introduction
G-Protein Coupled Receptors (GPCRs) play important roles in the healthy human
physiology and they represent the largest family of drug targets [129]. They are
the targets of 30 to 50% of all marketed drugs [130] that exhibit their pharma-
cological actions through GPCR-associated mechanisms. GPCRs are among the
most prominent proteins in the receptors family, hydrolases in the enzyme family
and voltage-gated Ca channels in the ion-channel family [131]. Gene family dis-
tribution of targets and drugs revealed that more than 50% of drugs target only
four gene families [132] as shown in Figure 5.1:
a Class I GPCRs
b Nuclear Receptors
c Ligand-gated Ion Channels
d Voltage-gated Ion Channels
5.1.1 GPCRs as Attractive Therapeutic Targets
GPCRs contribute a significant number of therapeutic targets to the current num-
ber of drug targets that are in the order of 102. The discovery of new drugs
acting against multiple GPCRs has been successful for decades and account for
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Figure 5.1: The percentage of all FDA-approved drugs based on the top 10
gene familes is displayed [132].
approximately 50% of all launched drugs [133]. Similarly, on the drug targets
side, GPCRs represent 50-60% of current drug targets for their involvement in
different indications such cardiovascular, metabolic, neurodegenerative, psychi-
atric and oncologic diseases [134]. They can accommodate thousands of different
ligands (e.g. agonists, antagonists or inverse agonists) because of their common
binding site structures bundled through seven-transmembrane α-helices [135]. G
protein-coupled receptors play an important role in many physiological functions
and pathophysiological processes involved in many diseases, including cancer and
cancer metastasis [136]. They are the subjects of intense research in both academia
and pharmaceutical industry [137]. Due to their important mediation, functions,
the GPCRs family of targets are one of the most successful targets for a broad
spectrum of diseases [138]. There is a continuous attempt to ”de-orphanize” the
GPCRs among the large receptorome (the portion of the proteome encoding re-
ceptors) to better characterize receptors with unknown functions [139]. Thus a
better understanding of signaling and regulatory mechanisms of GPCRs should
open new perspectives for GPCR-directed drug discovery [140].
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5.1.2 Role of GPCRs in Neurodegenerative Disorders
The role of GPCR trafficking and cell membrane expression is very important in
the abnormal processes during diseases caused by receptor misfolding [141] and
GPCRs are subjected to cellular quality control system. They play pivotal role in
regulating the function and plasticity of neuronal circuits in the central nervous
system due to their involvement in G-protein signaling pathway [142]. Alter-
ations in these signaling pathways have been extensively investigated in various
types of neurodegenerative diseases and neuro-inflammatory disorders [143]. Var-
ious studies have investigated the role of GPCRs in Parkinson’s disease, Hunting-
ton’s disease [144], [145], Alzheimer’s disease [146], Amyotrophic Lateral sclerosis
and Multiple Sclerosis [147],[148],[149]. Current Alzheimers disease therapeutics
mainly target Acetyle-choline esterase that stimulates cholinergic neurons [150],
even though the complex neurodegenerative process is not limited to a specific
neurotransimitter system [151]. Several studies have been reported the critical
role of GPCRs in the pathogenesis and amyloidogenesis of Alzheimers disease
[147]. Apart from the neuroprotection therapy through inhibition of mono-amine
oxidase-B [152], disruption in GPCR signaling is also a disease mechanism in
Parkinson’s disease [153], [154]. Similarly, GPCR such as Histamine receptors
play a potential role as therapeutic targets for anti-epileptic drugs [155]. Het-
eromerization of different GPCRs can have its effect on the activation of a variety
of signaling pathways in neurological disorders [156]. For example, functional in-
teractions between adenosine and dopamine receptors in basal ganglia [157] and
effect of adenosine receptors on glial functions [158] highlight the potential of
developing antagonists for these receptors to control neuromodulation in aspects
relevant to Parkinson’s disease.
5.1.3 GPCR Directed Ligand Library Design
The recent availability of a few high-resolution GPCRs structural data has opened
new opportunities for computational modeling to improve our understanding about
them [159]. Comparative homology modeling of 3D structures of GPCRs is a tool
that allows understanding of receptor-ligand interactions [160] and because of the
limited availability of GPCR crystal structures, theoretical coordinates can be
made available [161]. However, such homology based models require validations
[162]. With little and slowly expanding structural information of GPCRs targets,
validation of computational modeling approaches crucially depends on experimen-
tal data [137]. Different chemogenomic approaches, such as ligand centered, pro-
tein centered and protein-ligand centered [163], can be applied to the design and
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exploration of GPCR ligand space. The ligand-based approach relies on physio-
chemical properties of GPCR ligands [164] which can be used to categorize ligands
into ”GPCR-ligand-like” and ”non-GPCR-ligand-like” [165]. The structure-based
design methods rely on the three dimensional structure of proteins for rational
drug discovery [166] and can lead towards a better understanding of GPCR acti-
vation [167]. Once the focused libraries are designed, they can be combined with
structure-based methods, which also take into account, the structural information
and biological knowledge of the target receptors [168]. There exist several spe-
cialized GPCR databases that collect information about receptors (e.g. GPCRDB
[169], its natural variants in GPCR NaVa [170]) and GPCR ligand databases (e.g.
GLIDA [171] and GLL/GDD [172]). These databases provide useful information
about the GPCR target families and their respective ligands that we can use for
the design and validation of our in-silico models.
This chapter focuses on our study of GPCR antagonist ligands that includes:
a The exploration of molecular and physiochemical properties (i.e. descrip-
tors/features) of GPCR antagonist ligands and evaluate their usefulness
in discrimination of GPCR related bioactive molecules from the inactive
molecules.
b The application of machine learning based recursive feature elimination method
[117] to select and compare sets of molecular descriptors for the classification
of GPCR antagonists.
c The building of molecular descriptors based classifier models that will be
used to classify unknown ligands and GPCR subfamily ligands
d The application of such classifier models in the repositioning of approved
drugs that are used for other indications.
5.2 Methods and Material
5.2.1 Data Sets
A data set of antagonist ligands of four GPCRs is compiled from the GLL/GDD
database [172]. The GLL/GDD database contains more than 25,000 agonists and
antagonists ligands for 147 GPCR targets and approximately 1 million decoy com-
pounds, with a ratio of 39 decoy compounds per ligand. We preferentially selected
antagonist ligands over the agonist ligands for building the classifier models be-
cause there are more antagonist than agonist in this database for our selected
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GPCR receptors, and we are interested in designing antagonists for these recep-
tors later on. Four human GPCR receptors (beta 2 adrenergic receptor (ADRB2),
adenosine A2A receptor (ADORA2A), dopamine D3 receptor (DRD3) and his-
tamine H1 receptor(HRH1)) are selected due to their suggested polypharmaco-
logical profile that arise from their binding site similarities as described in more
detail in the chapter ”Drug Target Networks Analysis”. The distribution of their
antagonist ligands and decoys is listed in Table 5.1, which comprise total of 960
antagonists and 4000 decoy molecules for the selected targets. For the reason
of simplicity, for the fast calculation of molecular descriptors and to avoid bias
that can be introduced by including a large number of decoy compounds [173], we
selected 1000 decoy compounds per target.
Table 5.1: Total number of antagonist ligands and decoy compounds per
GPCR target.
Target Antagonists Agonists Decoys
Adenosine A2A Receptor 361 82 1000
beta-2 Adrenergic Receptor 204 206 1000
Dopamine D3 Receptor 317 6 1000
Histamine H1 Receptor 78 8 1000
5.2.2 Descriptors Calculation
A set of all 2D and 3D QSAR descriptors (features) are calculated for the antag-
onists and decoy compounds using MOE [92]. The compounds structures were
energy minimized with MMFF94x [119] force field within MOE prior to calcula-
tion of descriptors. The resulting descriptors that are meaningful were kept, while
some meaningless descriptors that have a value of 0 or 1 for all compounds, were
removed. Values of some descriptors could be zero (e.g. ”violate lipinski” rule will
result in 0 values for all the ligands that do not violate this rule) and value for
a descriptor could be 1 for most compounds (e.g. ”is drug like”). This resulted
in a total number of 274 molecular descriptors out of the total 334 available de-
scriptors. Similarly, compounds with missing values for some descriptors, which
are not calculated for various reasons, are also removed from the data sets. The
data set is randomly divided into a training set (474 antagonists, 2000 decoys) on
which an SVM model is trained and a test set (472 antagonists, 2000 decoys) on
which the model is evaluated.
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5.2.3 Descriptors Selection/Ranking
A ranked list of molecular descriptors is obtained by using the machine-learning
algorithm with recursive feature elimination (RFE) as discussed in the previous
SVM based Classification of NDD Drugs for Pharmacological Modeling chapter
[39]. This algorithm ranks features according to their contribution in binary classi-
fication of the GPCR antagonists from the decoys compounds. A list of top-ranked
molecular descriptors is given in Table 5.2. These selected top-ranked molecular
descriptors are used to build and train the SVM model on the training data set.
Table 5.2: Top ranked molecular descriptors selected by SVM-RFE
No. Code Descriptor Average
Rank
1 E strain Local strain energy: the current energy
minus the value of the energy at a near
local minimum.
1.0
2 E vdw van der Waals component of the potential
energy.
4.6
3 E ele Electrostatic component of the potential
energy.
8.5
4 pmiZ z component of the principal moment of
inertia (external coordinates).
8.9
5 E nb Value of the potential energy with all
bonded terms disabled.
9.4
6 E str Bond stretch potential energy. 9.8
7 pmiX x component of the principal moment of
inertia.
18.5
8 E oop Out-of-plane potential energy. 21.0
9 SlogP VSA0 The Subdivided Surface Areas are descrip-
tors based on an approximate accessible
van der Waals surface area (in A˚2) calcu-
lation for each atom, vi along with some
other atomic property, pi
21.2
10 GCUT PEOE0 The GCUT descriptors are calculated
from the eigenvalues of a modified graph
distance adjacency matrix.
21.5
Interestingly, the top ranked descriptors as shown in Table 5.2 are energy and elec-
trostatic based molecular descriptors, which is in strong agreement to the charge
related molecular properties of GPCR ligands. The vast majority of ligands for
several GPCR targets have non-zero charge [172], that contributes towards the
distinguished features of these GPCRs antagonists ligands.
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5.3 Results and Discussion
Classification accuracies of ∼0.98 have been observed for 10x internal cross vali-
dation and independent test sets. These results show that the top ranked selected
descriptors as given in Table 5.2 can be used to classify the data sets with a very
good classification performance. These descriptors are assigned high average ranks
among all 274 calculated that are calculated by RFE during internal 50 fold cross
validation. The training data set is used to first select the top ranking descriptors
from the 274 descriptors and then, on the basis of these few but highly relevant
descriptors, the underlying data is classified into their respective GPCR antag-
onists and decoy classes. The overall accuracy on the training data set with a
precision of 96% is shown in Figure 5.2. The classification result over the test set
is shown in Figure 5.3 and shows that a similar performance is obtained for the
binary classification.
Figure 5.2: A decision values scatter plot involving the training data set.
The points in red color represent the antagonist ligands while those in black
color represent the decoy compounds. Decision values above 0 mean the data is
classified in to GPCR antagonist class and below 0 mean the data is classified
into the decoys class.
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Figure 5.3: A decision values scatter plot involving test data set. The points
in red color represent the antagonist ligands while those in black present the
decoy compounds. Decision values above 0 mean the data is classified in to
GPCR antagonist class and below 0 mean the data is classified into the decoys
class.
5.3.1 Further Validation
The SVM model that is trained over the antagonist data of only four GPCR
targets (Table 5.1) is further evaluated on the antagonist data for another set of
81 GPCR targets. Table 5.3 shows a list of some GPCR families and the total
number of antagonists present in each family. A total of ∼18,000 antagonists
are collected for the 81 GPCR targets and approximately 4,000 decoy compounds
are randomly selected from the decoy sets of each target. The top 10 molecular
descriptors are calculated for the antagonist and decoy compounds. Not all the
decoys are used for the descriptors calculation because calculating descriptors for
the decoys for all 81 GPCR targets account for more than 600,000 compounds,
that would require more computation time. The SVM model is applied to predict
the correct classes of antagonists and decoys and a resulting classification accuracy
of 0.96 is achieved. However, there is about 15% overlap between the antagonists
that are shared by some GPCR family members. When these duplicate ligands
were removed, it did not affect the classification accuracy. Classification results
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are depicted in Figure 5.4 which shows that antagonists are fairly discriminated
from the decoy compounds.
Table 5.3: List of some GPCR target families and sub-types and total number
of antagonists per family.
Family Name Subtypes Antagonists
5HT 5-hydroxytryptamine 1/2 A,B,C,D,E,F 2436
AA Adenosine 1,2,3, A,B 1106
ACM Muscarinic acetylcholine 1,2,3,4,5 586
ADA Alpha adrenergic 1/2 A,B,C,D 3016
ADR Beta adrenergic 1,2,3 585
DRD Dopamine receptors 1,2,3,4,5 1711
HRH Histamine receptors 1,2,3,4 529
OPR Opioid receptors D, K, M, X 75
PE2R Prostaglandin E2 receptors 1,2,3,4 512
NK Substance-K/P receptors 1,2,3 1164
Total 11720
Other other families 6585
Duplicates 2616
Decoys 4,000
5.3.2 Multiple Classification
Multiple SVM classifier is evaluated for the classification of multiple classes of
GPCR antagonists at their target family level. Multiple classification, contrary
to binary classification that only classifies GPCR-ligands and non-GPCR-ligands,
was used to distinguish between antagonist ligands that are specific for different
GPCR families. A total of 6533 antagonists from the GLL database are grouped
into 8 target families (as listed in Table 5.4 with respective number of antago-
nists per target family) and then the descriptors based multiple classification is
evaluated. All 274 descriptors were used for the multiple classification that were
previously calculated for the binary classification. Approximately 50% of agonists
from each target family were used in the training set and the rest were kept in
the test set. Duplicate antagonists were removed from both training and test sets.
MSVMpack [174], an open source package for multi-class support vector machines
was used for the classification of antagonists of multiple GPCR target families.
An overall classification accuracy of 86.7% on the test data set is obtained for
classifying antagonists of individual target families. Classification matrix (also
known as confusion matrix) over the test data set has been given in Table 5.5.
Values across diagonal of the matrix are the number of antagonist samples correctly
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Figure 5.4: Classification of antagonists/decoys for 81 GPCR targets from
GLL/GDD database. GLL antagonists are represented in red color and GDD
decoy compounds are represented in black color. The decision boundary line is
drawn horizontally at 0.
Table 5.4: List of GPCR target families grouped into classes with correspond-
ing number of antagonists and decoys per target family class used in multiple
classificaiton.
Class Family Subtypes Antagonists Training
set
Test
set
1 5HT 1/2 A,B,C,DE,F 1930 975 921
2 AA A1, A2, A2B, A3 652 352 296
3 ADA 1A,B,D, 2A,B,C 780 386 373
4 ADRB 1,2,3 205 99 93
5 DRD 1,2,3,4,5 1300 649 587
6 HRH 1,2,3,4 474 95 83
7 NK 1,2,3 1053 544 494
8 PE2R 1,2,3,4 139 99 31
9 Decoys 5968 1000 4968
classified in to their respective target family classes, while the off-diagonal values
denote the number of antagonists of one family class classified inside another
family class. For example, 54 antagonists of ADRB were correctly classified into
its ADRB class, 17 were misclassified into 5HT class, 1 was misclassified into AA
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class, 6 were misclassified into ADA and so on. These results show that using
molecular descriptors, the antagonists can be distinguished between the major
GPCR families of targets. Such multiple classification scheme can help design
target family specific libraries of compounds. In comparison to binary classification
where we used the list of top-ranked descriptors produced by SVM-RFE, we used
all of the descriptors in multiple classification as MSVMpack does not provide
functionality for selecting and ranking descriptors. Although there is a number
of antagonists shared by different target families, due to which the chances of
misclassification would increase, MSVMpack still performed good predictions of
the classes for most of the target families.
Table 5.5: Confusion matrix of the multiple classification predictions over test
data set for 8 GPCR target classes
5HT AA ADA ADRB DRD HRH NK PE2R Decoy
5HT 703 23 47 1 131 0 15 1 0
AA 23 218 5 0 14 0 7 0 29
ADA 185 7 109 3 46 2 18 3 0
ADRB 17 1 6 54 2 0 2 0 11
DRD 167 0 21 0 380 0 5 0 14
HRH 46 0 2 0 21 14 0 0 0
NK 29 20 6 0 6 0 430 3 0
PE2R 0 2 0 0 0 0 7 22 0
Decoys 5 10 12 11 45 2 7 0 4876
5.3.3 Drug Re-purposing Application
The resulting performance achieved with SVM to classify antagonists from non-
antagonists of GPCRs suggests that the classifier model can be applied on a set
of drugs or compounds to predict their likelihood of being antagonist for GPCRs
in general. In order to apply the classifier model on a data set of approved drugs,
approximately 1400 FDA approved drugs were downloaded from DrugBank [? ].
Molecular descriptors were calculated for the drugs as done before and the SVM
classifier model was applied to them. The classifier model predicted approximately
60% of all approved drugs as GPCR binders as shown in Figure 5.5.
Ranking order over the predictions of SVM classifier model was performed on the
basis of the probability values for each drug obtained by SVM. The top 20 high
ranking predictions were selected for subsequent analysis. For these selected drugs,
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their interacting targets and mechanism of action information were also retrieved
from DrugBank. It was observed that 9 out of the 20 predicted drugs had a
GPCR listed as a target and 5 drugs are targeting bacterial proteins as shown in
Table 5.6. The 2D structural diagrams of these drugs are depicted in Figure 5.6.
These drugs made a set of potential candidate drugs that can be used for drug
re-purposing study, particularly the antibiotic drugs can be investigated for their
potential use in other indication areas. The drugs that are already interacting with
GPCR targets mentioned in DrugBank can also be studied for their interactions
with other target families of GPCRs that might suggest new indication areas for
these drugs.
Figure 5.5: Classification results obtained for all FDA approved drugs from
DrugBank. The data points above the decision boundary line represent the
drugs classified as active against GPCRs. The drugs presented with red color are
suggested as the drugs with higher probability of being active against GPCRs.
Table 5.6: List of FDA approved drugs, their targets and indications from
DrugBank, which are predicted as GPCR binders.
DrugBank
ID
Targets Indication
DB00769 NR3C1, CYP3A4 Used topically as an anti-inflammatory in the
treatment of steroid-responsive dermatoses.
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DB00177 AGTR1, CYP2C9 Used as a first line agent to treat uncompli-
cated hypertension, isolated systolic hyperten-
sion and left ventricular hypertrophy.
DB00485 LMHCC 2184,
LMHCC 2773,
pbp1b, bp2a,
pbp3,pbpA, penA
Used to treat infections caused by
penicillinase-producing staphylococci that
have demonstrated susceptibility to the drug.
DB01190 rplJ, 23S rRNA,
CYP3A4
For the treatment of serious infections caused
by susceptible anaerobic bacteria, including
Bacteroides spp., Peptostreptococcus, anaer-
obic streptococci, Clostridium spp., and mi-
croaerophilic streptococci.
DB06718 Stanozolol Binding
Protein (STBP)
Used in treating C1-inhibitor deficient hered-
itary angioedema.
DB00947 ESR1, CYP3A4 For the treatment of hormone receptor
positive metastatic breast cancer in post-
menopausal women with disease progression
following anti-estrogen therapy.
DB00301 pbpA, CYP3A4 Used to treat bacterial infection by susceptible
microorganisms.
DB00496 CHRM1-
5,CYP3A4,
CYP2D6
For the treatment of overactive bladder with
symptoms of urge urinary incontinence, ur-
gency and frequency.
DB01046 CLCN2, CBR1 For the treatment of chronic idiopathic con-
stipation in the adult population. Also used
for the treatment of irritable bowel syndrome
with constipation in women who are 18 years
of age or older.
DB00332 CHRM1-
3,CYP3A4,
CYP2D6
For maintenance treatment of bronchospasm
associated with chronic obstructive pul-
monary disease, including chronic bronchitis
and emphysema.
DB00219 CHRM1 For the treatment of visceral spasms.
DB00319 pbp3, penA, pbp2a,
pbp1b
For the treatment of polymicrobial infections.
DB08795 pbp2a, pbp1b,
pbp3, pbpA, penA
For the treatment of infection (Respiratory,
GI, UTI and meningitis) due to E. coli, P.
mirabilis, enterococci, Shigella, S. typhosa and
other Salmonella, nonpenicillinase-producing
N. gononhoeae, H. influenzae, staphylococci,
streptococci.
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DB00728 CHRNA2,
CHRM2, HTR3A
Used as an adjunct to general anesthesia to
facilitate both rapid sequence and routine tra-
cheal intubation, and to provide skeletal mus-
cle relaxation during surgery or mechanical
ventilation.
DB01413 mrdA, ftsl,
pbpB,pbpA
For the treatment of pneumonia (moderate
to severe) caused by Streptococcus pneumo-
niae, including cases associated with con-
current bacteremia, Pseudomonas aeruginosa,
Klebsiella pneumoniae.
DB00209 CHRM1, CYP2D6 For the treatment of overactive bladder with
symptoms of urge urinary incontinence, ur-
gency, and urinary frequency, detrusor insta-
bility and frequency of micturition.
DB01196 MAP2, MAP1A,
ESR1,ESR2,CYP3A4
For the palliative treatment of patients with
metastatic and/or progressive carcinoma of
the prostate.
DB00704 OPRD1, OPRK1 Used as an adjunct to a medically supervised
behavior modification therapy in the mainte-
nance of opiate cessation in individuals who
were formerly physically dependent on opiates
and who have successfully undergone detoxifi-
cation.
DB00246 DRDs, HTRs,
ADRAs, CHRMs,
CYP3A4
For the treatment of schizophrenia and related
psychotic disorders.
DB01586 AKR1C2, CYP2E1 The drug reduces cholesterol absorption and
is used to dissolve (cholesterol) gallstones in
patients who want an alternative to surgery.
5.3.4 Targets Analaysis of Predicted GPCR Drugs
Targets information for the predicted drugs were also retrieved from the STITCH
database [60] to see if they have any GPCR interacting target. Target information
retrieved from STITCH database showed that there were GPCRs and other nuclear
receptors that are interacting with 10 of the predicted drugs for which there was
no GPCR target mentioned in the DrugBank as shown in Table 5.7. This tells
us that the predictions made by the machine learning model are correct. Further
In-silico validations are performed by comparative QSAR modeling and analysis
tools available in MetaDrug [175] database.The selected drugs that are predicted
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Figure 5.6: 2D structural representation of the top 20 approved drugs pre-
dicted as GPCR binders.
as potential candidate drugs for use against GPCRs are compared with a set of
known GPCR drugs that are interacting with multiple GPCR targets. A set of 22
known GPCR drugs is selected from GLL database. In-silico comparison was made
for the two sets of drugs by using QSAR based algorithms available in MetaDrug.
The comparison results performed with MetaDrug prediction algorithms are shown
in Figure 5.7 which shows that as the known GPCR drugs are interacting with
multiple GPCR targets, most of the predicted drugs are also interacting with
multiple GPCR targets.
5.3.5 Discovery of Mode of Action by Gene Expression
Profiling
The mode of action (MoA) of some antibiotic drugs that are predicted as GPCR
binders in this study, was analyzed by studying their similarity to drugs that have
known transcriptional responses to drug treatments. The online tool MANTRA
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Table 5.7: Interacting targets information retrieved for the top 20 drugs pre-
dicted as GPCR binders from DrugBank and STITCH Database.
Drug Targets in DrugBank Targets in STITCH
Hydrocortamate
(DB00769)
NR3C1, CYP3A4 Nuclear harmone re-
ceptors
Valsartan
(DB00177)
AGTR1, CYP2C9
Dicloxacillin
(DB00485)
LMHCC 2184, LMHCC 2773, pbp1b,
bp2a, pbp3,pbpA, penA
GPR44
Clindamycin
(DB01190)
rplJ, 23S rRNA, CYP3A4 GPR124
Stanozolol
(DB06718)
Stanozolol Binding Protein (STBP)
Fulvestrant
(DB00947)
ESR1, CYP3A4 GPER, CDH2
Flucloxacillin
(DB00301)
pbpA, CYP3A4 Cytokine receptors
Darifenacin
(DB00496)
CHRM1 5, CYP3A4, CYP2D6
Lubiprostone
(DB01046)
CLCN2, CBR1 PTGER4, HRH2,
GHSR
Ipratropium bro-
mide (DB00332)
CHRM1 3, CYP3A4, CYP2D6
Oxyphenonium
(DB00219)
CHRM1
Piperacillin
(DB00319)
pbp3, penA, pbp2a, pbp1b GPR124
Azidocillin
(DB08795)
pbp2a, pbp1b, pbp3, pbpA, penA
Rocuronium
(DB00728)
CHRNA2, CHRM2, HTR3A
Cefepime
(DB01413)
mrdA, ftsl, pbpB,pbpA CD248 (membrane
bound signaling
molecule receptor
Trospium
(DB00209)
CHRM1, CYP2D6
Estramustine
(DB01196)
MAP2, MAP1A, ESR1, ESR2,
CYP3A4
OPN3
Naltrexone
(DB00704)
OPRD1, OPRK1, OPRM1, OPRS1,
UGT1A1
Ziprasidone
(DB00246)
DRDs1 - 5, HTRs, ADRAs, CHRMs
Ursodeoxycholic
acid (DB01586)
AKR1C2, CYP2E1 Cytokine/Nuc.Harmone
receptors
[176] was used to identify drugs that have similar gene expression profiles by using a
large collection of transcriptional responses following compound treatments in the
connectivity map project [177], [178]. Following is a comparison of some antibiotic
drugs that have similarities to drugs which have GPCRs as interacting targets in
their expression profiles.
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Dicloxacillin is an antibiotic drug which has bacterial targets and it has similar ex-
pression profile to Metixene which is an antipsychotic drug with antimuscarinic ac-
tivity by targeting muscarinic choline receptors CHRM1, CHRM2,CHRM3,CHRM4
and CHRM5. Dicloxacillin is also similar in expression profile to Velnacrine that
acts as inhibitor of proteins with cholinesterase activity and have therapeutic role
in Parkionson’s disease (Figure 5.8).
Clindamycin is another antibiotic drug that has similar expression profile to Molin-
done that has DRD2 as a drug target and acts by decreasing dopamine activity.
Clindamycin has also similar expression profile to Nalbuphine that exerts its ac-
tion by binding to mu, kappa and delta opiod receptors in the GPCR family of
drug targets (Figure 5.9).
Flucloxacillin is another antibiotic drug that has similar expression profiles to
Cyclizine which posses anticholinergic, antihistaminic and central nervous system
depressant properties by acting as antagonist of protein histamine H1 receptor and
muscarinic choline receptors CHRM1,CHRM2 and CHRM3. It has also similarity
to Prestwick-972 that has interaction as agonists of proteins with GABA receptor
activity that belong to GPCRs family and are chief inhibitory neurotransmitter
in the CNS (Figure 5.10).
5.4 Conclusions
The GPCR class of targets that play important role in the indication areas of
central nervous system and many neurodegenerative disorders make them impor-
tant therapeutic class of targets. With the availability of more structural data for
GPCR targets that allow to investigate them in structure-based design methods,
GPCR focused libraries will be needed to study the receptor-ligand interactions.
Similarly, the availability of specialized GPCR specific ligand databases provides
a means for undergoing QSAR modeling for the design of GPCR focused com-
pound libraries. Machine learning based classification approaches are very helpful
to classify GPCR binders from non-GPCR binders and can be used to design tar-
get family specific set of ligands that can be used to target a specific family of
GPCRs. The classifier model built in this work can be effectively used to pre-
filter a database of compounds that can be specifically used in virtual screening
against the GPCR targets. Using the predictive power of such machine learning
based approach can provide a set of potential re-purposing candidate drugs that
can be further investigated in more detail. We have identified a set of 20 known
drugs that includes 6 antibiotic drugs, are proposed to be studied for activities
against multiple GPCR targets. Some of the predicted drugs have similarities
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to drugs that have GPCR as drug targets as discovered by their gene expression
profiling. The proposed re-purposing candidates, however, need to be validated
experimentally.
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Figure 5.7: Heatmap of drug-target interactions predicted by MetaDrug algorithms for two groups of drugs. Drugs are given in rows
and targets are given in columns. Black lines divides the drug groups into FDA approved known GPCR drugs and predicted GPCR
binding drugs. Some GPCR targets are zoomed into the box.
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Figure 5.8: Drug similarity network of dicloxacillin. Drugs that have simi-
lar expression profiles are connected by edges that are labelled with similarity
values.
Figure 5.9: Drug similarity network of clindamycin. Drugs that have simi-
lar expression profiles are connected by edges that are labelled with similarity
values.
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Figure 5.10: Drug similarity network of flucoxacillin. Drugs that have simi-
lar expression profiles are connected by edges that are labelled with similarity
values.

Chapter 6
Pose Ranking and Selection to
Increase Virtual Screening
Accuracy and Hit Rate
6.1 Introduction
Virtual screening has emerged as an effective tool that plays important role in the
discovery of novel lead compounds [179], [180]. Among the various methodolo-
gies in this area, the use of structure based design methods is increasing rapidly
[181]. Having experimentally determined the protein structure of a potential drug
target, virtual screening by molecular docking, in combination with many other
methodologies, has become an established technique in lead identification and op-
timization [182]. In the molecular docking approach, the docking tools are used
to predict the binding modes of the small molecule that is docked to a 3D struc-
ture of a receptor, and to score the resulting fitted complex [183]. However, the
docking programs are generally more successful in predicting good binding modes
as compared to correctly ranking the binders due to the limitations in their built-
in scoring schemes [184], [185]. These limitations and challenges in the scoring
functions and their failures in efficiently scoring the near-native binding poses
have been reported often [186],[187]. Various alternate strategies and methodolo-
gies have been suggested with strong emphasis on post-docking strategies [188].
Regardless the docking programs are still frequently used as a tool for virtual
compound screening and their coupling with other tools, such as molecular dy-
namics simulations [189] or re-scoring by using MM-PBSA/GBSA methods, have
resulted in further improvements in achieving the goals [190]. Similarly, many
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other approaches such as utilizing structural interaction information in the com-
pounds screening process are gaining importance [191], [192]. Such approaches
have proved very useful in the improvement of efficiency of the in silico predic-
tions [188]. Among these approaches, protein-ligand interaction fingerprints have
shown to enrich the screening results by re-scoring the docking poses to facilitate
the filtering process [192], [193], [194], [195].
6.1.1 Protein-Ligand Interaction Fingerprints
Protein-ligand interaction fingerprints (PLIFs) are a linear arrays of bit strings
that encode the presence or absence of a particular interaction between a pro-
tein and a ligand atom within a protein-ligand complex. These can be used in
similarity searching to identify molecules with similar structures. Several studies
have utilized the PLIFs information in improving virtual screening results by post-
processing the docking poses [196], [197]. The main objective of utilizing PLIF
information in screening a large database of compounds is to speed up the filter-
ing process of biologically active compounds by reducing the burden of visually
analyzing a large number of protein- ligand complexes to select the compounds
with good binding modes. The filtering process becomes easier to sort out the
compounds by identifying the key compound-receptor atom interactions.
6.1.2 Comparisons to Other PLIF Approaches
Our approach of utilizing PLIFs is different from that shown in recent studies
[188], [193] where interactions are calculated from the protein-ligand complexes
by applying geometric rules to determine interaction fingerprints and use similar-
ity measures to find optimal interactions similar to that of a reference compound.
Contrary to this, we use a simple weighted binary feature vector to identify a
residue interaction that is either having a close contact interaction or hydrogen
bonding interaction with the ligand. Here we present an easy and improved method
of utilizing the interaction information based on knowledge of the receptor inter-
actions with known active compounds. Weights are assigned to key interactions in
order to generate a weighted-residue profile. The residue profile includes the inter-
actions that are more frequently present or absent in the set of active compounds.
The weighted-residue profile is also much simpler and very easy to calculate from
the available data set of known active compounds as compared to using complex
functions to calculate weighted PLIF profiles as shown in the literature [194], [195].
The weight values are simply added up to the final energy based scores already
calculated by the docking programs for a predicted docking pose resulting in a
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so-called Z-score. Thus, the built-in scoring function is not completely ignored,
but rather the individual key interactions weight scores from the profile are used
as an additional piece of information to rank the compounds.
This approach is an improvement to other approaches because we do not only
consider the structural interactions but also take the significance of the interactions
into account. Another improvement is that the residue profiles are created in a
simpler way by the knowledge derived from the interactions of a set of known
active compounds with the receptor. This approach, which is based on a set of
many active molecules, helps to solve the problem of selecting a single molecule as
a best reference in the studies of protein—ligand interactions. Moreover, different
profiles can be used for different docking programs which can be interactively
optimized and further improved. Interactive improvement of the profile is based
on visualizing the interactions of known active and inactive compounds with the
target receptor under study and identifying the key interactions that are shown
only for the active compounds.
The main focus of this study described in this chapter is to demonstrate an easy
and effective way of post-processing the virtual screening results. This chapter
includes the methodology of utilizing PLIF information to achieve gain in accuracy
and increase in hit selection rate. The improvements in virtual screening results by
this methodology are described for a human GPCR target A2A and the method
is also applied on a few more target proteins. The method is also compared to
a known methodology that also utilizes PLIF information for pose ranking and
selection. Finally, the general applicability of the method is discussed.
6.2 Methods and Material
6.2.1 Preparation of the Residue Profile
Given an experimentally known ligand-receptor interaction, an initial list of the
residues in the active site pocket that are involved in ligand binding is prepared.
Such interaction information can be easily obtained either from the available struc-
tural data of the X-ray structure (co-crystallized protein-ligand complex), LIG-
PLOT [198], PDBSum [199] or other tool [200] that can determine or visualize
the interactions. Once the key residues that are involved in the interactions are
identified, a simple residue profile is created from these interactions as shown in
Table 6.1.
Residues in the profile are listed with their interaction types and their initial weight
values which are set primarily to 1 for all interacting residues. A residue profile is
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just a plain text file containing the residue names and the interaction types. As
shown in Table 6.1, the weight values are equal in the initial profile, which are not
taken into consideration at this moment. We set it to 1 because we do not know
the relative importance of each residue in this list.
Table 6.1: A sample initial residue profile created from the interactions listed
in Figure 6.1. Interaction types and their initial weights are listed in front of
each residue.
Residue Number Interaction type Weights
LEU167 Contact 1
PHE168 H-Acceptor 1
PHE168 Contact 1
GLU169 H-Donor 1
GLU169 H-Acceptor 1
ASN253 H-Acceptor 1
6.2.2 Generation of Protein-Ligand Interaction Fingerprints
Protein-Ligand Interaction Fingerprints are generated from the interaction infor-
mation of the top best docking results produced by the two docking programs
FlexX [201] and AutoDock [202]. We used these tools successfully in our previous
projects [40], [203]. Both, FlexX and AutoDock are amongst the most widely used
docking tools [204]. FlexX is based on an incremental fragment construction and
a conformation sampling algorithm, while AutoDock is based on Lamarckian ge-
netic algorithm. FlexX can, by default, generate the interaction information of the
predicted binding poses along with the binding energy scores of the docked con-
formations of the ligand. However, AutoDock does not produce such interaction
information by default and therefore, AutoDockTools [205] scripts were modified
to produce similar interaction information for the docked conformation of the lig-
and like those of FlexX. The interaction information is written to a plain text or
comma separated file that contains the list of interacting residues and interaction
types. The programs SKIFP and SKIFP2SVG, which we have written in C/C +
+ language, are used to generate and visualize respectively, the fingerprints from
the protein-ligand interaction information from the text/CSV files produced by
FlexX/AutoDockTools script.
The initial list of residues is obtained from the available interaction data of the
co-crystallized ligand bound in the X- ray structure (PDB- Code: 3EML) of A2A
receptor [206], a G-protein coupled receptor (GPCR) subtype which is an impor-
tant therapeutic target in neurodegenerative disorders [207]. A data set of about
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Figure 6.1: Schematic representation of the interactions between A2A recep-
tor residues and ZM241385 (the cocrystallized ligand) at the ligand binding
site. The dashed lines represent the close contacts and hydrogen bonding in-
teractions of the ligand with the receptor residues and the semi-circles show
the hydrophobic interactions. ZM241385 is displayed in ball-and-stick model.
Residues mutations that are reported to disrupt agonist and/or antagonist bind-
ing are within blue squares [206].
160 known antagonists with experimentally determined binding affinities for A2A
were collected from the literature [208], [209], [210], [211]. These known active
compounds are not all similar but comprised of diverse compound classes of A2A
antagonists, including adenine derivatives together with xanthine, non-xanthine
and caffeine derivatives. All the compounds in the data set of known actives were
docked against A2A receptor using FlexX and AutoDock and interaction infor-
mation were extracted from the docking results. The fingerprints were generated
and visualized by SKIFP and SKIFP2SVG programs. The compounds were sorted
on the basis experimentally determined Ki values (i.e. highly active compounds
at the top, low active compounds at the bottom) and not by binding energies or
docking scores. This ordering facilitates building an efficient interaction profile by
the identification of the key residues involved in the interaction of highly active
compounds (Figure 6.2. In this figure, the top listed (80 out of 160 compounds)
represent the highly actives (smaller Ki values) while the bottom listed compounds
represent the less actives (larger Ki values) antagonists of A2A receptor. Each dark
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band in the pattern represents the presence of the interaction of a receptor residue
with a compound.
Figure 6.2: Fingerprint bits for the set of known active compounds by their
interaction with the receptor residues given in Table 2. (A: docked with FlexX,
B: docked with AutoDock). Compounds are listed on the basis of decreasing
affinity, highly actives (lower Ki values) at the top and less actives (greater Ki
values) at the bottom.
6.2.3 Preparation of the Weighted-Residue Profile
A weighted residue profile is prepared from the fingerprint patterns of interactions
as given in Table 6.2. This method takes into account the activity data of the
known active compounds. The weights in the residue profile are assigned based on
the fingerprint densities of the highly active compounds. More weights should be
assigned to those residues whose interaction bits are only present (darker) in the
top highly active compounds subset than the less actives. A fingerprint pattern
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present in all of the complete data set would mean that the interaction is present
in all of the compounds and therefore is not very significant in the activity and
would suggest a smaller weight value to be assigned to the respective residue in
the profile (Figure 6.3).
Table 6.2: Weighted residue profiles for FlexX and AutoDock.
Residues Interaction type FlexX Weights AutoDock
Weights
LEU167 Contact 15 20
PHE168 H-Acceptor 1 1
PHE168 Contact 1 1
GLU169 H-Donor 30 30
GLU169 H-Acceptor 20 30
GLU169 Contact 30 5
TRP246 Contact 5 15
LEU249 Contact 5 5
HIS250 Contact 10 20
ILE252 Contact - 5
ASN253 H-Acceptor 30 20
ASN253 H-Donor 30 30
HIS264 Contact 15 20
ALA265 Contact 15 20
LEU267 Contact 5 20
MET270 Contact 20 5
ILE274 Contact 5 5
HIS278 Contact 5 5
6.2.4 Data Sets for Method Evaluation
Two test data sets of about 1000 compounds in each set were randomly selected
from the focused library and included the 80 highly active known compounds.
The target-focused library was designed for the antagonist study of A2A receptor
using Pharmacophore models built with MOE [92], Feature-Trees [122] similarity
searching in the ZINC database [212] (that contained ≈6 million compounds) and
scaffold hopping in the large combinatorial Fragment Space [213] (that contained
≈2 billion virtual compounds). These data sets are taken from the focused library
instead of selecting compounds from any random ”drug-like” compound library.
This ensures that we avoid artificial enrichments in recovering the known actives
amongst the library [214]. One data set contained compounds from the ZINC
database while the other data set contained the compounds filtered from the com-
binatorial Fragment Space. Two different data sets are selected that are filtered
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Figure 6.3: Weighted-residues profiles comparison used with FlexX and
AutoDock dockings. Weight values are assigned to each interaction type based
on the fingerprint patterns presented in Figure 6.2 for the two docking tools.
With slight differences in the weight values for certain interaction types, both
profiles indicate significance of key interactions in the residue profiles.
from different sources by a variety of filtering methods to evaluate the performance
and stability of the method in recovering the known active compounds.
6.2.5 Virtual Screening by Molecular Docking
Docking calculations were carried out using FlexX (version 3.1.4) and AutoDock4
(version 4.1.2) for both data sets. Default parameter sets were used in FlexX
dockings, while Lamarckian genetic algorithm with default parameters were used
in AutoDock dockings. Rigid receptor docking calculations were used in both
docking programs. Docking jobs data management, execution and post-processing
of the results were performed on the compute clusters using our well-established
virtual screening framework [40]. The top 10 docking predictions (i.e. poses) for
each compound docked were retained for further analysis using the interaction
fingerprints yielding a descriptive set of receptor residues interactions for each
compound.
6.2.6 Rescoring by Z-Score and TC-MIF
Post-processing of the docking results is done by Z-scores and TC-MIF (Molecular
Interaction Fingerprints with Tanimoto-Coefficient metric). For each of the top 10
docking poses, Z-scores are calculated by the SKIFP program and TC-MIF scores
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are calculated by the FingerPrintLib [188] program that uses OpenEye [215] li-
braries. A docking pose at rank 3 or 7 out of 10 may have a docking score less than
the 1st ranked pose, but may have a better binding mode if the required interac-
tions are matched with those specified in the residue profile. A complete re-ranking
is achieved for a pose by simply adding the weight values to its docking score. The
Z-score, in this case, is similar to the pharmacophoric features that prioritize the
docking poses based on the significant interactions specified in a pharmacophore
model. However, Z-score is different than the pharmacophore model used within
FlexX docking program. In FlexX, pharmacophoric constrains lead to no docking
predictions if the pharmacophoric constraints need to be essentially fulfilled during
the pose filtering stage.
6.3 Results and Discussion
The top 10 poses for each compound in the data sets screened against the receptor
were retained for post processing. Post processing included ranking and filtering
the docking poses on the basis of three criteria:
1. On the basis of highest energy/binding energy scores of FlexX and AutoDock
2. On the basis of highest Z-score by using PLIFs with weighted- residue profiles
for the top 10 docking solutions, and
3. On the basis of TC-MIF values calculated for the top 10 docking solutions
with using the co-crystallized ligand as a reference.
Database enrichment is calculated from the percent active molecules recovered
from the percent database screened. Results quantified from both screening data
sets have shown that Z-score increases the hit rates in the top 5% to 15% of the
database in both docking programs for all data sets (Figure 6.4 and Figure 6.5).
The hit rate increases by ∼40% to ∼3 fold in the top 5% of the database docked
with FlexX and AutoDock respectively. For example, in the top 5% of the 1000
compounds database (i.e. top 50 ranked compounds), FlexX score recovered 25
active compounds, while Z-score recovered 35 active compounds (Figure 6.4, data
set 2). Similarly, in top 50 ranked compounds, AutoDock score recovered 10 active
compounds, while Z-score recovered 40 active compounds (Figure 6.5, data set 1).
This is desirable because only a fraction of the whole database is filtered (e.g.
top 1% to 10% depending on the database size) for subsequent detailed analysis.
Performance measures of the three filtering criteria were also quantified by ROC
(Receiver Operating Characteristics) curves as shown in Figure 6.6 and Figure 6.7.
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Z-score has shown similar performance, in terms of active compounds recovery in
the top ranked compounds to TC-MIF based filtering of the two data sets, and
thus improves the recall ratio over the docking score based ranking in the top
ranking results. Furthermore, the binding poses of the top ranked compounds are
more similar to the binding pose of the co-crystallized ligand in the case of Z-score
and TC-MIF than the energy based scoring. This indicates the usefulness of this
approach to re-rank the compounds with good binding modes without taking the
co-crystallized ligand as a reference.
The main purpose of this study is not to compare the results of different docking
tools or to compare the methodologies of using protein-ligand interaction finger-
prints. Instead, the current study demonstrates that PLIFs can be utilized as
additional source of information to improve the docking results. The molecu-
lar interaction fingerprint method (TC-MIF) has been taken as a reference tool
and used to evaluate the efficiency of the current approach for its applicability
in post-processing and filtering results of large scale virtual screening. However,
an improvement of this approach over TC-MIF and other automated PLIF based
filtering methods is that residue profile can be interactively modified to favor cer-
tain interaction types. Filtering for the desired interaction types can be used to
filter compounds on the basis of their mechanism of binding (e.g. agonists or
antagonists binding mechanisms).
As a cross validation test, when equal weight values are assigned to each inter-
action type in the weighted-residue profile, the results are not improved in terms
of hits enrichment. This indicates that certain residues interactions are more im-
portant than others and therefore a higher weight value should be assigned to
them. Similarly, interchanging the profile of FlexX with AutoDock and vice versa
(Table 6.2 and Figure 6.3) do not produce satisfactory results as compared to
using the respective profile of the docking tool, although the results in terms of
database enrichment are still better than the energy based scores. This tells about
a limitation of this approach that a general residue profile should not be used for
multiple docking programs.
To test the general applicability of the method, we evaluated the approach on a
few more targets. For this purpose we had the inhibitor data set for MAOB from
BindingDB [62] and additionally selected three more targets from a DUD [173]
data sets. The three targets (ACHE, ACE and INHA) were arbitrarily selected
from the DUD database. All the target structures and the compound databases
(their respective ligands and decoy molecules) were energy minimized using MOE
with MMFF94x fore field. The crystal ligands bound in the receptor complex
were re-docked to reproduce the crystal structures binding modes. The RMSD
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Figure 6.4: Z-score comparison with FlexX energy scores and TC-MIF based
rankings for two data sets. Z-score is calculated from the weighted-residue
profile and TC-MIF values are calculated from molecular interaction fingerprints
of the docked poses in the pro- tein complex.
values for the re-docked ligands of all targets were below 2 A˚. The re-docking
experiment is performed to validate the docking workflow and to indicate that
the target structure is prepared for docking other non-native ligands. The known
active compounds of the respective target proteins were used to generate the target
specific residue profiles. Afterwards, the compounds were screened against the
respective targets and the results of virtual screening were ranked on the basis of
docking score as well as Z-score. Improvements in terms of recovering the known
ligands from the decoy database were shown in the results obtained by ranking
with Z-score as presented in Figure 6.8.
In summary, the results demonstrate that PLIF based pose filtering approaches
generate a new ranking as compared to the docking based score. Such approaches
should be used to overcome the limitations in the default scoring functions of the
docking programs. Advantages of our approach include integration of the method
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Figure 6.5: Z-score comparison with AutoDock binding energy scores and TC-
MIF based rankings for two data sets. Z-score is cal- culated from the weighted-
residue profile and TC-MIF values are calculated from molecular interaction
fingerprints of the docked poses in the protein complex.
for automated post processing the virtual screening results and the potential to
perform mechanism based filtering, although the mechanism based filtering is not
evaluated. The docking results can be further improved if receptor flexibility is
introduced during the docking calculations.
6.3.1 Binding Mode Analysis
The results ranked on the basis of three criteria (i.e. energy score, Z-score and
TC-MIF score) showed a comparative performance in re-ranking the reference
compound (i.e. the co-crystallized ligand) in the top ranking hits. From the
rank order of the reference compound, we can suggest that the top ranking hits
will have good binding modes that are similar to the reported binding mode of
the reference compound. Table 6.3 shows the ranks for the compound ZM241385
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Figure 6.6: Performance measures of the three filtering criteria used in screen-
ing two data sets with FlexX. In both data sets, Z-score has greater recall of
the active compounds than TC-MIF and Energy based rankings in the top 5 to
15% of the filtered database as also shown in the enrichment plots.
in 1000 database compounds by the three scoring criteria. ZM241385 is the co-
crystallized ligand in the crystal structure of A2A receptor and is a selective A2A
antagonist [216]. The rank assigned to the reference compound highlights the
increase in accuracy of binding mode because it has been ranked among the top
1% of the database screened in the case of ranking by Z-score and TC-MIF in all
data sets as compared to docking score based ranking. This is obvious because the
PLIF based Z-score and TC-MIF score use the same interactions observed in the
co-crystallized ligand as reference. However, we can only suggest a similar binding
mode for the top ranking compounds but not necessarily a similar bioactivity
unless it is validated experimentally.
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Figure 6.7: Performance measures of the three filtering criteria used in screen-
ing two data sets with AutoDock. In both data sets, Z-score has greater recall
of the active compounds than TC-MIF and Energy based rankings in the top 5
to 15% of the filtered database as also shown in the enrichment plots.
Table 6.3: Reference compound ZM241384 ranked in two screening data sets
by three criteria.
Criteria FlexX Docking AutoDock Docking
Data set 1 Data set 2 Data set 1 Data set 2
Energy score 15 32 208 230
Z-Score 1 3 9 13
TC-MIF 3 2 1 1
6.4 Conclusions
Docking scores are a typical way to sort out and select the best hits while analyzing
virtual screening results. However, the inability of scoring functions to accurately
score and rank drug candidates in a virtual screening campaign is currently the
main limitation of docking tools. On the other hand, the docking programs are
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Figure 6.8: Improvements in recovering known ligands from the database
of decoys by ranking with Z-score. Top left: INHA (Enoyl ACP Reductase),
Top right: MAOB (Monoamine Oxidase-B), Bottom left: ACHE (Acetylcholine
Esterase), Bottom right: ACE (Angiotensin-Converting Enzyme).
generally good in providing good binding poses. Thus, by taking the available
knowledge of the protein 3D structure, its binding site and the ligand-receptor
constructs, selection of the candidate compounds from the docking results require
a lot of human post-processing that is time consuming. To help address this prob-
lem, we have developed a simple and semiautomated way of generating protein-
ligand interaction information from the docking results. This information can be
utilized efficiently in the analysis of large-scale structure-based virtual screening
results to prioritize candidate compounds with good binding modes. The PLIF
derived Z-score, which is based on the weighted- residue profile, is obtained for a
set of important residue interactions and then added to the docking score for a
predicted docking pose. In this study, Z-score has demonstrated sufficient increase
in the enrichment of active compounds against the randomly selected compound
data set. The data sets were obtained from the already prepared focused library
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of A2A receptor. Compared to docking-score alone (i.e. energy based), the addi-
tive Z-score methodology performed very well in retrieving the active compounds
against the database of decoys. In contrast to the protein-ligand interaction finger-
prints that were proposed previously (e.g. TC-MIF), the methodology proposed
in this study can be easily implemented in an existing virtual screening workflow,
which further makes this method easily applicable by structural biologists and
medicinal chemists. Though the importance of PLIF in rational drug discovery
was identified long ago [192] ,[194] and several other studies published along the
same lines [185], [193] the current study differs by deriving PLIFs from the gener-
ated docking results, rather than from the explicit use of protein-ligand complexes.
Furthermore, fingerprint bits are residue based and not determined from the atom
to atom contacts in the molecule complex. Weights in the weighted residue profiles
are determined from the initial fingerprints data of known highly active compounds
instead of using any mathematical function to calculate weights as presented in
[195]. The weights derived in this approach are simply based on the user’s prefer-
ence for certain interactions. Similarly, an another advantage of favoring specific
binding mechanism can help filter the results for specific binding modes. However,
this also imposes a limitation on building a residue profile that can favor multiple
possible binding modes. Another limitation of the approach is the requirement of
bioactivity data to signify certain interactions, which is sometimes missing.
The use of PLIF information can significantly enrich the number of positive hits
as compared to the number of decoy compounds in a virtual screening experiment
by molecular docking. The amount of time spent and efforts involved in filtering
by manual post-processing will be effectively reduced by integrating the current
approach in the virtual screening pipeline. We therefore propose to integrate
this approach at the crucial stage of analyzing and filtering the results of virtual
screening by molecular docking.
Chapter 7
Exploring Polypharmacology
through In-Silico Pharmacology
Approaches
7.1 Introduction
Computer aided molecular models based on novel approaches towards drug discov-
ery and development can speed up and enhance productivity while reducing costs.
Such models that have predictive power can be useful for establishing efficacy
and safety profiles of new drug candidates. Computer aided molecular modeling
started to develop some decades ago with the enhancement and capabilities of
computational methods and hardware [217]. These in-silico computational meth-
ods have increasingly developed over the past decades that is providing support at
every stage of the drug discovery development workflow through integrating and
analyzing heterogenous data in the field of computational drug discovery [218],
[219]. Heterogenous data in this field are used in in-silico pharmacology for the
creation of computational models or simulations. These simulations can be used
to suggest hypotheses and make predictions for the discoveries of new therapeutics
[220]. Computational methods can be applied at various drug development stages
with the emphasis to reduce the time and experimental costs [221], [222],[223]
that are involved at different stages of the drug development pipeline [224],[225].
Computational methods have been successfully applied in hit identification early
in the drug discovery process [226], [227],[228] and have gained popularity in both
academia and pharmaceutical industry, as evident in many journals that are re-
porting theory usage in drug development [229]. However, there is still a need to
re-examine the underlying principles in in-silico approaches [230] with the goal of
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the success rate of new drugs development [231], [232].
Virtual Screening (VS) [233], [234] is one in-silico approach for finding lead com-
pounds that is complementary to high-throughput screening [235]. The major
objective of VS is to accelerate the drug discovery process [236]. It is often used to
identify novel chemotypes [237] and to enrich a library of compounds that have an
increased chance to be active against certain molecular targets [238]. Integrated
target based [239] and ligand based [240] VS have emerged resource-saving tech-
niques that have been successfully applied in the screening of bioactive molecules
[241]. VS is divided into two classes namely ligand-based and target-based VS.
Ligand-based VS requires the structural information and properties of the ligands
and target-based VS requires 3D structural information of the targets, and the goal
is to identify bioactive ligands that will bind to the target structure [220]. Iden-
tification and validation of a successful target is one of the most important steps
in new drug development [224]. To maximize the success rate of new drug devel-
opment, rational drug design [242] approaches rely on the discovery of successful
drug targets [243]. However, the process of new target discovery and validation
is complex and bear a high degree of uncertainty [244]. Therefore, substantial
improvements in the underlying target discovery approaches are needed. On the
other hand, major improvements are needed in the approaches towards rational
design of new drug candidates [245],[246]. A frequent argument against in-silico
hit identification and optimization approaches is that finding hits is easier as com-
pared with the later stage challenges faced in drug discovery [247], However, these
approaches certainly allow us to cost-effectively streamline the drug discovery pro-
cess [248]. Improvements and advances in both structure-based and ligand-based
drug design methods [249] will have a dramatic impact on advancing new drug
candidates to the clinic [250].
7.1.1 Polypharmacology
Traditional drug design strategies have predominantly been developed with the
goal of identifying high affinity binders by high-throughput experimental screen-
ing of large chemical libraries, or by rational approaches based on the three-
dimensional structure of the target [251]. However, in the recent years several al-
ternative strategies, such as polypharmacology and systems biology, have emerged
that will likely affect the future of small molecule drug discovery [252]. Polyphar-
macology has appeared in the form of drug promiscuity, where a drug hits multiple
targets of the same family (e.g. kinases) [253] and multiple targets of different fam-
ilies [254]. This paradigm shift from the classical approaches, which are based on
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target selectivity, towards polypharmacology is supported by increasing evidences
[255],[256] that a drug can hit more than one target [76]. In contrast to the design
of selective ligands, therapeutic polypharmacology resulting from one drug binding
to multiple targets contributes to overall effectiveness of a treatment [90]. There
is emerging evidence that polypharmacology resulting from compound promiscu-
ity is key reason to the efficacy of many drugs [257], [258], [259]. A successful
approach has been reported that is based on automated design of ligands for dis-
covering their polypharmacological profiles [260]. These promiscuous drugs elicit
their therapeutic effects by acting on multiple targets [261] and their promiscuous
chemotypes are explored by studying them in combination with multiple targets
[262],[263]. The polypharmacological relationship between ligand structures is dis-
covered by identifying promiscuous scaffolds or ”privileged” substructures present
in these ligands [264]. Polypharmacology is also investigated on the target protein
structures by exploring the backbone skeletal structures of protein pockets [265]
to derive pocket similarities. The similarities in drugable pockets are also used
to classify target proteins having similar binding sites [266] that can be used to
predict the polypharmacology on the targets side. Therefore, promiscuity is not
only present in the ligand structures, but it also exists in the target structures.
This can help explain molecular recognition and functions of the target proteins
[267] that can be exploited for polypharmacology.
There exist two definitions for polypharmacology. In the first type, there are
multi-target drugs, where single drugs act against multiple targets and in the
second type, polypharmacology results from multiple concurrent therapies (com-
bination therapies) that involve the use of multiple drugs to treat complex diseases
[268]. The combination therapy can not be assumed to be completely safe because
of drug-drug interactions [269], [270], [271]. In this study, we will not focus on this
type of polypharmacology involving multiple concurrent or combination therapies,
but rather explore the promiscuity of a single drug acting against a set of multiple
target proteins.
7.1.2 Combining Docking and Molecular Dynamics
With the advancements in chemoinformatics and computational techniques, dock-
ing and molecular dynamics (MD) simulation studies have become widely used
in rational drug design [189], [272],[273] to identify novel ligands with detailed
binding modes and interactions [274], [275]. Tools and methodologies should con-
tinue to improve so that emerging research area such as polypharmacology, can
be explored [276]. Molecular dynamics is one such method that can be applied
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to predict properties of small molecules, which follows molecular behavior and
properties of molecules (e.g. biological or chemical entities) through time. The
underlying molecular behavior requires a deeper understanding of their dynamics.
Molecular mechanics (MM) and quantum mechanical (QM) calculations are often
coupled with docking and MD to accurately predict binding affinities [277]. QM
calculations are used for geometry optimization and MM minimizations are used
to relieve the close non-bonded conflicts in the protein-ligand complex and free
energy calculations.
A typical structure-based virtual screening workflow starts with obtaining a 3D
structure of a protein target and a target focused compound library. Machine
learning based methods are gaining popularity to filter a database of compounds
[278] enriched for specific area of interest [39], [279]. Docking is generally used to
obtain a favorable binding mode and to filter a large compound library by using
internal scoring functions and/or subsequently enriched by using external scoring
functions such as NNScore [280] and refinement with MD calculations [189]. To
overcome the limitation of docking scoring functions, MM based post-processing
methods serve as an automated procedure to re-score the docked protein-ligand
complexes[281] and thus obtain a better ranking ligand [282]. MD simulation
is extensively used to study a pre selected set of compounds for conformational
flexibilities and allow to select a reasonable ligand conformation followed by the
application of MM based methods (e.g. MMPBSA) for the prediction of bind-
ing affinities. Combined with docking and MD, various methods such as molec-
ular mechanics Poisson-Boltzmann Surface Area (MM-PBSA) and Generalized
Born Surface Area (MM-GBSA) are quite useful and effective in the prediction
of free energy of binding [283], [284]. MM-PBSA and MM-GBSA based methods
use molecular mechanics calculations and continuum solvation models to estimate
binding free energies [285]. MD simulations are among important computational
chemistry methods that are used for the investigation of the dynamic behavior of
candidate drugs in the early stage drug discovery and also continue to develop in
the future for better understanding the human biology [286]. However, MD sim-
ulations are time and resource expensive calculations, but with the availability of
modern hardware such as graphical processing units (GPUs), high-throughput MD
is now possible that is leading MD simulations as a standard tool in biomedical
research [287].
This chapter focuses on exploring polypharmacology through in-silico pharma-
cology approaches. The approaches include the application of in-silico methods
and tools to explore targeted polypharmacology in the area of neurodegenerative
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disorders (NDD). Both ligand-based and structure-based design methods are stud-
ied. Multiple target proteins that are selected through network pharmacology, are
studied and evaluated for their polypharmacology and new multi-target ligands are
identified. Known drug-target interactions are studied through molecular docking
and molecular dynamics simulations to reproduce experimentally determined in-
teractions. Focused libraries of compounds are generated using chemical similarity
searching and through the application of machine learning based classifier models
as discussed in Chapter 4. MM-PBSA/GBSA based methods are used to evaluate
binding free energies for the focused libraries against multiple targets. Further
in-silico predictions methods based on QSAR models are performed to reproduce
similar results.
7.2 Methods and Material
Know drug-target interactions are studied for exploring potential polypharmacol-
ogy. A set of protein targets and drugs is selected that is used subsequently in
candidate drug discovery by targeted polypharmacology. The protein targets are
selected by using network based approach and used in the structure-based virtual
screening. The selection of targets is critical and they should be involved in neu-
rodegenerative disorders. The rational behind the selection of targets is based on
their topology in the drug target network as described in detail in Chapter 3, and
they participate in a therapeutic role in neurodegenerative disorders. There exist
more than 400 FDA approved targets present in the NDD drug-target network
that are therapeutically relevant in neurodegenerative disorders, as mentioned in
Chapter 2. Therefore, it is necessary to define criteria that allow for prioritizing
targets for our study of polypharmacology. The targets, which are selected out of
those 400 available targets in the network will serve a representative set of targets
for exploring polypharmacology. Table-7.1 shows a list of target proteins and their
associated major disease categories that were selected for virtual screening based
on network pharmacology approaches.
The rational approaches towards target selection, as described Chapter 3, consist
of various criteria that are briefly described as follow:
1. The selected targets should be validated and approved targets with clear
therapeutic role in neurodegenerative disease indications.
2. The selected targets are interacting with FDA approved drugs that are cur-
rently used for the treatment of neurodegenerative disorders.
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Table 7.1: List of selected targets and their associated disease classes retrieved
from the curated CTD[49] database.
Target Full Name Disease Categories
ADRB2 Beta-2 Adrenergic Receptor CNSa/Immune, Cancer
ADORA2A Adenosine A2A Receptor CNS/Mental, Cardiovascular.
DRD3 Dopamine D3 Receptor CNS/Mental
HRH1 Histamine H1 Receptor CNS/Immune, Cardiovascular
CXCR4 Chemokine CXC4 Receptor CNS/Cancer
PDE4A Phosphodiesterase 4A Mental disorders
MAOB Mono-amine Oxidase B Blood/Cardiovascular, Men-
tal/CNS
a CNS: Central Nervous System.
3. The targets have experimental three-dimensional structural data available.
4. The targets exhibit polypharmacological profiles: they are one of multiple
targets that interact with an approved drug used for the treatment of NDDs.
5. The selected targets have significant binding site similarities.
Figure 7.1: Disease-target network generated from curated gene-disease asso-
ciations retrieved from CTD database. Target genes are shown in green color
and disease categories are shown in red and blue color. Disease categories shown
in red color highlight that most of the selected targets have therapeutic roles in
the these disorders.
A disease-target association network is depicted in Figure-7.1, which exemplifies
the importance of selected targets. The selected targets were queried in the CTD
database for gene-disease associations and their curated disease categories were
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retrieved. These targets have therapeutic role in various diseases including neu-
rodegenerative and other CNS related disorders, as shown from the disease-target
network built from CTD’s gene-disease associations. Most of the selected tar-
gets are G-protein coupled receptors (GPCRs), since many GPCRs lack crystal
structures, we selected targets that have X-ray crystal structure available to facil-
itate the structure-based molecular modeling studies. There is significant binding
site similarity between the selected 5 GPCR targets mentioned in Table-7.1 and
therefore, the selected target set represents a good example of exploring polyphar-
macology based on binding site similarity. Another reason for selecting this set of
targets was that they are the primary and secondary targets for FDA approved
drugs that are currently used in various NDDs. Additionally two enzymes (MAOB
and PDE4A) were also considered to validate the polypharmacology hypothesis
as these two targets have also, although very low, binding site similarity with the
other selected targets. According to our polypharmacology hypothesis, a set of
compounds will result in similar or lower free energy of binding by interacting with
those targets that have high binding site similarities. Conversely, the compounds
should have dissimilar or higher free energy of binding by interacting with those
targets having low binding site similarities.
Table 7.2: FDA approved drugs with their indication areas from DrugBank
(DB), Therapeutic Targets Database (TTD) and Comparative Toxicogenomics
Database (CTD), selected for polypharmacological study against the selected
targets.
Drug Indication Areas
Apomorphine Parkinsons disease (DB/TTD), Epilepsy (CTD)
Bromocriptine Parkinsons disease (DB/TTD), Seizure (CTD)
Buprenorphine Severe pain, opioid dependence (DB), Pain (TTD), Seizure
(CTD)
Cabergoline Parkinsons (DB), Hyperprolactinemic disorders (TTD), RLS
(CTD)
Dopamine Myocardial infarction, Trauma (DB), Seizure (CTD)
Epinephrine Anaphylaxis, Sepsis (DB/TTD), Amnesia, Seizure (CTD)
Haloperidol Schizophrenia (DB/TTD), Alzheimers, dementia, Epilepsy
(CTD)
Lisuride Parkinsons disease (DB/TTD), Depression, Seizure, Tremor
(CTD)
Pimozide Tourette’s Disorder, Antipsychotic (DB), Schizophrenia
(TTD)
Naltrexone Heroin/alcohol dependence (DB/TTD), Multiple Sclerosis
(CTD)
Risperidone Schizophrenia, dementia (DB/TTD), Dementia (CTD)
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The drug-target interaction sub-network, composed of the selected FDA approved
drugs around the targets, is depicted in Figure-7.2 that shows the structural sim-
ilarity of drugs together with the binding site similarities of their interacting tar-
gets. The sets of selected drugs and targets represent a good selection for the
study of targeted polypharmacology since many of the drugs interact with multi-
ple targets. Such interactions are experimentally known and direct interactions.
Possible interactions may also occur based on similarity theory. Moreover, many
drugs have reported experimental activity data available for the selected targets
as reported in BindingDB [62] and KiDB [63]. The experimental activity data was
used as a reference to validate our polypharmacolgy workflow and reproduce the
same interactions by estimating the free energy of binding. The drugs mentioned
in Table 7.2 and depicted in Figure-7.2 have experimentally determined Ki values
for ADRB2 and DRD3 receptors. For the rest of the GPCR targets, none of the
drugs have experimental activity data available. Activity values of most of the
drugs were also found for some other GPCR receptors not studied here, however,
those targets do not have three-dimensional structure available and hence were not
considered for comparison. Therefore, MD study was performed on the selected
drugs against 5 GPCR targets and comparisons with experimentally determined
activity values were carried out for ADRB2 and DRD3 receptors.
7.2.1 Workflow
The workflow outlined in Figure-7.3 represents the major components and models
applied in the study of targeted polypharmacology. The workflow is duplicated
in two parts. The purpose of the first part is to reproduce the known drug-
target interactions and explore polypharmacology on a set of multiple targets.
The purpose of the second part is to discover novel candidate compounds that
exhibit polypharmacological profiles. The second part extends the same workflow
by including focused compound libraries filtered by the classifier model (Chapter 4)
and fingerprint-based similarity comparisons. The set of selected approved drugs
are first screened by docking against the targets, then their best binding poses are
filtered. Afterwards, MD simulations are performed for all drug-target complexes.
Using MM-PBSA/GBSA based methods, the free energy of binding are estimated
for the complexes.
The aggregated knowledge and data that is coming from various knowledge base
resources and stored in the HBP forms a basis for designing data-driven mod-
els. The design, constructions and evaluation of computable models are used for
Chapter 7. Exploring Polypharmacology 117
Figure 7.2: A set of FDA approved drugs interacting with selected targets.
Red lines indicate drug-drug and protein-protein binding site similarities and
blue lines indicate drug-target interactions. 2D structural diagrams are shown
for the selected drugs.
studying targeted polypharmacology in brain disorders in general and in neurode-
generative disorders in particular. The workflow outlines three major modeling
approaches originating from the HBP after the initial data collection step is per-
formed. The first approach is the design of ligand-based models combining QSAR
and machine-learning methods to characterize drugs and ligands for their poten-
tial evaluation in NDD disorders. With the help of this approach, existing drugs
are evaluated for cross-indications (drug-repositioning), and for designing disease
specific focused libraries (e.g an NDD focused library). The second approach uses
network-based pharmacology to identify and select drug-target combinations for
prioritizing targets to be evaluated in the study of targeted polypharmacology. The
third modeling approach is exploring and validating (both in-silico and in-vitro)
polypharmacology by combination of structure-based design tools and method-
ologies. These methodologies include combining docking and molecular dynamics
into a single workflow, in which a series of structure based virtual screening tools
are applied. Molecular dockings are performed on an array of selected targets,
in which poses of a ligand are subsequently ranked and filtered for the respec-
tive targets. Molecular dynamics simulations are performed for the top-ranked
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poses. Finally, a molecular mechanics based re-scoring is performed to obtain a
free-energy ranking that incorporates the complex’s dynamic motion.
Figure 7.3: Workflow components for the study of targeted polypharmacology.
A) Workflow adapted for drug-targets selection, parameterization of individual
workflow components and validation by reproducing known drug-target inter-
actions from drug-target network. B) Extended workflow with same workflow
components but using focused compound libraries filtered through SVM based
classifier model and similarity searching.
In order to perform the virtual screening experiments, it is necessary to prepare
the molecular structures of both drugs and targets accordingly for use with the
modeling tool. The preparation steps include generation of 3D conformations
for the drug molecules and proper protonation and energy minimization of the
target protein structures. The compounds and protein structures preparatory
steps were performed with MOE 2011.10 [92], docking was performed by LeadIT
2.1.0 [288], pose ranking and selection was carried out using NNScore v2 [280] and
molecular dynamics simulations were performed by using Amber12 [289], [290]
and the inputs for MD were prepared with AmberTools-12 [289]. Binding free
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energies for all protein-ligand complexes were calculated using MM-PBSA/GBSA
[291] methods. In-silico validations for the newly predicted candidate hits were
performed by comparative modeling algorithms available in MetaDrug database
[175]. The major steps of the workflow are described as follow:
1. Target selection and prioritization as described in section ”Methods and
Material”. For both workflow steps, the same set of selected targets were first
used in reproducing known drug-target interactions and then for screening
focused libraries for the exploration of polypharmacology.
2. For the purpose of validating the polypharmacology workflow and repro-
ducing the experimentally determined drug-target interactions, a set of ap-
proved drugs around the selected targets (as described in section ”Methods
and Material”) was also selected. These drugs are used for the treatment of
various nervous system disorders particularly the major NDD disorders such
as Parkinsons, Alzheimers and Epilepsy. The set of selected drugs with their
indication areas are listed in Table 7.2 with respective references to different
database resources.
3. Drugs, compound library and target structures were prepared by generating
their 3D conformations, protonation at normal physiological pH, ionization
and energy minimization steps. The 3D conformations were generated using
MOE. Protonation, generation of tautomers, ionization states were generated
by using the Protonate3D algorithm implemented in MOE. The resulting
protonation states were energy minimized with MMFF94 forcefield using
MOE. The target protein structures were prepared by applying protonation
with Protonate3D implemented in MOE followed by energy minimization
using Amber99 force field in the presence of co-crystallized ligand(s) and
solvents.
4. Focused libraries of compounds are generated using machine-learning based
classifier model and similarity searching. The compound libraries are gener-
ated from a commercial catalog available from ASINEX (http://www.asinex.com).
Detailed description about the compound library generation is provided in
the coming section ”Focused Libraries Enrichment”.
5. Docking of selected drugs and filtered compound library was performed
against all selected targets by using LeadIT docking software. For each
drug/compound, top 10 docked conformations were retained for subsequent
filtering (i.e. by external scoring functions as described in the next step)
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of most favorable conformation. Further details are provided in the section
”Docking and MD of Focused Libraries”.
6. Pose ranking and selection was performed by using NNScore algorithm,
which facilitates the selection of favorable binding pose among the predicted
docked poses against each target protein. The first ranking pose was se-
lected for each compound that has the highest predicted activity against the
respective protein target. Further details are provided in the section ”Pose
Ranking and Selection”.
7. Protein-ligand complexes are prepared by using tools and utilities available
in AmberTools to apply respective force fields and parameters. Detail de-
scriptions are provided in the section ”Input Preparation”.
8. Molecular dynamics simulations were performed over the selected protein-
ligand complexes in a series of multiple steps. Details are given in the section
”Production MD Run”.
9. Binding free energies were calculated by using MM-PBSA/GBSA based
methods that were applied on the MD trajectories obtained from the pro-
duction MD runs. The trajectories of the protein-ligand complexes were
analyzed at the interval of every 10ps time as it was observed with autocor-
relation function that statistically different energy values could be sampled
at this time interval. The binding energies are not based on the entropy of
the protein-ligand complex, but are estimated from the interaction energy
and solvation energy for the complex, receptor and ligand.
10. In-silico validations of the known drug-target interactions observed with
docking-MD were carried out by comparison to experimentally determined
activity values derived from bioactivity databases. Likewise, in-silicovalidations
for the interactions of novel candidate drugs were performed with QSAR
modeling algorithms available in MetaDrug.
In the coming sections, a series of preparatory input setup is described for the
drugs and protein target complexes.
7.2.2 Input Preparation
Before performing simulations, the protein-ligand complexes were first parameter-
ized and equilibrated. For the ligands, general amber force field (GAFF) [292] was
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used and for the protein structures, FF99SB [293] was used. No missing param-
eters for the ligand atoms were reported by AmberTools. The protein structure
optimized with MOE was used as input for the receptor atoms having no co-
crystallized ligands. The protein and ligand atoms were combined by using Leap
module of AmberTools. The complexes were solvated by using explicit solvent
TIP3P water model [294] in an octahedron box with at least 8 A˚distance around
the complex. The total charge of the complex was neutralized by adding counter
ions (i.e. Na+ or Cl-). Disulfide bonds were explicitly specified if they occur be-
tween some residues of the protein. This is important because without specifying
these bonds, the protein conformation can drastically change during molecular
dynamics simulation.
7.2.3 MD Equilibration
Equilibration steps include heating, pressure and density equilibration of the protein-
ligand system. The complexes were minimized for 5000 steps of minimization. The
minimized complexes were subjected to heating from initial temperature of 0K to
300K for 50ps with NMR restraints, followed by density equilibration at constant
pressure for 50ps. The energy-minimized complex was subjected to gradual heat-
ing via the NMR option to avoid heat shocking the complex. Very weak restraints
(i.e applying a weak force of 2.0 k cal/mol–A˚2) were used to hold the heavy atoms
of protein residues fixed during the temperature, density and pressure equilibra-
tion steps. However, no restraints were used during the final equilibration step
that was carried out at constant pressure for 5ns.
7.2.4 Production MD Run
The equilibrated complexes (i.e having less fluctuations in RMSD of the back-
bone atoms) were simulated for further 5ns production MD runs at 300K and 1
atm anisotropic pressure scaling in a NPT ensemble. A time step of 2fs was used
for the simulations. The long range electrostatic interactions were treated by the
Particle Mesh Ewald (PME) method by using a nonbonded cutoff of 8 A˚. The
SHAKE algorithm was applied to constrain all bonds involving hydrogen atoms.
A periodic boundary condition was applied and snapshots were recorded at ev-
ery 2ps time interval. This resulted in 2500 snapshots for 5ns simulation run of
each protein-ligand complex. These snapshots were sampled later in performing
MM-PBSA/GBSA based calculation of free energy of binding. Protein conforma-
tional changes were analyzed by plotting variations in protein backbone atoms and
ligand atoms. Residue-wise fluctuations were also observed for the drug-protein
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complexes in order to observe the conformational changes in the protein residues
upon binding a ligand.
7.2.4.1 Free Energy of Binding
Binding free energies were estimated for all the selected drug-target complexes.
Using MM-PBSA/GBSA based methods to calculate binding free energies, rep-
resentative snapshots at every 10 ps were extracted from the MD simulation tra-
jectories. The estimated free energy values were compared against experimentally
determined activity values for two targets DRD3 and ADRB2. The experimental
Ki values were converted to ∆G values by using the following equation:
∆G = −RT lnKi (7.1)
where T is temperature in Kelvin, R is gas constant and Ki is the binding activity
in molar concentration. The Ki values for the selected drugs were converted from
nM to molar and then converted to ∆G with the temperature of 295 K.
7.2.5 Focused Libraries Enrichement
The NDD focused compound libraries were generated from a database that in-
cludes more than 400,000 compounds available in a commercial catalog ASINEX
[295]. The generated libraries were screened against multiple target proteins by
molecular docking and MD. Filtering of compound database was done by two
methods as described below.
7.2.5.1 SVM Classifier based Filtered Compound Library
A neurodegenerative diseases (NDD) focused library was enriched by using machine-
learning classifier model [39] built for discriminating NDD drugs from non-NDD
drugs as described in more detail in chapter-3. A set of NDD relevant molecular
descriptors were first calculated for all the compounds in the database and the
classifier was applied to predict a set of compounds that could be relevant and
useful in NDD. By using the classifier model (Chapter 4), the database was fil-
tered and top 500 compounds that were predicted as NDD ligands with highest
probability according to the classifier model, were selected.
7.2.5.2 Fingerprint Similarity based Filtered Compound Library
A fingerprint-based similarity approach was used to filter the database by using
extended connectivity fingerprint (ECFP) method [296]. For each compound in
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the database, ECFP fingerprints were calculated using MOE. ECFP based finger-
print similarity was used because it has been shown to perform better than other
fingerprint based similarity methods [297]. Similarly, the same fingerprints were
also calculated for the known NDD drugs taken as reference compounds. The
database compounds were ranked according to 5 nearest neighbors (5NN) search
strategy, in other words, the average similarities of the database compounds to
any 5 of known NDD drugs and 500 top ranking compounds were selected
7.2.6 Pose Ranking and Selection
As the first ranked pose obtained by docking score is not always the best bind-
ing pose due to the limitation in scoring functions of the docking programs [184],
[185]. To overcome this problem, the selection of the most favorable docked pose
was performed by using an external scoring function NNScore [280]. A compar-
ison of the docking score based pose ranking and external scoring functions was
carried out to evaluate the performance of external scoring function. A set of
known active ligands and decoy compounds sets were docked against four targets
(ADORA2A, MAOB, DRD3 and HRH1) and pose filtering was performed on the
basis of different scoring functions. A set of known active ligands for ADORA2A
and MAOB were collected from BindingDB [62] and decoy sets were generated by
DecoyFinger [298] and the sets of known active ligands and decoys for DRD3 and
HRH1 were collected from GLL/GDD database [172]. The mixed ligand-decoy
sets were docked against the respective targets and pose rankings were performed
by the docking score, NNScore and Protein-Ligand Interaction Fingerprint (PLIF)
based ZScore [41] as described in detail in Chapter 6.
7.2.7 Docking and MD of Focused Libraries
The fingerprint similarity and SVM classifier based filtering resulted in a small
library of compounds (total 1000) that were used in screening by molecular dock-
ing and MD simulation. The compounds in the library were protonated by using
Protonate3D algorithm in MOE, resulting in a set of 1632 molecules. The selected
compounds were docked against 7 target structures (5 GPCRs + 2 enzymes) and
for each compound 10 docked conformations were retained. Default docking pa-
rameters were used. Semi-flexible docking calculations were performed that con-
sisted of rigid receptor and flexible ligands. The docked conformations for each
compound were ranked for each protein target and the best pose was selected by
using NNScore algorithm. Finally, compound ranks for all protein targets were
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averaged. As a result, 50 high average ranking compounds were selected with fa-
vorable binding modes against multiple targets. MD simulations were performed
for the selected 50 compounds against multiple targets including 5 GPCRs and
2 enzymes. In a semi-automated way, 350 cross-docked ligand-protein complexes
were subjected to simulations study by MD. Each complex had a 5ns equilibration
simulation performed, followed by 5ns production simulation. For each complex,
2500 snapshots collected every 2 ps were recorded in each MD trajectory for the
respective protein-ligand complexes. 250 snapshots (i.e. every 10th snapshot out
of the total 2500 snapshots) were subjected to evaluation for free energy of binding
with MM-PBSA/GBSA.
7.3 Results and Discussions
7.3.1 Docking Workflow Validation
Docking was used to generate multiple binding poses for the ligands inside the
protein binding pockets. The re-docking experiments showed that the protein
structures are suitable for docking and are well prepared for use in screening a
compound library. With the re-docking experiments of the selected targets, it was
ensured that the protein structures’ binding sites are well defined and the docking
parameters governing interactions are sufficiently reproducing the experimental
binding modes. Table-7.3 shows a list of selected PDB structures, their native co-
crystalized ligands and the re-docking results obtained by docking with LeadIT.
Table 7.3: Re-docking results of co-crystallized ligand docked to the respective
protein targets. The RMSD (A˚) values are given for the first docking pose that
is ranked on the basis of docking score.
Target PDB ID Ligand ID Docking Score
(kJ/mol)
RMSD (A˚)
ADRB2 2RH1 [299] CAU -35.16 0.68
ADORA2A 3EML [206] ZMA -24.47 0.88
DRD3 3PBL [300] ETQ -18.97 0.80
HRH1 3RZE [301] 5EH -33.72 0.73
CXCR4 3ODU [302] ITD -14.67 4.17
MAOB 1S3E [303] RHP -20.21 1.02
PDE4A 2QYK [304] NPV -23.54 1.13
Default docking parameters were used for reproducing the crystal structures’
bound modes for all protein-ligand docking, however, with the exception of one
docking parameter, the ”maximum overlap volume” was increased from 2.9 A˚(default)
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to 5 A˚ to relax the protein-ligand clash penalties. The re-docking results show
that the RMSD of the docked pose with the co-crystallized ligand is below 1 A˚ or
very close to 1 A˚ for all the targets except for CXCR4 for which the RMSD is
above 4 A˚. The reason for this is due to the large size of the crystal ligand that
contains multiple rings. This docked ligand adapts a conformation that is slightly
shifted from the original conformation of the co-crystallized ligand, but the rings
positions still overlap to produce nearly similar interactions as shown in Figure 7.4.
Figure 7.4: The re-docked conformation of the co-crystallized ligand of
CXCR4. The crystal ligand is shown in green and the re-docked conformation
is shown in CPK coloring.
7.3.2 Docking of Known Drugs
Docking a compound to a protein structure produces different binding modes (i.e.
poses) for a single compound inside a binding pocket. Each pose is assigned a
docking score according to the underlying scoring function algorithm. Due to
the limitations in the scoring functions [184],[185], the best binding mode is not
always the one with the lowest docking score. Therefore, an alternative method
and scoring function, NNScore, was used to refine the scoring. Various binding
modes of the selected drugs (Table 7.2) were obtained after docking them against
the selected targets. For each drug docked to a target protein, 10 conformations
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filtered by docking score, were retained for visual analysis and post-processing to
select the best binding pose. Most favorable binding modes were selected that
were close to the native binding modes of the respective co-crystallized ligand
present in the X-ray structures of the selected targets. Visual analysis and manual
selection of binding poses was performed for each drug docked against all targets
and then by using pose-ranking and selection algorithm (NNScore). The binding
poses selected by NNScore were similar to the manually selected binding poses in 8
out of 10 drugs that were docked against the selected targets. These observations
provide a valid reason for using NNScore to filter the docking poses. Therefore,
the docking scores were not considered in the binding pose ranking, using instead
the NNScore algorithm to select the top ranking binding pose for each docked drug
structure. The docking scores for the drugs are not given here because the scores
are not used in ranking and selection of the favorable binding pose.
7.3.3 MD Simulations of Known Drugs
MD simulations were performed to evaluate free energy of binding for the selected
drug-target complexes. Additionally, through MD simulations, the interactions
of drug molecules with the target proteins were evaluated. MD simulations were
also carried out to incorporate dynamics and relaxation, and to investigate the
conformational changes on the target structures upon drug binding. The binding
energy estimated for the drugs were compared against the experimental activity
data for the drug-target pairs. However, not all drugs have experimentally deter-
mined affinity values against all the selected targets. Therefore, the binding energy
values for only two targets were used in the comparisons for which experimental
affinity values for most drugs have been reported in activity databases such as
ChEMBLdb, BindingDB and KiDB.
The drugs mentioned in Table 7.2 and depicted in Figure-7.2 have experimen-
tal activity values determined for ADRB2 and DRD3 receptors. For the rest of
the GPCR targets, none of the drugs have experimental activity data available
for these GPCR targets. Activity values of most of the drugs were also found for
some other GPCR receptors; however, those targets do not have three-dimensional
structure available so far and hence were not considered for comparison. There-
fore, MD study was performed on the selected drugs against 5 GPCR targets
and comparisons with experimentally determined activity values for ADRB2 and
DRD3 receptors.
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7.3.3.1 Equilibration
Figure 7.5 shows that the density has been equilibrated in the equilibration step
of 50ps density equilibration with constant volume and the density remains the
same during full equilibration with constant pressure for 5ns.
Figure 7.5: Plots showing density equilibration for the selected drugs (lines
shown in different colors) complexed with ADRB2 and DRD3.
The protein backbone atoms changes in terms of RMSD deviations in reference
to the initial docked protein-ligand complexes show that the complexes start to
equilibrate between 2 and 4ns time of simulation. The equilibration results for
DRD3 and ADRB2 targets are shown in Figure 7.6 and Figure 7.7 respectively.
The RMSD values are reported for the protein backbone atoms only. These results
indicate that a longer equilibration is necessary to obtain a stable protein-ligand
complex for performing production MD runs.
7.3.3.2 Production MD Run
Production runs of 5ns period were performed after the drug-target complexes were
equilibrated. As shown in Figure-7.8 and Figure-7.9, the protein-ligand complexes
do not change very much during the simulation run and remain stable with slight
changes in the backbone. These changes that occur in the backbone atoms are
caused by the residues in the loop regions of the proteins. Residue-wise fluctuations
(Figure 7.10) also indicate the conformational changes occur mostly in the intra-
and extra-cellular loop regions of the protein. It can be noticed that the loop
conformations changes occurring almost in a similar way for most drug-protein
complexes. As shown in Figure 7.10, the residues with higher fluctuations belong
to the loop structures that undergo dynamic conformational changes as demon-
strated in the case of Pimozide- and Bromocriptine-ADRB2 complexes shown in
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Figure 7.6: Plots showing backbone RMSD values for DRD3 complexed with
selected drugs (lines shown in different colors) during 5ns MD equilibration
period.
Figure 7.7: Plots showing backbone RMSD values for ADRB2 complexed
with selected drugs (lines shown in different colors) during 5ns MD equilibration
period.
Figure 7.12. It can also be observed that the drug molecules do not show con-
formational changes as compared to the protein atoms. The ligand atom RMSD
plots are shown in Figure 7.11. This also indicates that most of the drugs have
favorable binding modes for these receptors and they do not exhibit big conforma-
tional changes during the simulation. However, interatomic interactions could be
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investigated to determine what particular interactions are favored by these drugs.
Figure 7.8: Plots showing backbone RMSD values for DRD3 complexed with
selected drugs (lines shown in different colors) during 5ns MD simulation.
Figure 7.9: Plots showing backbone RMSD values for ADRB2 complexed with
selected drugs (lines shown in different colors) during 5ns MD simulation.
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Figure 7.10: RMSF fluctuations for all atoms of the receptors showing residue
fluctuations during the production MD simulation for the selected drugs com-
plexed with DRD3 and ADRB2 receptors.
Figure 7.11: RMSD plots calculated for the ligand atoms only during the
production MD simulation for the selected drugs complexed with DRD3 and
ADRB2 receptors.
7.3.3.3 Free Energy of Binding
Binding free energies were estimated for all the selected drug-target complexes.
Using MM-PBSA/GBSA based methods to calculate binding free energies, rep-
resentative snapshots at every 10 ps were extracted from the MD simulation tra-
jectories. The estimated free energy values were compared against experimentally
determined activity values for two targets DRD3 and ADRB2 for which the activ-
ity data of selected drugs were available. The experimental and calculated binding
free energy values (∆G) are given in Table-7.4.
A positive correlation was observed between the experimental ∆G values and cal-
culated ∆G values for both ADRB2 and DRD3 receptors. The observed correlation
is 0.79 and 0.80 for DRD3 determined by both MM-PBSA and MM-GBSA meth-
ods respectively, and correlation of 0.54 and 0.50 for ADRB2 using both methods.
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(a) Pimozide Complex (b) Bromocriptine Complex
Figure 7.12: Comparison of 166 MD snapshots taken at 15ps intervals each
from the production MD trajectory, with aligned coordinates of ADRB2 showing
fluctuating regions at the extra-cellular end of ADRB2 receptor.
Table 7.4: Experimental (exp.) activity values in nM and ∆ G values in kcal/-
mol for the selected drugs against DRD3 and ADRB2 receptors obtained from
KiDB and BindingDB. ∆G (exp.) values are obtained by using Equation 7.1.
DRD3 ADRB2
Drug Name Ki (nM) ∆G (exp.) Ki (nM) ∆G (exp.)
Apomorphine 36.15 -10.01 10,000 -6.75
Bromocriptine 7.06 -11.19 741 -8.27
Cabergoline 0.79 -12.29 10,000 -6.75
Dopamine 60 -9.75 50,000 -5.77
Epinephrine - - 2,065 -7.67
Haloperidol 9.49 -10.89 5,000 -7.16
Lisuride 0.79 -12.29 7.94 -10.93
Pimozide 5.7 -11.13 5,000 -7.16
Risperidone 6.08 -11.90 5,000 -7.16
The reason for low correlation of binding energy with activity values could be the
higher affinity values of these drugs for ADRB2 target as compared to DRD3. The
correlations of free energy of binding values with experimental ∆G values are plot-
ted in Figure- 7.13. The free energies of binding predicted by MM-PBSA method
are quite sensitive to the solute dielectric constant parameter [285]. Using the de-
fault dielectric constant (i.e. indi=1.0), the results were not satisfactory in terms
of binding energy estimation (Table 7.5). The predicted energies for some drugs
were positive and the correlation with experimental ∆G was 0.27 in case of DRD3
and 0.49 for ADRB2. Also there was very low correlation between the energy
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Table 7.5: MM-PBSA based estimated ∆G values (kcal/mol) for DRD3 and
ADRB2 receptors using default parameter (indi=1.0) for solute dielectric con-
stant.
DRD3 ADRB2
Drug Name ∆ G STD ∆ G STD
Apomorphine -12.73 5.73 14.16 7.15
Bromocriptine 3.71 5.66 -12.21 5.4
Cabergoline -8.75 6.07 8.55 6.53
Dopamine 2.17 6.48 9.31 6.12
Haloperidol -3.7 4.78 -0.79 4.88
Lisuride -9.77 4.95 -2.96 4.99
Pimozide -3.75 4.56 -7.87 4.66
Risperidone -4.7 5.82 11.29 6.08
Table 7.6: MM-PBSA/GBSA based estimated ∆G values (kcal/mol) for
DRD3 receptor using solute dielectric constant of 4.0 in PBSA calculations.
PBSA GBSA
Drug Name ∆ G STD ∆ G STD
Apomorphine -17.09 2.92 -34.54 2.70
Bromocriptine -23.11 3.32 -53.02 3.43
Cabergoline -29.81 3.78 -60.58 4.42
Dopamine -8.55 2.4 -21.51 2.86
Epinephrine -13.11 2.9 -31.40 3.13
Haloperidol -18.94 2.85 -45.54 3.01
Lisuride -21.00 2.74 -44.13 2.61
Pimozide -23.02 3.46 -50.93 3.56
Risperidone -20.08 3.44 -49.05 3.21
Table 7.7: MM-PBSA/GBSA based estimated ∆G values (kcal/mol) for
ADRB2 receptor using solute dielectric constant of 4.0 in PBSA calculations.
PBSA GBSA
Drug Name ∆ G STD ∆ G STD
Apomorphine -7.35 3.19 -25.62 2.43
Bromocriptine –36.88 3.93 -74.04 3.48
Cabergoline -19.61 3.36 -43.80 4.26
Dopamine -4.59 2.34 -10.25 3.14
Epinephrine -11.20 2.97 -26.55 4.24
Haloperidol -7.32 6.32 -15.62 10.44
Lisuride -18.11 3.76 -37.49 5.26
Pimozide -22.89 3.06 -55.36 2.99
Risperidone –21.27 2.89 -44.06 3.12
values determined by both MM-PBSA and MM-GBSA methods. A correlation
of 0.12 was observed between PBSA and GBSA for DRD3 and 0.53 for ADRB2.
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(a) (b)
(c) (d)
Figure 7.13: Correlation plots of experimental ∆ G compared to calculated ∆
G determined by MM-PBSA and MM-GBSA for selected drugs against DRD3
and ADRB2 receptors.
Therefore, the parameter for solute dielectric constant was increased from 1.0 to
4.0 that improved the results of MM-PBSA for both receptors (Table 7.6 and Ta-
ble 7.7). Using the higher dielectric constant resulted in agreement for binding free
energy estimation between MM-PBSA and MM-GBSA methods for both receptors
with a correlation of 0.98 and 0.96 for DRD3 and ADRB2 respectively.
The free energy of binding values were also estimated for the same set of drugs
against the remaining GPCR targets: ADORA2A, HRH1 and CXCR4. The drugs
were docked and the drug-bound complexes were simulated in the same way as
done for the DRD3 and ADRB2 targets. The resulting estimated binding energy
values obtained from cross-docking the set of selected drugs against the GPCR
targets shows that some drugs bind with high predicted free energy of binding to
more than one target as shown in Table-7.8. This indicates that certain drugs
have promiscuity and have dual and multiple targets.
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Table 7.8: MM-PBSA based calculated ∆G values kcal/mol for 5 GPCR
targets.
Drug Name DRD3 ADRB2 ADORA2A CXCR4 HRH1
Apomorphine -17.09 -7.35 -14.99 -6.55 -12.77
Bromocriptine -23.11 -36.88 -29.93 -12.25 ND
Cabergoline -29.81 -19.61 -13.02 -11.47 -13.48
Dopamine -8.55 -4.59 -2.44 -6.86 -12.41
Epinephrine -13.11 -11.20 -5.34 -6.06 -11.51
Haloperidol -18.94 -7.32 -20.05 -10.30 -24.32
Lisuride -21.00 -18.11 -10.43 -14.12 -13.68
Pimozide -23.02 -22.89 -22.82 -11.55 -16.31
Risperidone -20.08 -21.27 -17.59 -5.86 -26.94
ND: No docking predictions.
The results show that drugs such as Bromocriptine, Haloperidol, Pimozide and
Risperidone, who are active against DRD3 receptor with affinity less than 10nM
(see Table 7.4), can possibly demonstrate activity against a set of secondary tar-
gets. These drugs have higher affinities for their primary target DRD3, but addi-
tionally, high free energies of binding (highlighted in bold in Table 7.8) were also
predicted for the other GPCR targets such as ADORA2A and HRH1. Therefore,
these drugs may have polypharmacology and they could exhibit the characteristics
of multitarget interacting drugs.
7.3.4 Focused Libraries Enrichement
Top 500 ranked compounds were selected from the compound database on the ba-
sis of probability values calculated by the underlying classifier model. Figure-7.14
shows the decision values plot for the database compounds that were distributed
around the central decision line at 0. The decision values are calculated by the
underlying SVM model that assign class labels to the data points. The com-
pounds falling far from the central decision line (SVM decision boundary) towards
the positive scale are more likely to be useful in NDD. Therefore, the top 500
compounds were selected that have a greater probability of being similar to NDD
drugs in molecular properties. Similarly, the top 500 compounds were also filtered
from the compound database on the basis of similarity scores obtained by applying
fingerprint based similarity measure.
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Figure 7.14: Ranking and selection of NDD focused library by using machine-
learning classification model based on QSAR descriptors. Compounds falling
above the line at 0 are predicted as NDD compounds while compounds falling
the line below 0 are predicted as non-NDD like compounds. Top 500 ranking
compounds are selected that are indicated with red line and the compounds
below the blue line are taken as negative samples.
7.3.5 Docking, Pose Ranking and Selection
Docking was used to generate different conformations of a ligand inside the active
site pocket of the protein. The focused library was docked against all of the selected
targets and for each compound, with the top 10 docked conformations retained
for subsequent NNScore pose ranking and filtering. NNScore-based pose ranking
and selection was performed because it demonstrated performance in recovering
the known active ligands for four of the selected targets that were evaluated for
pose ranking. As shown in Figure 7.15, both NNScore and Protein-Ligand Interac-
tion Fingerprint (PLIF) based ZScore performed better in recovering known active
ligands as compared to the built-in scoring function of FlexX docking program.
NNScore performed better for DRD3 screening and demonstrated early enrich-
ment for ADORA2A screening, while for MAOB and HRH1, the early enrichment
achieved with NNSscore was similar to PLIF-based Zscore. Therefore, it is hard
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to choose a method on the basis of a screening datasets of a few targets. NNScore
was chosen as a method for pose scoring and ranking because its implementation is
comparatively simpler than that of PLIF based method. PLIF-based scoring and
pose selection method has been described in detail in Chapter 6. However, there
are still improvements needed in the scoring functions in general, for pose ranking
and selection, because an important point to note is that such performance evalu-
ations should be carried out between experimentally determined true non-binders
as decoys and the bio-active molecules.
Ranking among the top 10 conformations and between all compounds of the fo-
cused library were obtained for all the targets. Initially, ranks were obtained for all
the library compounds against individual targets. Afterwards, sorting was done
on the basis of average ranks obtained across all the selected targets. This resulted
in a set of 50 compounds that have high average ranks for the targets. The advan-
tage of prioritizing a compound that have high average rank for all targets is to
select a potential candidate that may act as a multitarget ligand. A disadvantage
in this approach will be down ranking a potential active and target selective com-
pound. Therefore, for the study of targeted polypharmacology, candidates with
higher average ranks obtained for all targets will increase the probability of select-
ing compounds that might exhibit polypharmacology. The selected compounds
are later evaluated through more rigorous methods based on MD simulations and
subsequent MM-PBSA/GBSA calculations.
7.3.6 MD Simulations of Selected Compounds
Figure-7.16 and Figure 7.17 show 2D structural representations of the compounds
that were finally selected for further screening against the selected targets using
MD simulation. Postprocessing of the MD trajectories resulted in free energy of
binding estimates for all the 50 compounds against the selected targets as shown in
Figure-7.18. These results show that there is high positive correlation between the
free energy values estimated by MM-PBSA and MM-GBSA methods for all GPCR
and enzyme targets. The correlation values between MM-PBSA and MM-GBSA
obtained for the targets are given in Table-7.9.
This indicates that for all the targets there is high positive correlation between the
binding free energy values determined by both methods. Therefore, both methods
can be used in the final ranking and selection of candidate compounds. Studies
have shown that MM-PBSA performs better than MM-GBSA in calculating bind-
ing free energies[285] and MM-PBSA based binding energy values provide good
correlation with experimental activity values [305] when longer MD simulations
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(a) MAOB (b) ADORA2A
(c) HRH1 (d) DRD3
Figure 7.15: ROC curves showing the performance of different scoring func-
tions in recovering known active ligands from a set of decoy compounds.
Table 7.9: Correlation between binding free energy values estimated by both
MM-PBSA and MM-GBSA methods for the selected compounds simulated
against the selected targets.
Target Protein Correlation
ADRB2 0.88
ADORA2A 0.90
DRD3 0.84
HRH1 0.75
CXCR4 0.90
MAOB 0.81
PDE4A 0.80
are run. However, MM-PBSA calculations are expensive as they use explicit sol-
vent models as compared to the computationally efficient MM-GBSA calculations
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Figure 7.16: 2D structural representations of selected compounds with corre-
sponding database IDs.
that use implicit solvation model.
7.3.7 Polypharmacology
The estimated binding energy values obtained for the selected compounds against
multiple target proteins showed that some of the compounds are predicted to be
more promiscuous than others. Therefore, it is assumed that compounds with
greater promiscuity will tend to interact with a similar strength of binding energy
with multiple target proteins that have binding site similarities. Likewise, the
compounds that do not exhibit possible polypharmacological interaction behavior
will not bind favorably to multiple targets. In other words, the same ligand should
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Figure 7.17: 2D structural representations of selected compounds with corre-
sponding database IDs.
bind with similar binding energy to multiple pockets that have high similar pockets
and the binding energy should vary in a dissimilar pocket. To test the hypothesis
that the compounds tend to interact with similar binding energies with multiple
targets having binding pocket similarities, a comparison is made between the cor-
relation of binding energy values of the same compounds with different targets,
and the pocket similarity values between different targets. A correlation matrix is
generated from the correlation values of the same compounds with multiple targets
that is compared with the pocket similarity matrix of the selected targets.
Figure-7.19 (A and B) shows the pocket similarity matrix visualized as heatmap
that indicates the pocket similarity range for 5 GPCRs and 2 enzyme targets.
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From this figure, it is clear that the GPCR targets have higher binding pocket
similarities with each other as compared to the two enzyme targets. Such similar-
ities are expected because the overall fold of these receptors is conserved [306] and
sharing similar ligands my reflect the conservation of identical ligands between un-
related receptors [307]. Figure (C and D) show the heatmaps generated from the
correlation of binding energy values computed for the selected compounds against
different targets through MM-PBSA and MM-GBSA methods respectively. It
can be observed that the correlation is slightly higher for some GPCR targets
as compared to the enzyme targets. Therefore, it can be assumed that the se-
lected compounds may exhibit polypharmacological behavior towards the GPCR
targets more than the enzymes, behavior that can be confirmed by performing
experimental validations.
7.3.8 Comparative QSAR Modeling of Novel Candidate
Compounds
The selected compounds that were predicted as potential candidates for use in
NDD disorders were compared with a set of FDA approved drugs for various NDD
disorders. The objective of this comparison was to find common features between
the newly predicted candidates and established NDD drugs. To test the func-
tionality of the QSRA algorithms, a set of compounds which were predicted as
non-NDD like compounds by the NDD classifier model, was used as a negative
control. QSAR-based predictions for interacting targets, pathways and involve-
ment in disease indications were made for the three sets of compounds/drugs
using QSAR-based algorithms available in MetaDrug [175]. The web interface of
MetaDrug was used to upload the three data sets. Tanimoto similarity cut-off
of 0.7 was used. For each data set, comprehensive reports were generated, which
were parsed to extract the following three types of predictions:
a Target predictions
b Pathways predictions based on common targets
c Disease predictions
Table 7.10 lists a set of known FDA approved drugs used for the treatment of four
NDD disorders (Alzheimer’s, Parkinson’s diseases, Epilepsy and Multiple Sclero-
sis) that are used as a reference set for the comparisons of predicted NDD+ and
NDD- compounds. Figure 7.20 shows the results of predicted targets for known
drugs, predicted NDD+ and predicted NDD- drugs. It was observed that similar
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targets were predicted for the NDD+ compounds that are interacting with known
drugs. Moreover, there were almost no targets predicted for the NDD- compounds.
Similarly, there were also similarities at pathways level and disease indications pre-
dicted based on similar interacting targets for the known drugs as well as for the
predicted NDD compounds. The predicted list of targets includes also those GPCR
targets against which the current virtual screening was performed, the predicted
pathways includes the important neurophysiological processes and the predicted
disease indications include Alzheimer’s and Parkinson’s diseases. These analyses
provide another basis for the relevance and potential of the selected compounds
for use in NDD indications.
7.3.9 Candidates Selection and Identificaiton of Multitar-
get Drug
Finally, a set of 14 candidate hits are selected for further experimental validation.
The candidate compounds are selected on the basis of binding energy values (i.e.
calculated with both MM-PBSA and MM-GBSA methods) that are average ranked
for the selected targets. As shown in Figure 7.18, the best candidate compounds
are selected that have higher binding energy values for multiple targets. The
candidate compounds are currently evaluated experimentally for activities against
the selected targets.
The first hit in the selected candidates list is identified to be a known antiasth-
matic and antiallergic drug, Oxatomide. Oxatomide is orally active histamine
H1 antagonist, chemically related to cinnarizine class [308], which is used for the
treatment of allergy and other related indication areas. Our results have shown
higher predicted binding energy for Oxatomide (BAS-01509783 in Figure 7.17 and
Figure 7.18) against 4 out of 7 targets. Our targeted polypharmacology approach
has predicted this drug as a multitarget drug, because experimental activities for
this drug against multiple targets have been reported. For its primary target,
HRH1 receptor, IC50 of 9 nM [309], for DRD3 receptor, Ki of 62 nM [310] and
for CACNA1H (Voltage-dependent T-type calcium channel subunit alpha-1H), an
EC50 of 5150 nM [311] have been reported. This shows that for two targets, the
predictions for this compound turned out to be correct and for the rest of the
targets it remains to be validated experimentally. Therefore, it is more likely that
some of the candidate compounds might also exhibit multitarget activities that
will demonstrate polypharmacology, after the activities are reproduced in in-vitro
experiments.
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Table 7.10: List of FDA approved drugs and their use in various NDD indica-
tions. Drug ids are pointing to the DrugBank, the TTD or STITCH databases.
Drug ID Name Indication area
DB00674 Galantamine Alzheimer’s Disease
DB00843 Donepezil Alzheimer’s Disease
DB01043 Memantine Alzheimer’s Disease
DB00989 Rivastigmine Alzheimer’s Disease
DB00382 Tacrine Alzheimer’s Disease
DB06262 Droxidopa Parkinson’s Disease
DB00190 Carbidopa Parkinson’s Disease
DB00494 Entacapone Parkinson’s Disease
DB01367 Rasagiline Parkinson’s Disease
DB00714 Apomorphine Parkinson’s Disease
DB00915 Amantadine Parkinson’s Disease
DB00387 Procyclidine Parkinson’s Disease
DB01200 Bromocriptine Parkinson’s Disease
DB01235 Levodopa Parkinson’s Disease
DB00413 Pramipexole Parkinson’s Disease
DB05271 Rotigotine Parkinson’s Disease
DB01037 Selegiline Parkinson’s Disease
DCL000972 Safinamide Parkinson’s Disease
DB00268 Ropinirole Epilepsy
CID000000444 Bupropion Epilepsy
CID000002771 Citalopram Epilepsy
CID000004763 Phenobarbital Epilepsy
DCL000791 Eslicarbazepine acetate Epilepsy
DCL000982 Seletracetam Epilepsy
DCL000730 Brivaracetam Epilepsy
CID000004192 Midazolam Epilepsy
CID000001986 Acetazolamide Epilepsy
DB00564 Carbamazepine Epilepsy
CID000003016 Diazepam Epilepsy
DB00593 Ethosuximide Epilepsy
DB00949 Felbamate Epilepsy
DB01320 Fosphenytoin Epilepsy
DB00996 Gabapentin Epilepsy
DCL000858 Lacosamide Epilepsy
DB01202 Levetiracetam Epilepsy
DB00776 Oxcarbazepine Epilepsy
DB00252 Phenytoin Epilepsy
DB00794 Primidone Epilepsy
DAP001516 Rufinamide Epilepsy
DB00906 Tiagabine Epilepsy
DB01080 Vigabatrin Epilepsy
DB00909 Zonisamide Epilepsy
CID000002265 Azathioprine Epilepsy
DB00181 Baclofen Multiple Sclerosis
DB00108 Natalizumab Multiple Sclerosis
CID005360515 Naltrexone Seizure
7.4 Conclusions
When dealing with complex diseases such as neurodegenerative diseases, knowl-
edge and data from different sources should be obtained because an individual data
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source is not always complete. This includes data for both drugs and their targets.
However, the key challenges arise from the lack of sufficient data at the desired res-
olution. In this chapter, we have explored polypharmacology through various as-
pects by combining network pharmacology with ligand-based and structure-based
design methods. An NDD focused ligand library was designed by using our NDD
classifier model and similarity searching. Protein targets for the study of targeted
polypharmacology were selected by using network pharmacology approach. Us-
ing classifier model and similarity search method for our ligand-based approach
provided highly enriched and focused library of compounds. This focused library
can increase the chances of hit finding as they have similar physiochemical prop-
erties to known NDD drugs. Another important aspect is to limit the number
of database compounds that are screened against multiple targets for the study
of polypharmacology because of the heavy demand for computational resources.
For our structure-based design approach, highly prioritized set of protein targets
that have clear therapeutic roles in the disease mechanism were selected. Such
highly focused set of important therapeutic targets can be thoroughly studied for
the binding interactions at both in-silico and in-vitro environments. If resources
are available, polypharmacology by high throughput MD simulations should be
performed on as many drug targets as possible that has the potential to reveal
interesting predictions of activity of new candidate compounds. This would ul-
timately facilitate the selection of potential multi-target inhibitors that can be
further investigated for the desired polypharmacological profiles and efficacies.
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(a) MM-PBSA (b) MM-GBSA
Figure 7.18: Heatmap of free energies of binding values calculated for selected
50 compounds simulated against 7 targets using MM-PBSA and MM-GBSA
based methods.
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Figure 7.19: Speculating polypharmacology by pocket similarity. A) Heatmap
of pocket similarity matrix. B) Pocket similarity scores. C) Correlation matrix
of MM-PBSA-based derived free energy values of selected 50 compounds be-
tween multiple targets. D) Correlation matrix of MM-GBSA-based derived free
energy values of selected 50 compounds between multiple targets.
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Figure 7.20: Heatmap of drug-target interactions predicted by MetaDrug algorithms for three groups of compounds. Compounds are
given in rows and targets are given in columns. Black lines divide the compounds groups into FDA approved drugs, predicted NDD
compounds and predicted non-NDD compounds. Important target interactions are zoomed into the boxes above the columns.
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Figure 7.21: Heatmap of drug-pathways involvement predicted by MetaDrug algorithms for three groups of compounds. Compounds
are given in rows and pathways are given in columns. Black lines divide the compounds groups into FDA approved drugs, predicted
NDD compounds and predicted non-NDD compounds. Some pathways are highlighted into the boxes above the columns.
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Figure 7.22: Heatmap of drug-disease associations predicted by MetaDrug
algorithms for three groups of compounds. Compounds are given in rows and
diseases are given in columns. Black lines divide the compounds groups into
FDA approved drugs, predicted NDD compounds and predicted non-NDD com-
pounds. Some diseases are highlighted into the boxes above the columns.
Chapter 8
Conclusions and Future
Perspectives
8.1 Conclusions
Studying integrative systems approaches towards brain pharmacology and polyphar-
macology starts with the collecting and interlinking of exiting data from available
resources that are disintegrated and heterogeneous. This collection of dispersed
pieces of data and interlinking them requires the design of a knowledge base sys-
tem that enables the proper organization of the collected data. The design of the
Human Brain Pharmacome is a first effort in this direction to build a comprehen-
sive knowledge base framework for the brain pharmacology that represents and
integrates therapeutic data around human brain disorders. Major components of
this knowledge base system are the known drugs used in the treatment of major
brain disorders and their interacting protein targets. For all of the drugs and their
protein targets, the biological and chemical properties and other relevant features
are also collected. This knowledge base system should be as complete and com-
prehensive as possible. The HBP design and foundation is developed during the
research work in this thesis, which is then used to study targeted polypharmacol-
ogy. There is no stand alone knowledge base publicly available that contains all
the required data regarding our target area in a single place. To build a complete
knowledge base system, it becomes necessary to combine multiple resources, cap-
ture the required data, organize and interlink the data and efficiently store them
at one place in a well structured format. The HBP pharmacome in this research
work, has been used as a central repository that enables the exploration of inte-
grative systems approaches towards targeted polypharmacology. Using network
pharmacology approaches, the HBP is analyzed in such a way that enables us to
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generate a system level view of a specific knowledge that exists in this knowledge
base. The underlying drug-target network in the HBP pharmacome is very large
and complex. A Cytoscape plugin, referred to as ”Pharmacome Tools”, has been
developed to filter the large networks generated from the HBP data and to re-
duce their complexity. The plugin has useful features to predict new drug-target
associations that could be investigated for the prediction of off-target effects and
drug repurposing. Another useful function of this plugin is to select a set of
protein targets by prioritizing them for the study of targeted polypharmacology.
Similarly, drugs used for the treatment of neurodegenerative disorders (NDD) are
investigated collectively to identify the unique properties of these drugs, build ma-
chine learning models over them and then apply the model to characterize new
potential compounds for use in NDD. The classifier models also demonstrate the
advantage of these methods over the conventional similarity based methods. We
have effectively used the classifier model to design a highly enriched and NDD-
focused library of compounds from a large compound database. This approach of
characterizing novel candidate compounds also has the ability to repurpose exist-
ing drugs. Using this approach, some drugs that are used in non-NDD indications
were predicted to be potential candidates for testing in various CNS disorders. The
same approach was also applied and evaluated on GPCR class of protein targets
to identify GPCR antagonists from non-GPCR antagonists and it also revealed a
clear potential of drug repositioning.
Polypharmacology has emerged as a new paradigm of drug discovery in the recent
years, and has led to a paradigm shift from the classical drug discovery approaches.
In polypharmacology, a single drug binds to multiple therapeutic targets that con-
tribute to overall effectiveness of a treatment. Various approaches were studied
during this thesis to explore polypharmacology in the existing drugs that are
used for major brain disorders, particularly in the indication areas of NDD. With
the goal of discovering new candidate drugs through the use of existing knowl-
edge concerning known drugs, new potential candidates with polypharmacological
characteristics were discovered and proposed for further investigation. Some new
indication areas different than the primary indication area were also proposed for
existing drugs.
Studying polypharmacology demands for a great amount of resources. In-silico
pharmacology approaches that combine ligand-based and structure-based tools on
an array of known drugs and protein targets need substantial time and resources.
Computational approaches that are applied in this study of polypharmacology
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include network pharmacology based multiple target selection, machine learning-
based compounds selection, molecular docking followed by automated pose selec-
tion and, afterwards, molecular dynamics simulations to evaluate protein-ligand
interactions. Selection of favorable binding modes for a compound inside multiple
protein targets is facilitated by automated pose ranking and selection by using
external scoring function. A set of 50 compounds was filtered for further study
that had favorable binding interactions with 7 different targets including 5 GPCRs
and 2 enzymes. Binding energy estimates for the compounds against all targets
enabled the ranking of each compound against each target. Finally, a small set of
highly promising candidate hits were identified that have the possibility of being
multi-target inhibitors. These candidate hits are taken forward for experimental
validation.
The first hit in the selected candidates list, Oxatomide, is identified as a known
antiasthmatic and antiallergic drug, which is an orally active histamine H1 antag-
onist and is used for the treatment of allergy and other related indication areas.
Our targeted polypharmacology approach has identified this drug as a potential
multi-target drug. Experimental activities for this drug against other targets have
also been reported. This indicates that the predictions for this compound to be
active against multiple targets are supported by independent evidences. For other
targets in our set of selected targets, the polypharmacology potential remains to
be validated experimentally. Therefore, it is more likely that some of the can-
didate compounds might also exhibit dual and multi-target activities that will
demonstrate polypharmacology, after the activities are reproduced in in-vitro ex-
periments. Similarly, some known antibiotic drugs were also predicted for their
potential use in neurodegenerative and other CNS related disorders.
8.2 Future Perspectives
The integrative systems approaches towards targeted polypharmacology in the
human brain, studied in this research work, have demonstrated their usefulness.
The successful identification of a known drug as a multi-target agent indicates
that these approaches we have undertaken can deliver valid outcome. If more of
the predicted multi-target compounds are validated in the experimental screening,
this will strengthen our hypothesis of polypharmacology. We believe that there
remain challenges and room for improvement at each step of this polypharma-
cology workflow. An up-to-date HBP pharmacome has the potential to play a
significant role in providing the foundation for a wide spectrum of approaches in
computational brain pharmacology. Therefore, an automated update mechanism
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is very crucial for frequently updating the HBP with new knowledge that arrives
in the subject domain. The HBP design allows for extension of the existing data
and can accommodate multidimensional chemical and biological data that can be
very useful for many purposes relevant to the pharmaceutical industry.
The HBP will continue to extend by adding and integrating more knowledge from
additional sources. The HBP design allows for the application of mining strate-
gies that will help grow the pharmacome by retrieving the hidden knowledge from
biomedical literature, patent documents and patients health records. The HBP
boundaries can be crossed to collect additional data for all FDA approved drugs
for research on drug repositioning. Mining strategies to collect data from litera-
ture about drugs intervention at pathways level and integrating gene expression
profiles of the interacting protein targets can be used for the identification of true
mode of action of drugs. Addition of tissue specific protein-protein interaction
data for the disease and normal states and linking them with phenotypic associa-
tions at the organ and organism levels will enable the pharmacome to be used for
in-silico target identification strategies. With the availability of growing compute
power and resources, HBP can support large scale virtual screening platforms by
providing ample data for pharmacology applications to reveal new and interest-
ing findings. The HBP, as a unique pharmacology knowledge base, continues to
develop along the future route for understanding complex biomolecular interac-
tions occurring in the brain, thus providing opportunities for developing effective
treatment strategies for complex brain diseases.
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